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Abstract 
 
Botulinum neurotoxins (BoNTs) cause flaccid paralysis by inhibiting 
neurotransmission at cholinergic nerve terminals. BoNTs consist of three essential domains 
for toxicity: the cell binding domain (Hc), the translocation domain (Hn) and the catalytic 
domain (LC). The binding function of the Hc domain is essential for BoNTs to bind the 
neuronal cell membrane, therefore removal of the Hc domain results in a product that retains 
the endopeptidase activity of the LC but is non-toxic. Functional derivatives (LHn) of the 
parent neurotoxin composed of Hn and LC domains have been recombinantly produced and 
characterised. The crystallographic structures of LHn from serotypes A and B are reported 
here and demonstrate the stability of the LHn fragment in comparison to the full length 
toxins. The activity of LHn has been assessed on recombinant substrates and on cultured 
neuronal cells. LHn retains the capacity to internalise and cleave its intracellular SNARE 
substrate when applied to the cells at high concentration. These activities demonstrate the 
utility of engineered botulinum neurotoxin fragments as analytical tools to study the 
mechanisms of action of BoNT neurotoxins and of SNARE proteins. Targeted secretion 
inhibitors (TSI) are a new class of engineered biopharmaceutical molecules derived from the 
botulinum neurotoxins. These functional derivatives are expressed as single-chain proteins 
and require post-translational activation into di-chain molecules for function. A range of 
BoNT derivatives are presented and demonstrate the successful use of engineered SNARE 
substrate peptides at the LC-Hn interface to give these molecules self-activating capabilities 
while retaining the functions of LHn. Several novel molecules with therapeutic potential 
have been produced and their crystallisation for structural investigation is reported. These 
results provide an understanding of the structural implications and challenges of engineering 
therapeutic molecules that combine functional properties of the LHn fragment from BoNTs 
with specific ligand partners to target different cell types. 
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Chapter 1. Introduction 
 
1.1. Overview of bacterial protein toxins 
The idea that bacteria could produce poisonous substances was developed early in the 
realisation that microbial agents were responsible for infectious diseases. Klebs, first in the 
late 19
th
 century, suggested the presence of toxic molecules secreted by staphylococci, 
although experimental evidence only came later. Pioneering work by Koch and Loeffler 
anticipated that soluble molecules were involved in the cholera (Vibrio cholerae) and 
diphtheria (Corynebacterium diphtheriae) infections, respectively (Alouf, 2006). As the 
understanding of infectious diseases expanded, protein toxins were discovered and their role 
in microbial pathogenicity put in evidence. Because of the threat they represent for human 
health, either as natural infectious agents or as biological weapons, protein toxins have been 
extensively studied. Careful analyses of the toxins’ mechanism of action have also led to 
their usage as therapeutic agents and also as important tools for understanding certain 
biological processes (Schiavo and Van der Goot, 2001). 
Diversity of activities 
The diphtheria toxin was the first to be isolated and described by Roux and Yersin 
(1889) as a toxic soluble product of the diphtheria bacillus and responsible for the illness. It 
took several decades however to extract the toxin and characterise it as a protein with potent 
enzymatic activity. The diphtheria toxin is responsible for the inhibition of protein synthesis 
in eukaryotic organisms by catalysing the ADP-ribosylation of elongation factor-2 inside the 
cell cytoplasm, thereby leading to cell death (Collier, 1975). This was to be the first of many 
virulence factors with ADP-ribosyltransferase activity. These toxins have been shown to be 
produced by a wide range of pathogenic bacteria of both Gram-positive and Gram-negative 
types. Modification of their target protein by the conserved ADP-ribosylation function 
disrupts essential processes of the eukaryotic cells and provokes cell death (Deng and 
Barbieri, 2008). 
Another major type of toxin that was among the first discovered consists of the 
clostridial neurotoxins, an array of zinc-metalloproteases expressed by Clostridia sp. causing 
paralysis by inhibition of neurotransmission (Turton et al., 2002). Among the most potent 
bacterial toxins, the lethal toxin component of anthrax toxin from Bacillus anthracis is also a 
metalloprotease (Agrawal and Pulendran, 2004). Other important bacterial protein toxin 
functions with role in human pathogens include:  
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 - phospholipases: cytolytic Clostridium perfringens -toxin (Sakurai et al., 2004); 
 - adenylate cyclases: Bordetella pertussis toxin, anthrax oedema factor (Ahuja et al., 
2004);  
 - RNA N-glycosidases: Shigella dysenteriae shiga toxins (Johannes and Römer, 2010); 
 - glucosyltransferases: Clostridium difficile toxins A and B (Davies et al., 2011); 
 - deamidase: Escherichia coli cytotoxic necrotising factors (Lemonnier et al., 2007); 
 - protease: Staphylococcus aureus exfoliative toxins (Ladhani, 2003), Streptococcus 
pyogenes cysteine proteinases; 
 - deoxyribonuclease: cytolethal distending toxins: cytolethal distending toxin (CDT) 
produced by a number of bacterial pathogens (Smith and Bayles, 2006). 
Another class of toxin, the superantigens, does not present any enzymatic activity but 
has important functions in bacterial pathogenicity. They bind to the major histocompatibility 
complex class II and T-cell receptors. They are mainly produced by the Gram-positive S. 
aureus and S. pyogenes and are the causative agents of the toxic shock syndrome (Fraser and 
Proft, 2008). 
Structural aspects 
Common structural features can be identified in bacterial protein toxins despite the 
diversity of functions they display. In particular, toxins may be classified according to their 
activity, and more generally the localisation of their action, with some acting intracellularly, 
and others that targets the surface of the cytoplasmic membrane.  
For toxins with intracellular targets, crossing of the cell membrane is an essential step 
of the intoxication process. Advances in the understanding of the mode of action of these 
poisonous molecules led to the general principle that most of these toxins possess two 
functional parts. The first component A is responsible for the intracellular enzymatic activity 
while B allows for specific cell binding and transport of A inside the cell (Menetrey et al., 
2005). These complex mechanisms regroup cell recognition, endocytosis, translocation and 
trafficking into the cytoplasm, with high specificity and potency for their receptors and 
substrates (Aktories, 2002). Over the last twenty-five years, determination by x-ray 
crystallography of the three-dimensional structure of many of these toxins has greatly 
contributed to the characterisation of their mode of action and biochemical properties. More 
particularly, it has highlighted the various possible domain organisations seen in the toxins. 
The A and B components can be part of a single-chain polypeptide with two distinctive 
domains (e.g. clostridial neurotoxins, diphtheria toxin), or can be two separate proteins 
either in an oligomeric form (e.g. cholera, shiga toxins) or as binary toxins. In the latter case, 
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the two different components associate at the target cell surface (e.g. C. difficile ADP-
ribosylating binary toxin, Davies et al., 2011).  
Biological and medical applications 
Bacteria have evolved to produce virulence factors with high potency and specificity 
towards eukaryotic organisms. These essential properties make bacterial protein toxins 
efficient biological instruments to analyse the cellular processes they target (Aktories, 2006). 
Many of the toxins have greatly contributed the discovery of important pathways in cell 
biology which in return have shed light on the toxin mode of action itself. This is 
particularly true for toxins with intracellular targets that have developed unique mechanisms 
to enter the cell without damaging the membrane (Schiavo and van der Goot, 2001). An 
evident example is the use of the tetanus toxin, a specific protease acting on a presynaptic 
membrane protein involved in vesicle formation, which helped drawing the mechanism 
underlying neurosecretion, and eukaryotic cellular secretion in general (Schiavo et al., 
1992). Likewise, pertussis and cholera toxins have been important in understanding the 
mechanism of adenylate cyclase activation and the role of cyclic AMP as a second 
messenger in eukaryotic cells. The toxins are responsible for ADP-ribosylation of G proteins 
that control these signal transduction pathways (Harnett, 1994; Neer, 1995).  
A direct medical application for bacterial toxins is the production of effective vaccines 
against corresponding bacterial pathogens. Derivatives of some of the toxins, cholera and 
heat-labile enterotoxin for examples, have been incorporated as adjuvants into human 
vaccines. Adjuvants are pharmacological or immunological agents that can stimulate the 
immune system and improve immunogenicity of co-administered antigens in order to 
improve the efficiency of vaccines. These novel toxin-based adjuvants have shown 
significant effects on vaccine potency in preclinical models (da Hora et al., 2011).  
An alternative approach to use bacterial protein toxins for medical purposes is to focus 
on some of their specific properties. Since many of the toxins present a structure divided into 
functional compartments, they represent ideal subjects for protein engineering. An early 
application for retargeting toxin consisted in harnessing the activities of cytotoxins as 
potential therapies for certain cancers. Such toxins can be engineered as components of 
immunotoxins where the potency of the toxin is combined with the specificity of an 
antibody partner to target and kill cancer cells (Pastan et al., 2006). This has been carried out 
with the diphtheria toxin and Pseudomonas aeruginosa exotoxin A. Their specific binding 
domains were replaced by antibody Fv fragments, thus allowing the targeting to a particular 
antigen at the surface of cancer cells, while retaining the toxin’s ability to reach its 
intracellular domain and cause cell death by inhibition of protein synthesis. Current 
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immunotoxins are being assessed for the treatment of leukaemia, adenocarcinomas, and T-
cell lymphomas among other diseases (FitzGerald et al., 2004). 
One of the toxins with the most potential has been the botulinum neurotoxin. With its 
potency and specificity to inhibit neurotransmission at the neuromuscular junction, it has 
been clinically used for a wide range of clinical applications. These applications and the 
alternative uses for BoNT in protein engineering are reviewed in details in section 1.4 of this 
chapter. 
 
1.2. Clostridia 
1.2.1. Microbiology and pathological association 
The genus Clostridium consists of Gram-positive, rod-shaped bacteria in the Phylum 
Firmicutes (Figure 1.1). It contains over 100 different species which have been characterised 
and classified according to their 16s rDNA sequences. All species are strictly anaerobic and 
form endospores. Clostridia have been one of the most studied bacterial classes since the 
early identification of its role in a number of human diseases (Melville, 2007). 
 
Figure 1.1. Clostridium botulinum. A photomicrograph of C. botulinum type A viewed 
using a Gram stain technique (from the Public Health Image Library, U.S). Gram-positive 
rod-shaped bacteria showing endospores. 
Clostridia are ancient organisms that are widespread in the environment, more 
precisely in anaerobic habitats where organic compounds are present, including soils, and 
aquatic sediments. Many Clostridia are transient or permanent members of the normal flora 
of the gastrointestinal tracts of humans and animals (Melville, 2007). In most cases, 
Clostridia are opportunistic pathogens. All pathogenic clostridial species produce protein 
exotoxins that play an important role in their pathogenicity. 
Several species are commonly listed as important human pathogens. C. difficile is a 
highly infectious bacterium that is increasingly being associated with hospital-acquired 
5 
 
infections. It is responsible for antibiotic-associated pseudomembranous colitis and involves 
several virulence factors that include glucosyltransferase toxins and the ADP-ribosylating 
binary toxin (Davies et al., 2011).  
C. perfringens is another human pathogen. It can produce up to 12 different toxins and 
is responsible for wound infections that may lead to gas gangrene. It produces a potent 
cytolytic -toxin that hydrolyses phosphatidylcholine and sphingomyelin, leading to cell 
death (Sakurai et al., 2004). Untreated infections are highly lethal. C. perfringens is also 
involved in cases of food poisoning and antibiotic-associated diarrhoea with strains 
producing a powerful enterotoxin. When released from the spores, the toxin binds to its 
receptor, claudin, at the epithelial cell junctions of the gut wall, and forms pores through the 
cell membrane (Briggs et al., 2011). 
Tetanus is an infectious disease caused by C. tetani, and is usually associated with 
wound contamination. The bacteria produce the tetanus neurotoxin (TeNT), or 
tetanospasmin. The toxin targets the central nervous system by inhibiting neurotransmission, 
thereby causing spastic paralysis and potentially leading to death. It binds to cholinergic 
motorneurons and is subjected to retrograde axonal transport to the spinal cord cells. It 
blocks neurotransmission by cleaving synaptobrevin, a protein involved in vesicular 
secretion (Poulain et al., 2006). The structure of TeNT is closely related to that of the 
botulinum neurotoxin which is described in details in the following sections. 
 
1.2.2. Botulism 
Botulism 
Botulism has been known for hundreds of years and was first described in the early 
nineteenth century by Justinus Kerner after a food poisoning outbreak that followed the 
ingestion of blood sausages. The illness was then named after the Latin term for sausage 
(botulus). It is a rare but serious paralytic illness caused by the botulinum neurotoxins 
(BoNTs), which are produced by Clostridium botulinum and other species under anaerobic 
conditions (Hatheway, 1990). The toxins are large proteins that act on cholinergic 
neuromuscular junctions and are responsible for inhibition of the neurotransmission. 
Botulism infections are characterised by progressive flaccid paralysis, firstly of the facial 
muscle. In most severe cases it can spread towards the limbs and cause respiratory failure, 
thereby leading to death.  
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There are three main clinical instances of botulism (Sobel, 2005). As it was first 
described in cases of food poisoning, one of the recurrent forms is foodborne botulism. This 
often results from contaminated food in which C. botulinum spores have been allowed to 
germinate in anaerobic conditions. This typically occurs in home-made preserves and 
fermented uncooked dishes where microbiological safety measures were not respected. 
Clinical cases of wound botulism appear to be increasing (Yuan et al., 2011). It 
follows infection of wounds caused by penetrating injuries where C. botulinum spores can 
germinate and produce the toxin in the anaerobic environment caused by abscesses. It is 
almost exclusively occurring among injection drug users and is the main form of botulism 
occurring in the UK (Brett et al., 2004). 
Intestinal (infant) botulism is the most common form of the disease and results from 
the absorption of toxin produced in vivo after colonisation of the intestines by C. botulinum 
in infants aged less than 1 year (Sobel, 2005). The lack of a fully competing intestinal gut 
flora allows for the colonisation of the Clostridium species from the ingestion of spores. 
Similar cases, although very rare, may happen in adults with a weakened intestinal 
microflora. The fatality rate for infant botulism is very low (< 1%) for hospitalised patients. 
Other minor clinical cases of botulism include inhalation by laboratory worker 
handling the toxin, and a few cases of patients treated with botulinum neurotoxin injections 
for therapeutic purposes. Inhalation botulism is a cause of concern from the bioterrorism 
perspective since an aerosol form of the toxin could be a very efficient and lethal weapon. 
The lethal dose is predicted to be as little as 7 mg when ingested or 700 ng when inhaled for 
a 70 kg individual (Arnon et al., 2001). 
Different types of botulinum neurotoxins 
Analysis of the strains responsible for the various outbreaks of botulism across the 
twentieth century led to the realisation that more than one toxin type was involved. Indeed, 
antitoxin serum prepared from the first described outbreak failed to react against some of the 
new cases (Hatheway, 1990). As new immunologically distinct strains were observed they 
were labelled from serotypes A to G in order of chronology. Epidemiologic data and later in 
vitro characterisation showed that only serotypes A, B, E, and F can cause human botulism 
(Coffield et al., 1997), whereas serotypes C and D are prevalent in bird and cattle botulisms 
(Hedeland et al., 2011).  
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Classification 
C. botulinum strains are commonly divided in four different groups (groups I, II, III, 
and IV) based on physiologic characteristics (Collins and East, 1998). The toxins produced 
are ordered into seven serologically distinct groups (serotypes A to G), based on recognition 
by polyclonal serum (Hatheway, 1990). Further to C. botulinum, other Clostridia species 
have been shown to produce the botulinum neurotoxins, namely C. butyricum (BoNT/E), C. 
baratii (BoNT/F), and C. argentinense (BoNT/G) (Collins and East, 1998).  
Each BoNT is encoded by an approximately 3.8 kb gene, which is preceded by a non-
toxic non-hemagglutinin gene and several other genes that encode toxin-associated proteins 
(hemagglutinins HA-17, HA-33, HA-70, and p21, and/or p47) (Kubota et al., 1998). The 
gene coding for BoNT serotypes A, B, E, and F are located on the bacterial chromosome. 
Strains producing serotypes C and D have the BoNT gene encoded on a phage genome. The 
gene for BoNT/G is present on a plasmid (Hill et al., 2007). 
C. botulinum strains producing cross-serotype chimera toxins, more particularly the 
C/D and D/C phage-encoded serotypes, have been described (Moriishi et al., 1996). 
Moreover, several strains have been shown to produce multiple toxins. Multivalent strains, 
producing two toxins of serotypes A-B, B-A, A-F, and B-F, have been reported (Barash and 
Arnon, 2004).  
Analysis of sequences from the toxin genes available from the databases has 
highlighted the significant sequence diversity within the BoNT subtypes in six of the seven 
serotypes (Smith et al., 2005).  The authors showed that the subtypes could differ from 2.5% 
to 30% at the amino acid level, and that these differences had effects on the binding and 
neutralisation by monoclonal and polyclonal antibodies. Further study into the genome of 
other Clostridium strains may reveal the presence more subtypes, although it is not known 
how the sequence variation may affect the toxins biochemical properties (Hill et al., 2009). 
Botulinum neurotoxin complexes 
C. botulinum expresses the toxin with other non-toxic components and form large 
protein complexes called the progenitor toxin. The constitution of the progenitor toxin varies 
with serotype and can consist of a non-toxic non-hemagglutinin element (NTNH), and 
several hemagglutinin components (HA). The complex formed is not covalently linked but 
the protein interactions are stable at acidic pH. C. botulinum type A can produce several 
complexes known as LL (19S), L (16S) and M (12S) which range from 300 to 900 kDa 
resulting from the association of BoNT/A with several of the components mentioned above 
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(Sharma et al., 2003). The most abundant component is the HA33-35 hemagglutinin which 
is involved in oligosaccharide binding.  
The progenitor toxin was shown to increase oral toxicity of BoNT by protecting it 
from the acidic pH of the stomach and from intestinal proteases. Furthermore, it was 
suggested that the hemagglutinins may have a role in attachment to the intestine epithelial 
layer and thus supports internalisation of the toxin into the bloodstream (Inoue et al., 2003). 
The progenitor toxin is therefore particularly important in foodborne botulism. 
1.3. Botulinum neurotoxins 
Botulinum neurotoxins (BoNTs) are the most powerful neurotoxins discovered to date 
and act by blocking the synaptic transmission at peripheral cholinergic nerve terminals. The 
seven serotypes of BoNT (A-G) are all expressed as single chain polypeptides of 
approximately 150 kDa. The toxins are later cleaved by clostridial or host proteases to its 
active form, a di-chain molecule that follows the A-B bacterial toxin motif with intracellular 
targets. The N-terminal catalytic light chain (LC), a zinc endopeptidase, is then linked by a 
single disulphide bridge to the heavy chain which is composed of the binding (Hc) and 
translocation (Hn) domains (Figure 1.2), both approximately 50 kDa (Turton et al., 2002). 
 
Figure 1.2. Domain organisation of botulinum neurotoxins. Each domain is 
approximately 50 kDa. LC (yellow) is an N-terminal zinc-endopeptidase domain linked to 
the heavy chain by a single disulphide bridge (marked). The translocation domain (Hn, 
green) is at the N-terminal of the heavy chain while the binding domain (Hc, blue) is at the 
C-terminus. 
 
BoNTs bind specifically to the nerve terminals and are endocytosed into a vesicle 
where the acidic environment provokes a conformational change. This allows translocation 
of the BoNT catalytic component across the endosomal membrane and into the cytosol. The 
protease domain is then free to cleave one of the soluble N-ethyl-maleimide-sensitive fusion 
protein attachment receptor (SNARE) proteins (Figure 1.3). Impairing the function of the 
SNARE complex causes inhibition of neurotransmission, leading to flaccid paralysis and 
potentially death (Montal, 2010).  
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1.3.1. SNARE complex and exocytosis 
The N-ethyl-maleimide-sensitive fusion protein attachment receptor (SNARE) 
proteins form a complex essential in the docking and fusion of synaptic vesicle (Südhof et 
al., 2009). Each BoNT targets one of the SNARE proteins, with BoNT/A, /C and /E cleaving 
the synaptosomal-associated membrane protein of 25 kDa (SNAP-25); serotypes B, D, F and 
G are specific for the vesicle-associated membrane protein synaptobrevin (VAMP); syntaxin 
is cleaved only by BoNT/C (Schiavo et al., 2000). It should also be added that BoNTs only 
cleave the SNARE proteins in their free form, before assembly of the complex. The SNARE 
complex was shown to be resistant to the proteolytic activity of the toxins as the recognition 
sites are made inaccessible (Hayashi et al., 1994). 
 
Figure 1.3. Mode of action of botulinum neurotoxins. Reproduced from Turton et al., 
2002. A four-step mechanism, (1) cell binding, (2) endocytosis, (3) translocation of LC in 
the cytosol, (4) LC cleavage of one of the SNARE proteins. (Ach, acetylcholine; AChR, 
acetylcholine receptor). 
 
In neuronal exocytosis, syntaxin and synaptobrevin are anchored by their C-terminal 
domains in the cell and vesicular membranes, respectively. SNAP-25 is attached to the 
plasma membrane via several cysteine-linked palmitoyl chains. The SNARE proteins are 
usually divided into two broad categories, v-SNAREs and t-SNAREs after their cellular 
location, i.e. transport vesicles and target membranes respectively (Brünger, 2005). 
The complex formed by the SNARE proteins folds into a four-α-helix bundle, where 
one α-helix is contributed by syntaxin-1 (residues 183-256), one α-helix by synaptobrevin 
10 
 
(residues 30-85) and SNAP-25 contributes two α-helices labelled sn1 (residues 7-83) and 
sn2 (residues 141-204) corresponding to the N- and C-terminal helices respectively (Sutton 
et al., 1998) (Figure 1.4). These helical domains correspond to the SNARE motif, a 
structural feature common to all SNARE proteins. Furthermore, the SNARE complex is 
stabilised together by the hydrophobic core of the helices that expose either a central 
glutamine (Q) or an arginine (R) residue. This led to the reclassification of SNARE proteins 
into Q-SNAREs, with syntaxin and SNAP-25 providing Q-containing coils, and R-SNAREs, 
with synaptobrevin presenting the R-containing helix (Fasshauer et al., 1998). The four 
helices are believed to interlock with a zippering action in the N- to C- terminal direction, 
thus bringing into juxtaposition the synaptic vesicle surface and the neuronal lipid bilayers. 
This action is mediated by the force applied by syntaxin and synaptobrevin on their 
transmembrane regions (Südhof et al., 2009). 
 
 
Figure 1.4. Crystal structure of a SNARE complex involved in synaptic exocytosis. 
(PDB 1SFC, Sutton et al., 1998). Ribbon diagram representation of the four-helix bundle 
complex with VAMP in purple, syntaxin in orange and SNAP-25 (sn1 in light blue; sn2 in 
dark blue). 
 
Noticeably, SNARE proteins are not only involved in all neurotransmission events, 
but it is also broadly accepted that they are essential in universally mediating membrane 
fusion processes. The SNARE proteins have ubiquitously expressed homologs in eukaryotic 
cells and tissues, which are implicated in various cellular processes, including cell growth, 
membrane repair, cytokinesis, and cellular secretion (Jahn and Scheller, 2006). 
1.3.2. Crystal structure of botulinum neurotoxins 
The first crystal structure of a full length botulinum neurotoxin to be determined what 
that of serotype A (Lacy et al., 1998). It presented a linear arrangement of the three 
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functional domains (catalytic, translocation and binding) with the translocation domain 
holding a central location (Figure 1.5A). Swaminathan and Eswaramoorthy (2000) then 
described the high resolution structure (1.8Å) of BoNT/B which confirmed the modular 
arrangement of the toxin’s structure. The two serotypes share 39 % identity (and 56 % 
similarity; Lacy and Stevens, 1999) and present common structural features. This is 
illustrated by the root mean square (rms) deviations between the binding, translocation, and 
catalytic domains of the superposed BoNT/A and BoNT/B which are 1.43, 1.56 and 1.43 Å, 
respectively (Swaminathan and Eswaramoorthy, 2000). 
Structure of BoNT serotypes A and B 
The catalytic domain (LC), a zinc protease of the thermolysin family, is a mixed 
bundle of -helices and -strands (Figure 1.5A). The translocation domain (Hn) is mostly 
helical with two long helices forming a coiled-coil fold. Part of Hn is also a large and 
unstructured loop region which had not been identified by primary sequence analysis. This 
region corresponds to approximately 100 residues on the N-terminus of Hn and include the 
cysteine bridge with LC. The crystal structure showed this loop is unique to BoNT in the 
way it surrounds and closely associates with LC, also preventing access to the catalytic cleft. 
It was termed “the belt” region (Lacy et al., 1998). The binding domain (Hc) has limited 
interaction with Hn as it is angled away from it. Hc consists of two subdomains, HcN and 
HcC. HcN consists of 14 -strands in a jellyroll motif, a fold usually associated with lectins, a 
class of sugar-binding proteins (Drickamer, 1988). The HcC domain is composed of loops 
and -strands forming a -trefoil fold which is the main region involved in the domain’s 
binding function.  
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Figure 1.5. Crystal structure of botulinum neurotoxins. (A) Crystal structure of BoNT/A 
(PDB 3BTA, Lacy et al., 1998). BoNT/A. Ribbon diagram representation with LC in cyan; 
Hn in blue; “belt” in pink, Hc in grey (HcN and HcC, light and dark respectively). Zinc ion 
shown as an orange sphere. (B) Crystal structure of BoNT/E (PDB 3FFZ, Kumaran et al., 
2009). Ribbon diagram representation with same colour as in (A). 
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Structure of BoNT/E 
The level of sequence homology between the BoNTs (approximately 35%) would 
predict a conserved structure and domain organisation over the seven serotypes (Lacy and 
Stevens, 1999). However, structural analysis on BoNT/E led to the discovery of an 
alternative conformation. Fischer et al. (2008a) first observed the different molecular 
architecture of the holotoxin serotype E by single particle electron microscopy. The low 
resolution images showed a more globular fold and a likely rearrangement of the domains 
which was recently confirmed by the determination of the crystal structure by Kumaran et 
al. (2009) (Figure 1.5B). Interestingly, each individual domain has conserved its typical fold 
with the rmsd between the catalytic, translocation, and binding domains of the superposed E 
and B serotypes corresponding to 1.4 Å, 1.4 Å, and 1.9 Å, respectively. The main 
differences appear in unstructured loop regions and the belt which shows the highest 
sequence variation. In the BoNT/E conformation, Hc is located on the same side of the 
translocation domain as LC and thus this implies new inter-domain interactions, particularly 
between Hc and both Hn and LC. 
Noticeably, although not as potent as BoNT/A, BoNT/E has been shown to act faster 
in the intoxication process with emphasis on the rate of translocation (Keller et al., 2004; 
Wang et al., 2008). Considering the unique arrangement of BoNT/E, Kumaran et al. (2009) 
suggested that LC was in a preferential position in relation to Hn which favoured the 
translocation process.  
Overall, the crystal structure determination of the three holotoxins indicates that the 
general BoNT fold may be more diverse than expected. Furthermore, the modular aspect of 
the botulinum neurotoxins has allowed focusing on individual domains and their structural 
studies have provided essential information in the comprehension of the toxin’s mode of 
action. These functions are described in details in the following section.  
1.3.3. Mode of action 
The botulinum neurotoxin is a single molecule capable of multiple functions to reach 
its aim, i.e. inhibition of neurosecretion. It first recognises and binds to cholinergic motor 
neurons with high affinity and specificity, and achieves entry into the cells where it can 
release a potent enzyme (Schiavo et al., 2002). A step-by-step analysis allows a better 
understanding of the BoNT design. 
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Receptor-binding 
The early findings on the binding mode of botulinum toxins to neuronal membranes 
led to the hypothesis of a double receptor formed by both a ganglioside and a protein 
component (Montecucco, 1986). 
The neuron cell surface is particularly rich in gangliosides, a group of complex 
glycosphingolipids with poly-sialic acid moieties. Initial studies identified members of the 
G1b class as likely receptors, with GT1b and GD1b, tri- and di-sialo gangliosides 
respectively, presenting the highest affinities for BoNT binding (Montecucco, 1986). Kozaki 
et al. (1998) confirmed the importance of GT1b by inhibiting BoNT/A and /B activity on rat 
brain synaptosomes using a monoclonal antibody specific to this ganglioside. In an 
alternative approach, Yowler et al. (2002) demonstrated that gangliosides were essential for 
the binding of BoNT/A in ganglioside-deficient murine or human neuronal cells. The 
preferred ganglioside receptors for all of the serotypes have been identified. GT1b is 
recognised by all types but D, while GD1a and GD1b bind to most of the same serotypes 
with various affinities (Montal, 2010). Interestingly, BoNT/D presents unique neuron 
binding properties. While serotype D was first shown to lack the classical binding motif 
common to other BoNTs (Rummel et al., 2004), it was recently demonstrated that it still has 
the ability to recognise b-series gangliosides, including GT1b and GD1b, via a different 
binding mode (Kroken et al., 2011). 
Although ganglioside binding is essential for the entry of BoNT in neurons, it is not 
sufficient. BoNTs exploit the synaptic vesicle recycling pathway further by also targeting 
receptor proteins at the surface of the presynaptic membrane (Montecucco, 1986). 
Synaptotagmin (Syt) was the first protein described to be involved in BoNT recognition, and 
more particularly of serotype B (Nishiki et al., 1996). Synaptotagmins (Syt) are synaptic and 
secretory vesicle proteins that contain a single transmembrane region, and two C-terminal 
calcium-binding domains. Upon calcium binding, Syt triggers the SNARE fusion machinery 
in the events leading to exocytosis (Pang and Südhof, 2010). The protein receptor for 
BoNT/A was later identified as the synaptic vesicle protein 2 (SV2) by Dong et al. (2006). 
SV2 is a membrane glycoprotein that mediates calcium-stimulated transmitter release in 
neuronal and endocrine cells. Indeed, SV2 regulates the expression and trafficking of 
synaptotagmin in synapses (Nowack et al., 2010). There seem to be a correlation between 
the sequence homology among the BoNT binding domains and their specific protein 
receptors, with serotypes A, E and F recognising SV2 (glycosylated in the case of E and F), 
while types B and G bind to synaptotagmins (I and II) (Binz and Rummel, 2009). The 
receptor for serotype C is not yet discovered while the role of SV2 in the binding of BoNT/D 
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remains unclear (Kroken et al., 2011). Expectedly, the region within the protein receptors 
that is responsible for binding to BoNT is located in the vesicular lumen. For synaptotagmin, 
it was confirmed to be in the N-terminal ectodomain region for both serotypes B and G, in 
the segment which is closest to the membrane (Rummel et al., 2007). Two crystal structures 
were simultaneously published of the BoNT/B binding domain in complex with a 
synaptotagmin II fragment (Chai et al., 2006; Jin et al., 2006). Both structures showed the 
SytII peptide adopting a -helical conformation when bound to the HcC domain of the toxin 
(Figure 1.6).  
 
Figure 1.6. Model of the dual-receptor complex for botulinum neurotoxins binding to 
neuronal cells. Crystal structure of Hc/A in complex with GT1b (PDB 2VU9, Stenmark et 
al., 2008) and crystal structure of Hc/B in complex with SytII (PDB 2NP0, Chai et al., 2006) 
were superposed. Only Hc/B is shown as a ribbon diagram representation in grey (HcN and 
HcC, light and dark respectively) with SytII in red, and GT1b in brown stick representation. 
 
The binding domain of BoNTs consists of two subdomains, N-terminal (HcN) and C-
terminal (HcC) which are connected by a short helix (Figures 1.5, 1.6). The binding domains 
of all botulinum toxins share a similar fold (Swaminathan, 2011) and have been observed in 
the crystal structures of BoNT/A, /B and /E holotoxins as well as in the structures of Hc on 
its own for serotypes C (Karalewitz et al., 2010), D (Strotmeier et al., 2010; Kroken et al., 
2011), F (Fu et al., 2009) and G (Schmitt et al., 2010; Stenmark et al., 2010). The structure 
of Hc/A in complex with the GT1b ganglioside (Stenmark et al., 2008) complemented with 
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the structures of Hc/B bound to the SytII protein receptor (Chai et al., 2006; Jin et al., 2006) 
have provided essential information in understanding the detailed binding mechanism of 
BoNT (Figure 1.6). The two sites involved are located solely on HcC. The first site is a 
hydrophobic cavity constituted of a conserved lactose-binding motif (H…SXWY…G; 
Rummel et al., 2004). In particular, residues Trp1266 and Tyr1267 of BoNT/A were shown 
to be directly in contact with GT1b. These two residues are highly conserved (except in 
BoNT/D, Kroken et al., 2011) therefore all serotypes are likely to share the same ganglioside 
binding mechanism (Stenmark et al., 2008). The protein receptor binding region is separated 
from the ganglioside site by a single loop. It consists of a hydrophobic pocket organised by 
two -strands which are part of the -trefoil fold. In both structures of the Hc/B – SytII 
complex, SytII residues 45 to 59 in one case (Chai et al., 2006) and 47 to 58 in the second 
(Jin et al., 2006) presented a -helical conformation (Figure 1.6) while the rest of the 
peptide was not observed, and thus likely unstructured. With the difference in specificity 
observed among BoNTs, it is likely that this mode of protein interaction will vary from one 
serotype to another. However evidences suggest that the second binding site would 
correspond to the same, structurally conserved, hydrophobic pocket (Swaminathan, 2011). 
Interestingly, comparison of the structures of Hc with and without binding partners shows no 
visible conformational changes upon ligand binding. It demonstrates the rigidity of the -
trefoil motif and shows that the two binding sites, although in close proximity, do not 
interact with each other.  
Despite the amount of structural information available, the role of HcN in the 
mechanism of BoNT intoxication remains unclear. Its jelly-roll fold is typical of lectins and 
other proteins involved in sugar-binding and protein interactions. A recent study showed 
HcN could bind to sphingomyelin-enriched membrane microdomains (Muraro et al., 2009). 
More particularly, HcN could interact directly with phosphatidylinositol phosphates (PIP) 
which are molecules involved in vesicular traffic events. A potential binding site was 
identified from sequence comparison with PIP-binding protein. However this site would be 
located on the other side of Hc compared to the gangliosides and synaptotagmin binding 
region. Noticeably, PIP has been shown to promote the diphtheria toxin pore formation 
inside the membrane (Donovan et al., 1982). Further work is necessary to understand the 
role PIP may have in the mechanism of BoNT either in terms of cell binding or mediation of 
membrane insertion (Muraro et al., 2009). 
Translocation 
The only structural information available on the translocation domain comes from the 
crystal structures of the three holotoxins described previously (Swaminathan, 2011) (Figure 
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1.7). The most striking feature of Hn consists in a pair of long, anti-parallel and 
amphipathic,-helices (approximately 100 Å in length) forming a coiled-coil fold. On both 
sides of these helices a shorter -helix can be observed and packs in parallel to them. An 
unstructured region, traditionally associated with Hn from sequence analysis, forms an 
unusual loop which wraps around LC and was thus termed the “belt” (Lacy et al., 1998). Hn 
shows a high sequence conservation among all the serotypes except for the belt region (Lacy 
and Stevens, 1999). 
 
Figure 1.7. Structure of the botulinum neurotoxin translocation domain (Hn). Ribbon 
diagram representation of Hn in the crystal structures of BoNT/A (in dark blue, PDB 3BTA, 
Lacy et al., 1998), BoNT/B (in marine blue, PDB 1EPW, Swaminathan and Eswaramoorthy, 
2000) and BoNT/E (in light blue, PDB 3FFZ, Kumaran et al., 2009).  
 
The translocation domain of BoNT is structurally distinct from the other pore-forming 
toxins such as the diphtheria toxin and pseudomonas exotoxin that share a common 
structural motif (Parker and Pattus, 1993) which is not visible in the BoNT structures. The 
pore-formation mechanism necessary for translocation in BoNT intoxication remains 
elusive. The nature of the channel itself is not well understood and may involve a multimeric 
assembly of the toxin. A study by Schmid et al. (1993) showed a low-resolution electron 
micrograph of BoNT⁄B interaction with reconstituted vesicles in which it is suggested that 
the toxin forms a tetrameric channel. Further structural evidence has yet to confirm this 
analysis.  
A channel is nevertheless formed and is expected to be approximately 15 Å wide 
(Koriazova and Montal, 2003) and thus not large enough to accommodate a translocating 
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light chain in its integral form. In order to explain the translocation process, Montal and 
collaborators have developed a single-molecule detection assay (Fischer and Montal 2007b). 
Their analysis with BoNT/A and a derivative molecule composed of LC and Hn have 
allowed determination of the minimum conditions required for translocation and deducted a 
step-by-step mechanism (Fischer et al., 2008b). The conditions offered by the vesicle are as 
follow: (i) a pH gradient, going from a low endosomal pH (5.0) to a neutral cytoplasmic one; 
(ii) a redox gradient from an oxidising environment inside the endosome into a reducing 
cytosol; (iii) a transmembrane potential. The low pH in the endosome incites a 
conformational change which is likely to involve membrane insertion of Hn and the 
unfolding of LC (Koriazova and Montal, 2003). At this stage the single disulphide bond 
linking Hn to LC plays an essential role (Fischer and Montal 2007a). It stays intact up to the 
complete translocation of LC across to the intracellular milieu. Only then does the reducing 
environment allow release of LC in the cytosol. Interestingly the cysteine bridge is located at 
the C-terminal end of LC in all the serotypes. The unfolding and subsequent refolding of LC 
inside the cell is not fully understood but is essential to the intoxication process. A similar 
phenomenon has been observed in other bacterial protein toxins with translocation activity. 
The recent crystal structure of the anthrax protective antigen oligomers in complex with an 
unfolded lethal factor intermediate provided a unique insight into the mechanism of 
translocation-coupled protein unfolding (Feld et al., 2010). There is no direct evidence 
available for the refolding mechanism of LC apart that it is active on its SNARE protein 
substrate once released and thus must be in its original conformation. The refolding is likely 
to involve intracellular chaperone proteins such that were reported for the diphtheria (Ratts 
et al., 2003) and the ADP-ribosylating C. botulinum C2 toxins (Haug et al., 2003). 
While each domain of the botulinum neurotoxin has its own specific function, the 
intoxication process as a whole relies on complex interactions between the three functional 
elements so that the potent catalytic LC can reach its final intracellular destination. 
Proteolysis  
Once inside the cell the catalytic light chain is free to find its SNARE substrate. The 
location of the SNARE proteins differs, with VAMP attached to the vesicular membrane 
while SNAP-25 and Syntaxin are on the plasma membrane (Südhof et al., 2009). 
Accordingly the various BoNT serotypes have adapted different means to access its target. A 
study on the cellular localisation of LC was performed with recombinant GFP-fusion 
molecules. This demonstrated the ability of LC/A to reside along SNAP-25 at the plasma 
membrane whereas LC/E was distributed in the cytoplasm (Fernandez-Salas et al., 2004). 
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Figure 1.8. Structure of the botulinum neurotoxin catalytic domain (LC). Ribbon 
representation of LC of all serotypes; LC/A (in dark green, PDB 1XTF, Breidenbach and 
Brünger, 2004), /B (in light blue, PDB 2ETF, Swaminathan and Eswaramoorthy, 
unpublished), LC/C (in pink, PDB 2QN0, Jin et al., 2007), /D (in orange, PDB 2FPQ, Arndt 
et al., 2006), /E (in purple, Agarwal et al., 2004), /F (in grey, Agarwal et al., 2005) and /G 
(in slate blue, PDB 3FFZ, Arndt et al., 2005).  
 
The catalytic light chain is a zinc protease with similarities to thermolysin (Lacy et al., 
1998). This domain has been particularly well characterised biochemically and structurally. 
Indeed the crystal structures of LC from all serotypes have been determined and are shown 
in figure 1.8 (Agarwal et al., 2004, 2005b; Segelke et al., 2004; Arndt et al., 2005, 2006; Jin 
et al., 2007). LC is constituted of a mixture of -helices and -strands and its individual fold 
is similar across all serotypes (which share approximately 35 % sequence identity, Lacy and 
Stevens, 1999), and also has the same overall conformation as the full length toxin. The 
active site is buried approximately 20 Å deep inside an open pocket with negative 
electrostatic potential. The zinc ion is coordinated by two histidines and one glutamate. The 
tetrahedral coordination, which is classical of a HEXXH zinc-binding motif seen in other 
proteases of the same family, is completed by a water molecule linked to the conserved 
glutamate of the motif and acting as the nucleophilic base. The residues involved in the 
catalytic pocket are particularly well conserved (Lacy and Stevens, 1999) and several 
mutation studies have highlighted their importance for the catalytic activity (Binz et al., 
2002; Agarwal et al., 2005a). Furthermore, the structural studies demonstrated that the zinc 
ion was not involved in the site’s architecture and thus only had a functional role 
(Breidenbach and Brünger, 2004).  
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Figure 1.9. Schematic structure of SNARE proteins with BoNT cleavage sites. 
Schematic structures of SNAP-25, syntaxin, and VAMP2 and their respective cleavage sites 
by BoNTs (Schiavo et al., 2000). The -helical SNARE motif is shown in grey, the 
transmembrane domains in vertical stripes, region of SNAP-25 with palmitoylated cysteines 
in dots (responsible for membrane anchorage).  
 
The botulinum neurotoxins are remarkably specific proteases. Except for serotype C 
which can cleave both SNAP-25 and syntaxin, each of the BoNTs only targets one of the 
SNARE proteins. Interestingly, each serotype cleaves its substrate at a different site (Figure 
1.9). Early experimental evidence suggested the BoNT-SNARE interaction was unusual in 
that a long substrate was required for efficient proteolysis. Rossetto et al. (1994) put this 
hypothesis in evidence by identifying two sites essential for the enzymatic activity in the 
SNARE proteins. The first site was the target peptide bond. The second site was a region 
located further on the N-terminal side which was part of the -helical SNARE motif and was 
involved in substrate recognition. The information provided by the crystal structure of 
enzyme-substrate complexes was essential in identifying the full extent of this interaction. 
Breidenbach and Brünger (2004) could solve the structure of the complex my mutating two 
key residues of the catalytic site. Thus, although it could not provide detailed information on 
the catalytic site, it demonstrated a complex binding mechanism with several exosites 
located around LC and away from the catalytic sites (Figure 1.10A). While SNAP-25 is 
known to be unstructured in its free state (Fasshauer et al., 1997) and have a -helical fold 
when in complex with its SNARE partners (Figure 1.4), it is mainly unstructured when 
bound to LC/A, with the exception of its N-terminus (i.e. residues 147-167) which binds at 
the -exosite. SNAP-25 wraps around a crevice on LC/A’s surface which is stabilised on its 
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C-terminus by a short -strand forming the -exosite. Binding of SNAP-25 causes the 
movement of flexible loops in proximity to the catalytic site. 
 
Figure 1.10. SNARE interaction with LC. (A) Crystal structure of LC/A in complex with 
SNAP-25 (sn2 segment, residues 146-204; PDB 1XTG, Breidenbach and Brünger, 2004). 
Cartoon diagram representation with LC/A in cyan and SNAP-25 in red. (B) Crystal 
structure of LC/F in complex with a VAMP peptide inhibitor (residues 22-58/Q58D-Cys 
146-204; PDB 3FIE, Agarwal et al., 2009). Ribbon diagram representation with LC/F in 
blue and VAMP in purple. Sites important for substrate binding are indicated. 
 
The crystal structure of LC/A in complex with a short peptide inhibitor (QRATKM) 
allowed for a clear analysis of substrate binding at the catalytic site (Kumaran et al., 2008). 
Furthermore, it confirmed the importance of several residues of the catalytic pocket that are 
not involved in the zinc coordination but are conserved among all BoNT serotypes (Binz et 
al., 2002). Indeed, residues P1 (Gln197) and P1’ (Arg198) present strong hydrogen bonds 
with Tyr366 and Arg363, respectively (Figure 1.11). A catalytic mechanism was deduced 
from the crystal structure of the complexes and mutational studies available. Residues Tyr 
and Arg help position and stabilise the substrate in the active site. The nucleophilic water 
attacks the carbonyl carbon of the scissile bond. A transition intermediate is formed that may 
be stabilised by Zn
2+
 and the tyrosine. Residue Glu 224 (LC/A) absorbs the transferred 
proton and mediates the formation of the amino group (Swaminathan, 2011).  
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Figure 1.11. LC/A interaction with a SNAP-25 peptide inhibitor. Crystal structure of 
LC/A in complex with the SNAP-25 peptide QRATKM (PDB 3DDA, Kumaran et al., 
2008). Cartoon diagram representation of LC/A in cyan with residues involved in the 
catalytic site shown in stick and ball representation, QRATKM in red. Zinc ion shown as an 
orange sphere. 
 
The mechanism of substrate binding and catalysis are expected to be the same for all 
serotypes. Extensive mutagenesis work on synaptobrevin allowed the identification of the 
regions involved in substrate binding for cleavage by BoNTs located on both sides of the 
scissile bond (Chen et al., 2008; Sikorra et al., 2008). The crystal structure of LC/F in 
complex with a VAMP-based peptide inhibitor (Agarwal et al., 2009) confirmed this 
common mode of an extended substrate binding (Figure 5.10B). Although only a limited 
part of the peptide was visible, it clearly put in evidence several exosites that were different 
from the ones observed in the LC/A – SNAP-25 complex. Therefore the diversity of the 
exosites dictates the specificity of each serotype for its substrate. 
Interestingly, the period of activity of BoNT is different for each serotype and has 
been linked to the intracellular longevity of the protease domain (Forlan et al., 2003). The 
study showed that while BoNT/A can be active for several months, BoNT/E only lasts a few 
days. The mechanism underlying these differences and the spectacular longevity of BoNT/A 
is not well understood. It likely involves several factors that allow LC/A to be resistant to 
intracellular degradation pathways (Montal, 2010). The intracellular localisation of LC/A on 
the plasma membrane was proposed as a potential explanation for its longevity (Fernandez-
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Salas et al., 2004). Two sites involved in the LC/A interaction with the membrane were 
identified. A recent study confirmed one of these sites, a di-leucine on the C-terminus of 
LC/A, to be essential in the resistance of LC/A to degradation (Wang et al., 2011). 
Understanding the longevity of LC/A offers interesting prospect for protein engineering on 
BoNT in order to optimise its therapeutic properties. 
Functional role of the belt 
One of the most interesting observations from the crystal structures of the holotoxins 
is the belt, an extended loop of Hn that wraps around LC and is common to all serotypes 
(Montal, 2010). The belt is the primary interface between LC and Hn and thus is expected to 
play a key role in the intoxication process. This role is however not well understood. The 
most interesting observation was made after determination of the LC/A – SNAP-25 crystal 
structure (Breidenbach and Brünger, 2004), which is that the belt in BoNT/A actually 
occupies the same crevice as SNAP-25 at the surface of LC (Figure 1.12).  
 
Figure 1.12. Superposition of the belt region with SNAP25. Superposition of the crystal 
structures of LC/A in complex with SNAP-25 (PDB 1XTG, Breidenbach and Brünger, 
2004), BoNT/A (PDB 3BTA, Lacy et al., 1998) and BoNT/E (PDB 3FFZ, Kumaran et al., 
2009). Surface diagram representation of LC/A in cyan, ribbon diagram representation of 
SNAP-25 in red, .BoNT/A belt (pink) and BoNT/E belt (blue). 
 
The belt thus seems to play a role of pseudo-substrate and proteolysis inhibitor by 
preventing binding of the SNARE substrate when the toxin is in its di-chain form. The belt 
lacks the scissile bond and thus is not cleaved by LC/A (Brünger et al., 2007). Information 
provided by the crystal structures of BoNT/B and LC/F-VAMP show that a similar 
relationship exist for the other serotypes (Swaminathan, 2011). Further functional roles for 
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the belt have also been investigated which particularly look at the translocation process. 
Brünger et al. (2007) proposed a role as a chaperone for protein-assisted unfolding of the LC 
protease. In another study, it was shown that lowering the pH neutralised acidic residues of 
the belt region and thus eliminated repulsive electrostatic interactions between Hn and the 
membrane, consequently allowing its penetration into the membrane (Galloux et al., 2008). 
Further work is necessary to fully determine the role of the belt in the translocation and 
whether it helps initiates or control this process. 
1.3.4. Inhibition of the botulinum neurotoxins 
The botulinum neurotoxins are among the most poisonous protein toxins and as such 
have been feared for their use in biologic warfare and terrorism. Despite this threat there is 
still no efficient drug available for treating or preventing the potentially lethal botulism. 
So far, a pentavalent toxoid vaccine composed of formalin inactivated botulinum 
neurotoxin has been used as the botulinum neurotoxin vaccine (Smith, 2009). The 
decreasing immunogenicity of the toxoid vaccine and the recent production of non-toxic 
subunit immunogens have led to the development of novel botulinum vaccines that are based 
on recombinant fragments of the heavy chain. More particularly a recombinant botulinum 
vaccine based on the cell binding domain (Hc) is being tested in human clinical trials (Staats 
et al., 2011). 
An alternative approach is to find small molecule inhibitors able to prevent or stop 
intoxication. The recent advances in understanding the BoNT mechanism of action, and the 
determination of the crystal structures described previously, have allowed the development 
of molecules targeting specifically one of the BoNT functions: cell binding, translocation or 
proteolysis. While Hc has been the main target for antibody recognition, it also represents a 
potential target for small molecule inhibition. For example, Eswaramoorthy et al. (2001) 
presented crystallographic evidence for the binding of doxorubicin (a DNA intercalator) at 
the ganglioside binding site. More recently, toosendanin, a natural molecule found in the 
bark of the tree Melia toosendan has been reported to block the translocation channel in a 
single-current assay (Fisher et al., 2009). Finally, inhibitors of the catalytic domain have 
been investigated. Early studies focused on heavy-metal chelators with cell permeability 
ability, including hydroxamate zinc-binding molecules (Thompson et al., 2011). However 
such molecule may interfere with other host proteases (Dickerson et al., 2006). Peptide and 
peptidomimetics based on the SNARE substrates were showed to bind efficiently to LC, 
particularly the heptapeptide QRATKML. Thus smaller peptides and derivatives are being 
investigated (Zuniga et al., 2010). Although they are potent ligands, these molecules are 
likely to be limited by their serotype specificity. The crystal structures of all LCs should help 
25 
 
the development on future generations of potent inhibitors that are active on all BoNT 
serotypes. 
 
1.4. Biological and pharmaceutical applications of the botulinum neurotoxins 
1.4.1. Current clinical applications 
Despite their high toxicity, various preparations of BoNTs are available commercially 
for the treatment of diseases and conditions involving neuromuscular or autonomic neuronal 
transmission where at safe doses they can be used as therapeutic and cosmetic agents. 
The first clinical use of a botulinum neurotoxin was for the treatment of strabismus in 
humans, where purified BoNT/A was injected (Scott, 1980). Following this first step, 
BoNT/A was used for the treatment of dystonia, a neurological movement disorder. The 
Food and Drug Administration (US) approved BoNT/A as a drug for these specific disorders 
in 1989. Since then, it has received approval for a growing number of diseases, including 
cervical dystonia, hyperhidrosis and more famously, for glabellar wrinkles. Its clinical use 
has been extended to over 100 conditions (Barnes et al., 2007). Beyond its effect in 
neuromuscular pathologies, the toxin has also shown interesting analgesic activities. 
Although the underlying mechanism is not understood, it has led to the utilisation of the 
toxin for various pain-related conditions such as myofascial pain syndrome and migraine 
(Moore et al., 2007). The mode of delivery consists simply in direct and localised 
intramuscular injection of a saline solution containing the diluted toxin. This allows for very 
little side effects, although some individuals may develop an immune response after repeated 
injections. A single injection of BoNT/A is usually effective for 3-6 months (Barnes et al., 
2007).  
BoNT/A and /B are the most potent serotypes and have been the only ones approved 
for clinical use until now. Several formulations are commercially available in various parts 
of the world, with BOTOX® (Allergan Inc., US) and DYSPORT® (Ipsen Ltd, UK) 
corresponding to serotype A, while BoNT/B is distributed as MYOBLOC® and 
NEUROBLOC® in the US and Europe respectively (Solstice Neuroscience Inc., Ireland). 
Serotypes C and F have also been investigated for clinical applications (Eleopra et al., 1997; 
Mezaki, 1995) but have not been commercialised.  
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1.4.2. Engineering botulinum neurotoxins 
The botulinum neurotoxins are powerful molecule with already a wide range of 
therapeutic applications. This is the result of a single molecule with three domains 
responsible for specific functions i.e. cell binding, translocation inside the cells, and 
cleavage of intracellular substrate. The modular arrangement of BoNT and the natural range 
of biochemical properties provided by the seven serotypes have made it a molecule of choice 
for protein engineering. Several approaches have been considered which consist in 
enhancing the toxin’s capabilities or retargeting one of its functions, thus leading to novel 
BoNT-derived applications. 
Enhancing the botulinum neurotoxin activity 
BoNT targets cholinergic motor neurons and its substrate is specifically involved in 
neuronal transmission, which limits the effect of the toxin to neuronal targets. SNARE-
mediated secretion is a universal mechanism in eukaryotic cells (Südhof et al., 2009), it 
however involves various SNARE protein homologs which are not all susceptible to BoNT 
cleavage (Schiavo et al., 2000). Therefore, attempts to retarget BoNT to non-neuronal 
targets may require a modification of its enzymatic specificity. Chen and Barbieri (2006) 
designed a BoNT derivative that could cleave both SNAP-25 and SNAP-23. SNAP-23 is a 
non-neuronal isoform that is involved in the secretion process of various cell types, thus 
mediating the release of mucus, antibodies and many hormones (Jahn and Scheller, 2006). 
The novel design consisted in a single mutation of the BoNT/E light chain (K224D) (Figure 
1.13A). This engineered molecule was able to cleave intracellular SNAP-23 when delivered 
to cultured human epithelial cells, consequently inhibiting the secretion of mucin and IL-8. 
This study illustrated the potential for extending the therapeutic application of BoNT to a 
wider range of hypersecretory disorders. 
One of the most striking differences between the serotypes is in the speed and 
duration of intoxication (Forlan et al., 2003). For example, although both BoNT/A and /E 
cleave SNAP-25, serotype E was shown to block neurotransmission faster and more 
potently. Wang et al. (2008) first identified the domains of BoNT responsible for these 
properties by engineering chimera proteins consisting of mixed fragments from serotypes A 
and E. They demonstrated that the speed of translocation was dependent on Hn while the 
potency and duration of toxicity came from LC. The same group later managed to design a 
novel molecule that combined the resistance of LC/A with the potency of LC/E (Wang et al., 
2011). The engineered protein consisted of LC/E fused to the amino terminus of a modified 
enzymatically inactive BoNT/A (Figure 1.13B). The novel molecule was able to target 
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neurons and demonstrated a potent and persistent cleavage of SNAP-25, thus providing an 
optimised BoNT derivative. 
 
Figure 1.13. Engineering of BoNT for enhanced activity. (A) Domain organisation of 
modified BoNT/E(K224D) able to cleave both SNAP-25 and SNAP-23 (Chen and Barbieri 
2006). (B) Domain organisation of engineered (1, 2) BoNT/A-/E chimeras (Wang et al., 
2008); and (3) a novel construct combining an inactive BoNT/A (designated here as 
“LC/A(0)”) with LC/E and that have the potency of LC/E and the longevity of LC/A (Wang 
et al., 2011).  
 
The botulinum neurotoxin as a protein transporter 
The first investigation in the use of BoNT to transport a cargo protein different from 
LC into the cytosol came from the need for intracellular BoNT inhibitors. Goodnough et al. 
(2002) designed a delivery machinery which consisted in the heavy chain of BoNT/A 
(HC/A) covalently attached to a chimeric glycoprotein with a 10-kDa amino dextran (Figure 
1.14A). Thus HC/A served for specific neuronal cell targeting and internalisation of the 
complex while the dextran represented an inert carrier of BoNT/A antagonist. The cellular 
uptake of this molecule was successfully demonstrated using fluorescent markers and 
confirmed BoNT could be used for the intracellular transport of proteins. 
Further attempts were made to use BoNT as a protein transporter and helped 
determine the conditions required for successful intracellular delivery. Bade et al. (2004) 
fused various proteins to the amino terminus of the full-length BoNT/D (Figure 1.14B) and 
assessed the delivery efficiency of this system using the neurotoxin’s enzymatic activity. 
Cargo proteins consisting of LC/A, a dihydrofolate reductase, and luciferase were 
successfully translocated inside neurons. A less efficient translocation rate was however 
observed for the luciferase- and a GFP-fusion protein. This was linked to the structural 
constraints associated with the translocation process in which the cargo protein needs the 
ability to unfold in order to cross the narrow pore formed by BoNT. This study demonstrated 
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the potential of BoNT for the delivery of active enzymes inside neurons, and thus as a 
biological tool to investigate intracellular processes. 
 
Figure 1.14. Engineering of BoNT as a cargo protein. (A) Domain organisation of a 
BoNT/A derived molecule for transport of a BoNT inhibitor (dextran, attached with a 
reporter dye; Goodnough et al., 2002). (B) Domain organisation of engineered BoNT/D 
derivatives for intracellular transport of (1) dihydrofolate reductase (DHFR); (2) Green 
fluorescent protein (GFP); (3) LC/A; (4) firefly luciferase (Bade et al., 2004). 
 
The LHn fragment 
Trypsinisation of BoNT/A led to the discovery of a fragment composed of the LC and 
Hn domains only, termed LHn/A (Shone et al., 1985). This fragment was resistant to light 
trypsin treatment and could be recovered from the holotoxin. Additionally it was cleaved 
into a di-chain by the exoprotease thus mimicking host protease activation necessary for 
BoNT activity. The LHn fragment retains the catalytic activity of BoNT/A and the ability to 
form pores through membranes under acidic conditions (Shone et al., 1987). The fragment 
was not toxic due to the loss of Hc and thus the lack of a cell targeting domain (Figure 
1.15A). This fragment was later produced by recombinant expression as a GST-fusion 
protein and showed catalytic properties similar to the previously prepared fragment. LHn/A 
was active on neuronal cells when added at high concentration (Chaddock et al., 2002). 
Further work on the recombinant production of LHn led to the development of optimised 
construct for serotypes A, B and C. These novel constructs were codon optimised for 
expression in E. coli and included a MBP-fusion tag as well as a protease cleavage site 
between the LC and Hn domains. These molecules were shown to be suitable for vaccine 
preparation and potential tools to investigate SNARE-mediated events (Sutton et al., 2005). 
The LHn fragment represented a first step in the development of retargeted toxins for 
therapeutic use. 
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Figure 1.15. Engineering of BoNT for targeted secretion inhibition. (A) Domain 
organisation of BoNT and the LHn fragment, star marks site of engineered exoprotease 
cleavage site produced by recombinant expression (Chaddock et al., 2002). (B) Domain 
organisation of engineered LHn derivatives as targeted secretion inhibitors (1) NGF-LHn/A 
(nerve growth factor, Chaddock et al., 2000a); (2) WGA-LHn/A (wheat germ agglutinin, 
Chaddock et al., 2000b); (3) ECL-LHn/A (Erythrina cristagalli lectin, Duggan et al., 2002); 
(4) Recombinant EGF-LHn/C (epidermal growth factor, Foster et al., 2006). 
 
Engineering targeted secretion inhibitors 
LHn is a fragment that combines the translocation and catalytic functions of BoNT. 
By associating LHn with various ligands, it was proven possible to inhibit cellular secretion 
of several cell types, neuronal and non-neuronal, by cleavage of their intracellular SNARE 
proteins (Foster, 2009). 
The principle for retargeting BoNT derivatives was first demonstrated in two studies 
in which LHn/A, purified from BoNT/A, was chemically conjugated to the nerve growth 
factor (NGF) (Chaddock et al., 2000a) and the wheat germ agglutinin (WGA) (Chaddock et 
al., 2000b) (Figure 1.15B). In the first case, NGF-LHn/A was shown to inhibit the release of 
noradrenaline in neuronal cells, in correlation with intracellular SNAP-25 cleavage. The 
second investigation added incremental interest in that WGA-LHn/A not only inhibited 
neurotransmission in several neuronal cell types but could also inhibit insulin secretion from 
a pancreatic cell line. The potential of this technology was therefore demonstrated in 
neuronal and non-neuronal cells. 
Further work looking into possible therapeutic application for retargeted LHn 
derivatives led to the design of several novel molecules. With the proven length of BoNT/A 
activity in clinical practices, LHn derivatives could prove a great relief in the treatment of 
chronic hypersecretory disorders. LHn/A was chemically conjugated to a lectin from a tree, 
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Erythrina cristagalli (ECL) (Figure 1.15B), which was shown to specifically bind 
nociceptive afferent neurons (Duggan et al., 2002). This molecule was tested both in vitro 
and in vivo, demonstrating its ability to successfully inhibit substance P release in several 
models of pain. This was the first example of specific retargeting of LHn to a particular cell 
type, albeit a neuronal one. 
To extend the principle of specific targeting to other cell types, it is essential to 
consider the LHn fragment from alternative serotypes. Indeed the specificity of BoNT/A for 
SNAP-25 limits its use to neuronal cells and cells of a neuroendocrine origin. Using the 
endopeptidase domain from other BoNTs should allow intracellular cleavage of SNARE 
isoforms involved in non-neuronal cell secretion (Jahn and Scheller, 2006). The production 
of a recombinant molecule associating LHn/C to the epidermal growth factor (EGF) 
represented another step in the development of targeted secretion inhibitors (Foster et al., 
2006) (Figure 1.15B). This molecule was able to inhibit in vitro the release of mucin in a 
human pulmonary epithelial cell line, thus showing a therapeutic potential in the treatment 
of chronic obstructive pulmonary disease. Furthermore it provided the proof of principle that 
the BoNT retargeting technology was efficient on non-neuronal cell lines that do not rely on 
SNAP-25 in its secretory pathway.  
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1.5. Aims 
The botulinum neurotoxin is a powerful molecule that inhibits neurotransmission at 
the cholinergic nerve terminal. The modular architecture of BoNT has been highlighted, 
with each domain responsible for a specific function (Montal, 2010). It was demonstrated 
that a fragment of BoNT consisting of the catalytic and translocation domains (LHn) could 
be associated with novel ligands to bring the toxin’s activity to newly targeted cells, leading 
to the development of a new class of therapeutic products (Foster, 2009). 
The LHn fragment represents the essential framework on which these novel 
engineered molecules are based. The structure and function of the LHn fragment from 
several serotypes was therefore analysed. This was first carried out by the optimised 
production of various recombinant LHn constructs. The purified proteins were prepared for 
investigation by x-ray crystallography as a mean to solve their three-dimensional structure. 
Additionally, analysis of LHn’s structure by alternative methods such as small angle x-ray 
scattering also provided useful information. Furthermore, the functionality of the LHn 
fragment was analysed by considering its proteolytic activity on recombinant SNARE 
substrates and in neuronal cell cultures. Such information should prove essential in 
understanding the behaviour of LHn as a basis for future optimisation of therapeutic 
molecules. 
In the context of biopharmaceutical production, the LHn fragment is particularly 
challenging, owing to the necessity of obtaining an active di-chain form (Wey et al., 2006). 
Thus proteolytic activity of BoNT towards SNARE peptides was investigated as a tool for 
engineering both self-activating and LC-activating molecules. A SNARE peptide region was 
inserted between the LC and Hn domains in several LHn constructs. The activity and 
structure of these novel molecules were investigated, providing valuable information to the 
design of self-processing pharmaceutical products.  
Finally, several molecules representing LHn-based potential targeted secretion 
inhibitors were purified in order to be studied by x-ray crystallography. This led to 
preliminary crystallisation successes which may offer a basis for future structural 
investigations. 
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Chapter 2. Materials and methods 
 
2.1. Chemical and reagents 
All chemicals and reagents were purchased from Sigma-Aldrich unless otherwise 
stated. 
 
2.2. Bacterial strains and plasmids 
Competent cells 
The E. coli One Shot TOP 10 Chemically Competent cells (Invitrogen) were used for 
cloning and plasmid propagation. 
Several strains of E. coli were used for protein expression, including One Shot BL21 
(DE3) Chemically Competent cells (Invitrogen), and Origami 2 (DE3) Competent cells 
(Novagen). 
Expression plasmids 
All the plasmids used for cloning were kindly provided by Syntaxin Ltd.  
The plasmids used for expression of C. botulinum neurotoxin derivatives consisted in 
modified pET vectors (Novagen). These vectors carry an N-terminal pelB signal sequence 
for potential periplasmic localisation, plus optional C- or N-terminal His-Tag sequences. The 
plasmids contain an antibiotic resistance gene (either ampicillin or kanamycin) and a T7 
promoter region for protein expression. 
Other plasmids used for expression included modified pMal from New England 
BioLabs (NEB) and pGEX vectors (GE LifeSciences). The pMal vector encodes for 
maltose-binding protein (MBP) as a cleavable N-terminal tag. The pGEX vector encodes for 
glutathione S-transferase (GST) as a cleavable N-terminal tag. Both these vectors have an 
ampicillin resistance gene and rely on the Ptac promoter for protein expression. 
The epidermal growth factor receptor extracellular domain (EGFR ECD) was cloned 
into a pPICZ vector from the EasySelect Pichia Expression Kit (Invitrogen). This vector 
encodes for a zeocin resistance gene, and a signal peptide for extracellular secretion of 
proteins expressed in P. pastoris and promoted by the AOX1 promoter. 
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2.3. Media and supplements 
Competent cells for subcloning were grown in Luria Bertani (LB) medium which 
contained 10 g tryptone, 5 g yeast extract and 10 g sodium chloride per litre of distilled 
water. Medium was sterilised by autoclaving prior to use. 
LB agar plates were prepared as per LB medium with the addition of 12 g agar per 
litre. After sterilisation by autoclaving, the medium was allowed to cool down before being 
supplemented with the appropriate antibiotic, and poured in Petri plates. Plates were stored 
at 4°C until use.  
Expression cells were grown in Terrific Broth (TB) medium which contained 12 g 
tryptone, 24 g yeast extract, 4 ml glycerol, 9.4 g dipotassium hydrogen phosphate and 2.2 g 
potassium dihydrogen phosphate per litre of distilled water. Medium was sterilised by 
autoclaving prior to use. 
During bacterial growth, cultures were supplemented with the appropriate antibiotic. 
Stock solutions of ampicillin (100 mg/ml) and kanamycin (30 mg/ml) were prepared and 
used to supplement culture medium at a 1/1000 dilution.  
 
2.4. Molecular biology 
2.4.1. Agarose gel electrophoresis 
Agarose gel electrophoresis was utilised to analyse DNA samples. Gels of 1 % 
agarose were prepared by dissolving agarose in TRIS acetate EDTA (TAE) (40 mM TRIS 
acetate, 1 mM EDTA). Samples were prepared with SYBR Safe DNA gel stain (Invitrogen) 
before being loaded onto the agarose gel. NEB DNA ladders were used as markers (1 kb or 
100 bp as appropriate). Electrophoresis was carried out using Bio-Rad apparatus. 
Visualisation was performed under UV light on an InGenius system (Syngene).  
2.4.1. Cloning 
Synthetic genes 
All the designed synthetic genes were purchased from GeneArt and kindly provided 
by Syntaxin Ltd. The sequences for all proteins had been obtained from the UniProt 
Knowledgebase (UniProtKB). Sequences were back-translated and the corresponding genes 
optimised for the expression host codon usage (Entelechon tool). Restrictions sites were 
added as appropriate for sub-cloning.  
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Plasmid isolation 
For plasmid DNA propagation, 10 ml cultures of LB supplemented with the 
appropriate antibiotic were inoculated from a glycerol stock and grown overnight at 37°C in 
a shaking incubator (200 rpm). Cells were harvested and plasmid DNA was then isolated 
from the cultures using a PureYield Plasmid Miniprep System (Promega) following the 
manufacturer’s instructions. 
Restriction digestion 
DNA vectors and fragments were digested using the appropriate restriction 
endonucleases. A general overview of the cloning cassettes is presented in figure 2.1. All 
restriction enzymes were purchased from NEB and used with the supplied digestion buffers 
according to the manufacturer’s instructions. When the restriction endonucleases could be 
optimally used together, double digestions were set up. All digestions were carried out at 
37°C for 2 hours. 
Double digestions were set up simultaneously on the plasmid containing the fragment 
to insert and the one carrying the vector. Each digestion reaction contained 30 l DNA, 2.5 
l of each restriction enzymes, 5 l buffer (10X), 5 l Bovine Serum Albumin (BSA, 10X), 
5 l water (all reagents from NEB).  
 
Figure 2.1. Schematic of cloning cassette used for BoNT derivatives. Regions coding for 
protein domains and endonuclease restriction sites are represented. LC and Hn of BoNT are 
white rectangles, N- and/or C-terminal tag in yellow, specific protease sites in orange 
(Factor Xa/Enterokinase), C-terminal ligand in green, all endonuclease restriction sites in 
blue. Details of the constructs used are given in the following chapters. 
 
For VIP-LHn/A, the pET vector carrying LHn/A and the vector with the VIP gene 
fragment were double digested with NdeI and XbaI. 
The plasmid carrying the VPAC1 extracellular domain and the modified pMal and 
pGEX vectors were digested with EcoRI and HindIII. 
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The plasmid with the EGFR gene and the pPIZa vector were digested with EcoRI and 
NotI. 
The reaction samples were loaded onto 1 % agarose gel for analysis. The digested 
DNA fragment and vector required were cut from the gel and extracted with a DNA gel 
extraction kit (QIAGEN). 
Ligation 
Restricted DNA fragment and vector were ligated using T4 DNA ligase (NEB). Each 
ligation reaction was carried out in a total volume of 20 l and contained 3 l vector DNA, 
13 l fragment DNA, 2 l T4 ligase buffer (10X) and 2 l T4 ligase. The reaction was 
incubated for 2 hours at room temperature before being used for transformation in cloning 
competent cells. 
Transformation 
Ligated DNA was used to transform TOP10 competent cells (Invitrogen) according to 
the manufacturer’s instructions. The competent cells (50 l) were thawed on ice from their -
80°C storage. For each experiment 5 l of ligation mixture was added to the cells and 
incubated for 10 minutes on ice. Samples were then heat-shocked at 42°C for 90 seconds 
and incubated back on ice for 10 minutes. Then 150 l of pre-warmed SOC medium was 
added to the reaction and incubated for 1 hour at 37°C in a shaking incubator (200 rpm). 
Reactions (50 – 150 l) were plated on LB agar (with antibiotic) and incubated overnight at 
37°C. 
Purified DNA plasmids were used to transform expression competent cells (BL21 
(DE3), Invitrogen; Origami 2 (DE3), Novagen) according to the manufacturer’s instructions. 
The competent cells (50 l) were thawed on ice from their -80°C storage. For each 
experiment 5 l of plasmid DNA was added to the cells and incubated for 30 minutes on ice. 
Samples were then heat-shocked at 42°C for 30 seconds and incubated back on ice for 5 
minutes. Then 250 l of pre-warmed SOC medium was added to the reaction and incubated 
for 1 hour at 37°C in a shaking incubator (200 rpm). Reactions (50 – 200 l) were plated on 
LB agar (with antibiotic) and incubated overnight at 37°C. 
Screening for positive clones 
After ligation and transformation into cloning competent cells, resulting transformants 
were tested for the presence of the desired inserts. Individual colonies of transformants were 
used to inoculate 10 ml LB cultures (with antibiotic) and their plasmid DNA extracted as 
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described previously. A test digest was performed on the resulting DNA. Each test reaction 
contained 6 l DNA, 1 l buffer (10X), 1 l BSA (10X), and 1 l of each restriction 
enzymes (same as previously). After 1 hour incubation at 37°C, reactions were analysed by 
agarose gel electrophoresis. Samples showing DNA fragments at the expected size were sent 
for sequencing (Geneservice, Oxford, UK).  
Glycerol stock preparation 
After being transformed with the sequence-verified plasmid DNA, cells were plated 
on LB agar with the appropriate antibiotic and incubated overnight at 37°C. A colony was 
picked and used to inoculate 5 ml LB broth (with antibiotic) and the culture was grown at 
37°C (shaking) until the absorbance at 600 nm (OD600) reached between 0.6 and 0.9. For 
each glycerol stock, 500 l of culture were added with 500 l of 50 % glycerol in a cryovial 
containing ceramic beads (Mast Group) and frozen at -80°C for storage. Primary cultures 
were inoculated using beads from these stocks.  
2.5. Protein methods 
2.5.1. SDS PAGE electrophoresis 
At every steps of the protein purification process, samples were analysed by SDS-
PAGE. Fractions of interests (column loads and wash, elution) were prepared by dilution 
with NuPAGE LDS Sample Buffer (4X, Invitrogen) with or without 1 mM DTT for oxidised 
and reduced samples respectively. Samples were denatured by heating for 5 minutes at 95°C 
before loading onto a 4-12 % BIS-TRIS gel (Invitrogen). Depending on samples, 5 to 15 l 
were loaded. BenchMark molecular weight markers (Invitrogen) were used as standards. 
Gels were run for 45 minutes at 200 Volts in MOPS buffer (Invitrogen) using a Novex 
system (Invitrogen). 
Gels were washed 3 times 5 minutes in distilled water. Staining was carried out using 
Simply Blue Safestain (Invitrogen) according to the manufacturer’s instructions. After 
staining gels were washed with distilled water. Gel scanning and densitometry (when 
performed), were done using a Dyversity system and the GeneTools software (Syngene). 
2.5.2. Protein expression 
Typically, 100 ml primary cultures of TB (in 500 ml conical flasks) supplemented 
with the appropriate antibiotic were inoculated from a bead of the glycerol stock and grown 
overnight at 37°C in a shaking incubator (200 rpm). The following day, 10 ml of these 
cultures were used to inoculate 1 L secondary cultures of TB (with antibiotic) and grown at 
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37°C in a shaking incubator (200 rpm) until OD600 reached between 0.6-0.9. Protein 
expression was then induced by addition of isopryl-1-thio--galactopyranoside (IPTG) to a 
final concentration of 1 mM after the incubation temperature was lowered to 16°C. Cells 
were grown overnight and harvested by centrifugation. For storage, cell pastes were 
resuspended in 15 ml 50 mM HEPES pH7.2, 200 mM sodium chloride and frozen at -80°C 
until day of use. 
2.5.3. Protein purification 
Details of the purification methods are given in each chapter for the various proteins 
purified. A summary of the common experimental procedures used is given below.  
Cell preparation 
Stored cell pastes (corresponding typically to 10-15 g) were thawed and resuspended 
in approximately 100-150 ml of buffer used for the first purification stage. Cell lysis was 
carried out using a cell disruptor (TS Series, Constant Systems) at 20,000 Psi at 4°C. Lysate 
was centrifuged at 18,000 g for 30 minutes at 4°C to separate the clear soluble fraction. The 
resulting supernatant was used for further processing by loading onto an appropriate 
chromatography medium. 
Protein purification 
Each protein was purified according to its biochemical properties and the presence of 
affinity tags. Typically, the process started by an affinity chromatography stage, followed by 
treatment with a selective exoprotease for tag removal or protein activation. Details of the 
chromatography media used are detailed in the following chapters. In all cases, purifications 
were carried out using the manufacturer’s instructions for each column and media. Table 2.1 
summarises the proteins purified for this study and the techniques that were used. All 
proteins were purified using AKTA systems (GE Healthcare). 
When dialysis was performed between protein purification stages, the pooled eluate 
fractions were set to dialyse in a SnakeSkin Dialysis Tubing (Thermo Scientific) with an 
appropriate molecular weight cut-off) against 10 L of buffer used for the following 
purification step and left overnight at 4°C. 
Specific protease treatment 
Before addition of the specific exoprotease for treatment, protein concentration was 
assessed by measuring absorbance at 280 nm (A280). All LHn-derived molecules have an 
extinction coefficient such that an absorbance of 1 (A280) corresponds to approximately 1 
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mg/ml. Enterokinase (NEB) was added at 6.4 ng and Factor Xa (NEB) at 10 g units per mg 
of protein. PreScission protease (GE Healthcare) was used according to the manufacturer’s 
instructions. Reactions were incubated overnight at 25°C unless otherwise stated.  
Protein concentration determination 
Final concentration of the pure proteins was determined by A280 measurements using a 
NanoDrop 2000 instrument (Thermo Scientific). For each samples, absorbance was 
averaged from three readings at an appropriate dilutions (so that A280 is between 0.1 and 
1.0). The specific extinction coefficient derived from the protein sequence was used in the 
calculations.  
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Table 2.1. Summary of proteins purified. 
 
Proteins Purification stages 
 
  I II III IV V 
Proteins for 
crystallisation 
LHn/A AC(His) F. Xa AC(His) HIC   
LHn/B AC(His) F. Xa HIC     
LHn/C AC(His) F. Xa AC(His) IEX   
LHn/D AC(His) Ek HIC     
scLHn/D AC(His) HIC       
LHn/E AC(His) HIC       
      
LC/A-SNAP23-Hn/A AC(His) HIC       
LC/A-SNAP25(0)-Hn/A AC(His) GF      
LC/B-GS-Hn/B AC(His) F. Xa HIC   
      
ZZ-LHn/A AC(His) Ek AC(His)     
VIP-LHn/A AC(His) F. Xa HIC    
VPAC1 ECD AC(MBP) F. Xa AC(MBP) AC(His)  
EGF-LHn/A AC(His) Ek AC(His) HIC GF 
EGF-LHn/C AC(His) Ek AC(His) HIC   
EGF-LHn/D AC(His) Ek AC(His) HIC   
Other 
proteins 
VAMP1-GFP AC (GST) PreSc. AC(GST)     
VAMP2-GFP AC (GST) PreSc AC(GST)     
VAMP3-GFP AC (GST) PreSc AC(GST)     
SNAP25-GFP AC (GST) PreSc AC(GST)     
scLHn/A AC(His)         
LC/A-SNAP25-Hn/A AC(His)         
LC/A-VAMP2-Hn/A AC(His)         
LC/A-VAMP2 AC(His)         
LC/B-SNAP25            
AC, affinity chromatography using His-, GST- or MBP- tags; Exoprotease treatment with F. 
Xa, Factor Xa, Ek, enterokinase, PreSc., PreScission; HIC, hydrophobic interaction 
chromatography; IEX, ion exchange chromatography; GF, gel filtration chromatography. 
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2.6. Biochemical assays 
2.6.1. Western blotting 
Samples were prepared as per SDS PAGE analysis, with the addition of a MagicMark 
protein ladder (Invitrogen) for molecular weight standards. After electrophoresis, gels were 
set up in a blotting cassette with filter papers and either nitrocellulose of PVDF membranes 
(Millipore). Blotting was carried out in SDS running buffer with 20 % methanol for 1 hour 
at 40V, 100 mA. The blots were then blocked for 1 hour in 3 % Marvel milk powder in PBS 
with 0.001% Tween (PBS Tween). Primary antibodies were diluted appropriately in 3 % 
Marvel milk powder in PBS Tween and added to the blots. After incubation for 1 hour at 
room temperature (shaking), blots were washed three times 10 minutes in PBS Tween. 
Secondary (peroxidase conjugated) antibodies were diluted appropriately in 3 % Marvel 
milk powder in PBS Tween and added to the blots with a 1 hour incubation period. After a 
washing step, blots were revealed using an enhanced chemiluminescent (ECL) detection 
system (Thermo Scientific). 
Details of the antibodies used for specific detection are given in the following 
chapters. 
2.6.2. Protein N-terminal sequencing 
Samples prepared for N-terminal sequencing were run on SDS-PAGE and blotted on 
an ImmobilonP membrane (Millipore) as described previously. Blots were stained by 
Ponceau S (Sigma) for 5 minutes and rinsed in water. The bands corresponding to the 
proteins to be analysed were cut and sent to AltaBioscience (UK) for sequencing by Edman 
degradation. 
2.6.3. Substrate cleavage assays 
Purification of recombinant SNARE substrates 
Clones corresponding to recombinant SNARE-GFP fusion proteins were kindly 
provided by Syntaxin Ltd. The soluble region of SNAP25 (2-206), VAMP-1 (2-96), -2 (1-
94) and -3 (2-77) were cloned to include an N-terminal cleavable GST tag and a C-terminal 
GFP tag. Protein expression and cell preparation were carried out as described previously. 
Cell pastes were resuspended and lysed in 50 mM HEPES (pH 7.2), 0.2 M sodium chloride 
(buffer A) with 5 mM DTT added freshly before use. Cell lysate supernatant was loaded 
onto a Glutathione Sepharose 4B column (GE Healthcare) and washed with buffer A. 
Elution was carried out with 100 mM reduced glutathione (in buffer A). The pooled eluate 
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was treated with PreScission protease (GE Healthcare) for tag removal and dialysed against 
buffer A (three times 1 L buffer A for 3 hours at 4°C). The dialysate was loaded onto the 
same affinity chromatography media and the unbound fraction collected. Sample was then 
concentrated using Vivaspin 5000 MWCO concentrator (Millipore). Figure 2.2 presents a 
summary of VAMP2-GFP purification by SDS PAGE analysis. Final protein concentrations 
were determined by densitometry analysis on SDS PAGE against a BSA standard curve. 
Protein was stored at -20°C until further use. 
 
Figure 2.2. Purification of VAMP2-GFP. SDS-PAGE summary of VAMP2-GFP 
purification. Lane 1, cell lysate supernatant; 2, unbound fraction from first purification step; 
3, pooled eluate from first purification step; Tag removal by PreScission treatment; 5, Eluate 
from final purification step; 6, Final and concentrated VAMP2-GFP fraction. 
 
Cleavage of recombinant SNARE substrates by BoNT derivatives 
All the assays were optimised by performing preliminary experiments to determine 
the most appropriate concentration range for substrate and test proteins. Details of the 
experiments are given in the following chapters. As a summary, test proteins were diluted in 
buffer containing 50 mM HEPES pH 7.2, 20 M zinc chloride, 1 g/l BSA, 10 mM DTT, 
and incubated at 37°C for 30 minutes. Recombinant substrates were diluted and incubated 
with the test enzyme at 37°C for 1 hour. Reactions were stopped by adding 2x reducing 
sample buffer (NuPAGE, Invitrogen). Samples were then analysed by SDS PAGE along 
with BSA standards. Assay results were quantified by densitometry (Syngene). 
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2.6.4. Embryonic spinal cord neuron (eSCN) assays 
Details of the BoNT serotype specific experimental conditions are given in the 
following chapters. A general summary for the eSCN assays is given below. 
Spinal cords dissected from 14–15 day old foetal Sprague Dawley rats were cultured 
for 21 days using a modification of previously described method (Chaddock et al., 2002) 
and provided by Syntaxin Ltd. eSCN were treated with serial dilutions of the test enzymes, 
and incubated at 37 °C with 10% CO2 for 24 hours. Cells were lysed by removing all media 
and adding sample buffer (25% NuPAGE buffer (Invitrogen), 10 mM DTT). After 20 
minutes, samples were transferred into microcentrifuge tubes and heated at 95°C for 5 
minutes. All samples were run on 12 % BIS-TRIS gels (Invitrogen) and proteins were 
transferred onto nitrocellulose membranes using an iBlot Dry Blotting System (Invitrogen) 
following the manufacturer’s instructions. Substrate cleavage was monitored by measuring 
the disappearance of the specific substrate immunoreactive bands (and for VAMPs 
compared to an internal control protein). Specific binding of substrate primary antibodies 
was visualised using peroxidase-conjugated secondary antibodies and an enhanced 
chemiluminescent (ECL) detection system (Thermo Scientific), similarly to the Western 
blotting protocol described previously. Analysis was performed by densitometry (Syngene). 
Assay results (calculations and curve fittings) were processed with Prism5 (GraphPad 
Software). 
 
2.7. X-ray crystallography 
2.7.1. Crystallisation 
Vapour diffusion method 
Proteins may form crystals when set in the right environment. In the crystallisation 
process, the protein in a soluble state is slowly transformed towards precipitation. When 
conditions for crystallisation are met, the protein molecules arrange themselves in regular 
orientations to form repeating unit cells. The saturation curve for protein crystals illustrates 
the conditions required for this mechanism (Figure 2.3). 
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Figure 2.3. Protein crystallisation saturation curve. Crystallisation can happen under 
supersaturated conditions after nucleation occurs. In the precipitation zone, the level of 
saturation is too high and makes the protein precipitates out of solution. Crystals may be 
grown in the metastable zone from previous nucleation. 
 
Vapour diffusion is the most commonly used methods for protein crystallisation and 
regroups two techniques known as hanging drop and sitting drop. Both rely on the same 
principle whereby a drop, containing the protein to crystallise along with buffer and 
precipitant, is set to equilibrate against a reservoir of solution composed of the same buffer 
and precipitant but at higher concentration. This allows the water to vaporise from the drop 
and transfer to the reservoir. Consequently the precipitant concentration within the drop 
increases until equilibrium is reached and permits crystallisation (McPherson, 1985). The 
difference between the two techniques is in the position of the drop in regard to the well, 
with the drop being set on a shelf next to the reservoir in a sitting drop arrangement, while 
the drop is suspended above the reservoir in the hanging drop situation. 
Preliminary automated crystallisation screens 
A common method was used to determine the crystallisation conditions for all of the 
purified proteins. Preliminary crystallisation screens were carried out using an automated 
nano-dispenser (Crystal Phoenix, Art Robbins Instruments). 96-well INTELLI-plates (Art 
Robbins Instruments) were set up following a sitting-drop vapour diffusion method with 40 
l mother liquor in the reservoir, and 200 nl drop size with 2:1 and 1:1 protein to mother 
liquor ratios. Available commercial crystallisation screens were used (all from Molecular 
Dimensions): Structure screen I + II HT-96; Clear Strategy Screen I HT-96; Clear Strategy 
Screen II HT-96; - Heavy + Light twin pack HT-96; PACT premier HT-96; JCSG-plus HT-
96; Morpheus HT-96; PGA Screen HT-96. 
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All plates were incubated at 16°C. Typically, crystallisation plates were checked after 
2 days, 1 week, 2 weeks and then regularly until drops had dried. When potential 
crystallisation hits were observed, further optimisation trials were performed, either 
manually or by using the robot and commercially available additive screens (Additive 
Screen HT, Silver Bullets HT, from Hampton Research). 
Crystallisation manual optimisation trials 
When crystals were observed in the preliminary screens, the corresponding conditions 
were further tested. Trials by the hanging-drop method using 24-well plates (XRL plate, 
Molecular Dimensions) were set up. Typically, the precipitants were tested at a broad 
concentration range (5-200 % of initial concentration), and with different buffer systems for 
pH optimisation. Other parameters tested included the protein to mother liquor ratio (1:1; 
2:1; 1:2), drop size (1 to 4 l) and reservoir volume (200 to 1000 l). Alternatives to the 
initial precipitants were also trialled such as, for examples, PEG of different molecular 
weights, and various salts with a common element (i.e. sodium, potassium salts…). 
Several seeding methods were also used to optimise the crystals, particularly for 
transferring crystals from the preliminary 96-well plate to the 24-well plate format. Firstly 
streak-seeding was performed for smaller crystals using a thin needle. Secondly, when 
crystals of a suitable size were obtained, they could be isolated and inoculated in a new drop 
with lower precipitant concentration, thus favouring crystal development in the metastable 
zone (Figure 2.3) after nucleation. 
Details of the crystallisation conditions obtained for each protein is given in the 
following chapters. 
2.7.2. Data collection and processing 
Data collection at the synchrotron source 
All the data presented in this study were collected at the Diamond Light Source (UK), 
macromolecular crystallography stations IO2, IO3, IO4 or I24 (microfocus beamline). 
Crystals were mounted in cryoloops on site on the day of experiment. When possible, 
various cryoprotectants were tested depending on the crystallisation conditions. Crystals 
were centred and tested for x-ray diffraction. When diffraction spots were observed, 
appropriate settings were applied for data collection (resolution, oscillation range, beam 
transmission) and images were collected. Depending on the radiation damages observed, and 
unit cell parameters, 100 to 200 images with a 1° oscillation range would usually be 
collected from a single crystal when using a regular beamline. 
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At the time of experiments, beamlines IO2, IO3, and IO4 were equipped with a 
Quantum-4 CCD detector (ADSC Systems, CA). The I24 microfocus beamline was 
equipped with a PILATUS-6M (Dectris) detector. 
Data processing 
The data were processed and scaled using MOSFLM and SCALA of the Collaborative 
Computational Project No. 4 softwares for macromolecular x-ray crystallography (CCP4, 
1994; Leslie, 2006). Indexing in the appropriate space group was supported by analysis with 
POINTLESS (CCP4, 1994). 
Details on data collection and processing are given in the following chapters. 
2.7.3. Structure determination and validation 
Molecular replacement 
Molecular-replacement is one of the main methods for determining the crystal 
structures of macromolecules. It relies on the existence of known structural models for 
molecules that share a degree of homology with the macromolecular structure to be solved. 
The different botulinum neurotoxin serotypes share 30 to 60 % homology (Lacy and 
Stevens, 1999). With the crystal structures of three full-length toxins available, along with 
the catalytic domain from each serotype (Swaminathan, 2011), the BoNT fragments and 
derivatives described in this study presented an ideal case for molecular replacement. 
The molecular replacement method is based on the Patterson function properties. 
Phase information is not necessary to calculate the Patterson function which can be extracted 
from a potential structural model, and compared to the experimental, measured Patterson. 
There are six dimensions in the molecular replacement problem which may be simplified in 
a subset of two three-dimensional searches. The program MolRep (Vagin and Isupov, 2001) 
is based on the Patterson method. A molecular replacement solution is found when the 
search model is correctly located in the crystallographic unit cell. Its Patterson function 
should then be similar to the experimental one. The first three-dimensional search 
corresponds to a cross-rotation function. The spatial points with a high rotation function 
values are kept as the most likely orientations of the search model. Then a search with the 
translation function, the second three-dimensional function, is applied on these orientations. 
A more recent technique to molecular replacement has been including the maximum 
likelihood method to these functions. The program Phaser (McCoy et al., 2007) allows for 
calculation of the probability that the data would be measured with the given model. Hence 
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this provides an indication of the consistency between the model and the experimental data, 
and offers a more sensitive approach to molecular replacement. 
Details on molecular replacement are given for each of the structures solved with this 
method in the following chapters. 
Refinement and validation 
Refinement of the crystal structures was carried out with REFMAC (Vagin et al., 
2004) and manually with Coot (Emsley and Cowtan, 2004). The REFMAC program can 
perform rigid body, TLS (Translation-Libration-Screw motion), and restrained or 
unrestrained refinement against x-ray data. It minimises the coordinate parameters to satisfy 
either a maximum likelihood or least squares residual. Typically a first round of rigid body 
refinement was performed on the molecular replacement solution, and then several rounds of 
restrained refinement. Weight of geometrical parameters and the presence of non-
crystallographic symmetry were adjusted according to each structure. Between REFMAC 
refinement rounds, manual adjustments and model fitting were done with Coot using real-
space refinement and regularisation options. Coot was also used to add solvent and ligand 
molecules when appropriate. TLS refinement was usually performed in the final stages of 
refinement after validation of the structure’s geometry. 
Quality of the final structures was assessed by the figure of merit, R factors and 
geometric statistics. All structures were checked with the MolProbity program (Davis et al., 
2007) and protein geometry optimised for acceptable Ramachandran statistics, C deviation, 
bond length and bond angles (CCP4, 1994).  
Details of the final crystal structures and their refinement statistics are given in the 
following chapters. Coordinates and structure factors of new structures were deposited to the 
Protein Data Bank, Research Collaboratory for Structural Bioinformatics, Rutgers 
University, New Brunswick, NJ (http://www.rcsb.org/), using the AutoDep server (EBI). 
 
2.8. Small-angle x-ray scattering 
Principles of small-angle x-ray scattering 
Small-angle x-ray scattering (SAXS) is a technique for studying the solution structure 
of biological molecules and macromolecular complexes. SAXS is particularly useful for 
analysing large conformational changes such as transitions in folding states due to ligand 
binding or to modifications of the physicochemical environment. These observations are 
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allowed by the non-intrusive sample preparation where the proteins are left in a simple 
soluble environment. 
X-rays are a form of radiation characterised by their wavelength and amplitude. Their 
interaction with individual atoms of a macromolecule causes the formation of secondary 
wavelets which results in a coherent scattering. In SAXS, the protein sample is exposed to x-
rays and the scattered intensity “I(s)” is measured as a function of the momentum transfer 
“s” against the solvent scattering intensity which is subtracted (Jacques and Trewhella, 
2010). It is important that the macromolecule sample be pure and monodisperse in solution. 
Indeed the intensity measured is an average of the isotropic intensity distribution which is in 
relation with all the random orientations of the molecules in solution. The net particle 
scattering is in correlation with the contrast which corresponds to the squared difference in 
electron density between particle and solvent. The signal measured is dependent on the size 
and shape of the particles being analysed and may thus provide information on the tertiary 
structure and molecular assembly of proteins. The resolution of the structural information 
obtained is limited by the smallest angles at which the data are measured. In the real space 
dimension, this corresponds to the longest distance that can be observed from the data. 
Analysis of SAXS data may be performed following the Guinier approximation 
(Guinier, 1938). This analysis at small scattering angles gives a direct estimation of two 
important parameters: the radius of gyration, Rg, and the derived intensity at zero scattering 
angle, I(0). Rg is defined as the mass distribution of the molecule around its centre of 
gravity. Variation in Rg may be an indication of conformational change in the 
macromolecule structure. Furthermore, an important characteristic and another tool for 
determining the shape of a molecule is the distance distribution function, P(r) (Putnam et al., 
2007). This function describes the paired-set of distances between all of the electrons within 
the molecule. 
Ab initio modelling  
Recent advances in SAXS data analysis have led to the development of ab initio 
algorithms that allow the modelling of a molecular shape from the data alone. The DAMMIF 
(Franke and Svergun, 2009) program allows representation of the macromolecule by finite 
volume elements (or “dummy atoms”) and fits the experimental data using simulated 
annealing. The computed model provides a compact shell corresponding to the surface of the 
molecule. This ab initio approach usually produces several models that need to be averaged 
to provide for a more accurate representation. The DAMAVER (Volkov and Svergun, 2003) 
program can be utilised to classify structurally similar models and generate an average 
structure. 
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Details of SAXS experimental procedures for sample preparation and data analysis are 
given in chapter 3.4.  
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Chapter 3. Structure and activity of the LHn fragments from 
Clostridium botulinum neurotoxins 
 
3.1. Structure and activity of LHn/A 
3.1.1. Introduction 
Toxins from Clostridium botulinum species are the causative agent of the rare 
neuroparalytic illness botulism. There exist seven distinct serotypes (A–G) of botulinum 
neurotoxins (BoNTs) that affect humans and other species to varying degrees. Once inside 
the neuronal cell, BoNTs block the release of neurotransmitters leading to paralysis. Despite 
their potent toxicity, various preparations of BoNT/A are available commercially as 
therapeutic and cosmetic agents.  
BoNT/A is synthesised as a single polypeptide chain (150 kDa), which is post-
translationally cleaved into a di-chain molecule composed of light chain (LC/A) (50 kDa) 
and heavy chain (HC/A) (100 kDa). LC/A is the catalytic domain and a zinc-endopeptidase, 
while HC/A is further divided into two sub-domains of equal molecular mass called the 
translocation domain (Hn/A) and the membrane binding domain (Hc/A). The crystal 
structure of serotype A was solved and presented a linear arrangement of these three 
functional domains (Lacy et al., 1998). On binding to the nerve terminals, BoNT/A is 
endocytosed into a vesicle, where the acidic environment causes some conformational 
changes and LC/A is translocated into the cytosol (Montal, 2010). Inhibition of 
neurotransmission takes place by proteolysis of the pre-synaptic membrane protein SNAP-
25 (synaptosomal associated protein of 25 kDa; Schiavo et al., 2000). SNAP-25 is one of the 
soluble N-ethyl-maleimide-sensitive fusion protein attachment receptor (SNARE) proteins 
which mediate cell secretion (Südhof et al., 2009).  
LHn/A is a non-toxic fragment of BoNT/A. It consists of only the LC and Hn of the 
whole type A toxin, hence it is incapable of binding extracellularly to cell membranes, but 
retains its full catalytic activity (Chaddock et al., 2002). LHn/A was originally prepared by 
trypsinisation of whole BoNT/A (Shone et al., 1985). However, preparation of recombinant 
LHn/A has subsequently been achieved by Chaddock et al. (2002). LHn/A was proposed as 
a component in the design of a range of therapeutic molecules for the treatment of pain, 
control of secretion from multiple cell types and other muscular disorders. By coupling the 
LHn/A molecule to a ligand that selectively binds to a specific target cell that plays a role in 
the maintenance of a chronic disease state, it is proposed that the retargeted LC/A activity 
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will result in inhibition of secretion from said cell, thereby leading to alleviation of 
symptoms and improvement in quality of life. As proof-of- principle, retargeting of LHn/A 
in fusion with other cell binding proteins such as Erythrina cristagalli lectin (Chaddock et 
al., 2004), wheat germ agglutinin (Chaddock et al., 2000a), and nerve growth factor 
(Chaddock et al., 2000b) have been successfully tested in vitro and in vivo models.  
Elucidation of the tertiary structure of LHn/A to confirm its native state and to aid in 
designing suitable ligands as delivery vehicle has become important. Details of the first 
crystal structure of the LHn non-toxic fragment from BoNT/A at 2.6 Å resolution are 
presented here. The catalytic activity of LHn/A was confirmed by SNAP-25 cleavage assay, 
and the stability of the fragment assessed. These results have provided the structural basis 
for the LHn/A protein and should lead the way forward for the design of a new class of 
therapeutic molecules. 
 
3.1.2. Materials and methods 
LHn/A cloning and expression  
The synthetic gene encoding 877 amino acids of LHn/A was cloned into modified 
pMAL-c2x vector (NEB, UK) with a Factor Xa cleavable N-terminal poly-His(6x) tag and 
transformed into E. coli BL21 expression cells. The LHn/A gene was engineered to encode 
for Factor Xa cleavage site (IEGR) between the LC and Hn domain between positions 443-
446. The clone was provided by Syntaxin Ltd. Expression of LHn/A was carried out by 
inoculating terrific broth complex medium (100 g/ml Ampicillin) with an overnight culture 
grown at 37
o
C. The cultures were grown in 2 L conical flasks at 200 rpm and 37
o
C until the 
OD600 reached 0.5. Cultures were then set at 16°C for induction with 1 mM IPTG and left 
growing overnight (200 rpm). The cells were then harvested and stored at -80
o
C until further 
use. 
LHn/A purification  
Cells were resuspended in 50 mM M HEPES, pH 7.2, 0.2 M NaCl and lysed using a 
homogeniser (Constant Systems Ltd). Lysate was centrifuged for 45 minutes at 18,000 g. 
Soluble fraction was loaded onto a Ni
2+
-charged chelating sepharose column (GE 
Healthcare). Bound proteins were then eluted in steps at 10, 40, 100 and 250 mM imidazole 
(dissolved in 50 mM HEPES, pH 7.2, 0.2 M NaCl) (Figure 3.1A). The fractions of interest 
were pooled together and dialysed overnight at 4 °C against 50 mM HEPES, pH 7.2, 0.2 M 
NaCl. 
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Factor Xa (BioLabs) treatment was carried out to remove the N-terminal 6xHis-tag. 
This step was also necessary to mimic the native protein endoprotease activation by C. 
botulinum, allowing formation of the two-chain (LC and Hn) protein. Digestion was carried 
out by adding 1 unit of Factor Xa per 0.1 mg fusion protein and incubated at 25°C overnight.  
The cleaved fusion protein was loaded onto a Ni
2+
-charged chelating sepharose 
column equilibrated with 50 mM HEPES, pH 7.2, 0.2 M NaCl. The protein of interest did 
not bind to the column as its tag was cut-off. The flow-through was therefore collected and 
further purified. Ammonium sulphate was added to the fraction to make up a 1 M 
concentration, and the sample was loaded onto a phenyl sepharose column (GE Healthcare) 
previously equilibrated with 1 M ammonium sulphate in 50 mM HEPES, pH 7.2. Elution 
was performed in steps at 0.7, 0.6, 0.4, 0.3 and 0 M salt in 50 mM HEPES, pH 7.2. LHn/A 
eluted at 0.7 and 0.6 M (Figure 3.1B) and corresponding fractions were pooled together. 
Pooled sample was dialysed overnight against 50 mM HEPES, pH 7.2, 0.2 M NaCl at 4°C. 
The sample was finally concentrated using Vivaspin 50000 MWCO concentrator 
(Millipore), spinning at 2500 g until concentration reached approximately 5 mg/ml. All 
concentrations were determined by absorbance measurement at 280 nm. Protein was stored 
at -20°C until further use. 
Enzymatic assay  
The SNAP25 cleavage assay allows the monitoring of botulinum toxin serotype A 
catalytic activity by SDS PAGE and is described below. 
LHn/A was diluted down to 1.5 mg/ml in buffer containing 50 mM HEPES pH 7.2, 20 
M ZnCl2, 1 g/l BSA, 10 mM DTT, and incubated at 37 °C for 30 minutes. SNAP25-
GFP recombinant substrate (Syntaxin Ltd, UK) was diluted and used at a final concentration 
of 4 M and incubated with the test enzyme at appropriate concentrations, at 37 °C for 4 
hours. Reaction was stopped by adding 2x reducing sample buffer (Invitrogen). Sample was 
loaded on a NuPAGE 4-12 % BIS-TRIS gel (Invitrogen) and visualised by staining with 
Simply Blue Safestain (Invitrogen). 
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Figure 3.1. Purification of LHn/A. (A) Chromatograph from first purification step using a 
Ni-charged chelating sepharose column (imidazole concentration is indicated). (B) Elution 
profile from final purification step using a phenyl sepharose column (ammonium sulphate 
concentration is indicated). Absorbance at 280 nm, blue; gradient concentration, green; 
conductivity, brown. (C) SDS-PAGE summary of purification. Lane 1, cell lysate 
supernatant; 2, 3, pooled eluate from first purification step in oxidised (O) and reduced (R) 
conditions (respectively); 4, 5, Factor Xa-activated O and R sample; 6, 7, Eluate from 
second affinity chromatography (O and R); 8,9, Eluate from final purification step (O and 
R).  
 
Stability assay 
Purified LHn/A sample was dialysed in either 50 mM HEPES pH 7.2, 200 mM NaCl 
or 100 mM TRIS Acetate pH 8.5, 1.5 M Ammonium Sulphate, 15 % glycerol. Samples were 
then diluted down to 1.5 mg/ml in corresponding buffer, aliquoted and stored at -20˚C, +4˚C 
and +25˚C until day of testing. All samples were loaded in duplicate (2 g) on non-reduced 
and reduced gels (4-12 % BIS-TRIS, Invitrogen). The percentage purity of LHn/A was 
determined by densitometry (GeneTools, Synoptics Ltd). 
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Crystallisation 
Final purified LHn/A (residues 1-877) was stored as a frozen stock (-20°C) at 4.8 
mg/ml in solution with 50 mM HEPES (pH 7.2) and 0.2 M sodium chloride. Initial 
crystallisation condition was identified from automated preliminary trials (Phenix, Art 
Robbins instruments) with Structure Screen I and II (Molecular Dimensions). The condition 
was repeated by the hanging-drop vapour diffusion method, with 3 l drops (2 l protein and 
1 l mother liquor) against a reservoir (500 μl) at 16°C. Microcrystals were observed with 
12% glycerol, 0.1 M TRIS pH 8.5, 1.5 M ammonium sulphate. Optimisation gave small 
reproducible crystals after 14 days. Macro-seeding was necessary to obtain crystals of 
suitable size and quality, presenting a single rectangular prism, in 15% glycerol, 0.1 M TRIS 
Acetate pH 8.5, 1.5 M ammonium sulphate. LHn/A crystals were also obtained by using 15 
% sucrose for glycerol and diffracted at 2.6 Å resolution (Figure 3.2). 
Data collection and structure solution 
X-ray diffraction data for LHn/A were collected at Diamond Light Source (DLS, UK), 
beamline I03. Prior to data collection, LHn/A crystals were transferred to a cryoprotectant 
solution with 25% (v/v) glycerol for 1 min, and then flash-frozen under a nitrogen stream. 
The crystals grown with glycerol diffracted to 2.75 Å in space group P212121 (a= 78.4; b= 
157.0; and c= 211.7 Å) with two molecules per asymmetric unit. Crystals grown in sucrose 
required annealing for 30 seconds to show diffraction up to 2.6 Å in a similar cell. The data 
were processed in primitive orthorhombic space group P212121 using MOSFLM version 
7.0.3, and scaled up to 2.6 Å using SCALA from CCP4 suite (CCP4, 1994; Leslie, 2006). 
Initial phases were obtained by the molecular replacement (MR) method using MolRep 
(Vagin and Isupov, 2001) with the coordinates of a homology based model of the LHn/A 
fragment from the holotoxin model (PDB 3BTA, Lacy et al., 1998). Crystallographic 
refinement were carried out using CNS suite version 1.2 (Brünger et al., 1998) and model 
fitting were done using Coot version 0.4.1 (Emsley et al., 2004). PROCHECK (Laskowski 
et al., 1993), and MolProbity (Davis et al., 2007) were used to check the geometry of the 
structure. Data collection and processing statistics are provided in Table 3.1. 
The atomic coordinates and structure factors (codes 2W2D and r2W2Dsf, Masuyer et 
al., 2009) have been deposited in the Protein Data Bank, Research Collaboratory for 
Structural Bioinformatics, Rutgers University, New Brunswick, NJ (http://www.rcsb.org/). 
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Figure 3.2. Crystals and x-ray diffraction of LHn/A. (A) Diffraction image collected at 
DLS IO3 where LHn/A crystals diffracted at 2.6 Å. (B) Crystals of LHn/A after optimisation 
in 15% sucrose, 0.1 M TRIS Acetate pH 8.5, 1.5 M ammonium sulphate. 
 
  
55 
 
Table 3.1. Data collection and refinement statistics of LHn/A 
A. Data Collection Statistics 
Space Group P212121 
Cell a = 78.4, b =157.0, c =211.7 Å ; = 90° 
Resolution range (Å) 50-2.6 
Rsym
1
 (%) 10.9 (55.3) 
I/I (outer shell2) 11.5 (2.0) 
Completeness % 97.1 (98.4) 
Redundancy 1.9 (1.8) 
B. Refinement Statistics  
Resolution range (Å) 50-2.6 
No. of reflections 528,420 
Unique no. of reflections 82,260 
Rcryst
3
 (%) 21.2 
Rfree
4
 (%) 25.3 
Number of non-H atoms  
Protein 13,740 
Ligand (ions) 2 Zinc, 3 Chloride, 1 Acetate, 4 Sulphate, 5 Glycerol 
Water 309 
Average temperature factor (Å
2
) 41.0 
RMSD for bond lengths (Å) 0.009 
RMSD for bond angles (°) 1.3 
1
 Rsym = Σh Σi |I(h) – Ii(h)| / Σh ΣiI(h), where Ii(h) and I(h) are the ith and the mean 
measurements of the intensity of reflection h, respectively. 
2
 Outer shell is 2.74Å – 2.60Å. 
3
 Rcryst = Σh |Fo – Fc| / ΣhFo, where Fo and Fc are the observed and calculated structure factor 
amplitudes of reflection h, respectively. 
4
 Rfree is equal to Rcryst for a randomly selected 814 (1.0 %) reflections not used in the 
refinement. 
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3.1.3. Results and discussion 
3.1.3.1. Structure 
First crystal structure of LHn/A 
The structure of LHn/A using X-ray diffraction studies has been determined at 2.6 Å 
resolution. The structure was refined to a final Rfree = 25.3%, and Rcryst = 21.2% (Table 3.1, 
Figure 3.3), with 98.6% of amino acids in allowed region and 1.4% in the Ramachandran 
plot generously allowed region. The two molecules in the crystallographic asymmetric unit 
are tightly packed against each other in a dimeric arrangement. The interactions are 
stabilised by 15 potential H-bonds and 152 van der Waals contacts. However, the 
interactions between the two molecules could be due to crystal packing and may not be an 
inherent property of LHn/A. The buried surface area between the two molecules is 377 Å
2
 
compared to the total surface area of 21802 Å
2
. Engineered Factor Xa site for LC activation 
was confirmed both by SDS-PAGE analysis and in the crystal structure where there is a 
clear evidence of break in electron density between LC and Hn (Figure 3.3C). Furthermore, 
ordered electron density allowed model building of the full-length LC C-terminus and the 
disulphide bridge (Cys 430–Cys 454) between LC and Hn which are stabilised through an 
anti-parallel -sheet arrangement.  
The overall structure of LHn/A (Figure 3.3) resembles BoNT/A without the binding 
domain, and superposition of LHn/A on BoNT/A gives an overall root mean square 
deviation of 0.85 Å for 830 C-atoms (Figure 3.3B). This proves that the absence of binding 
domain in LHn/A did not produce any major conformational change compared with the 
structure of full length BoNT/A. LC is characterised by a mixture of -helix and -strands 
and has the conserved zinc binding motif HEXXH. Hn consists of three long anti-parallel -
helices of length 110 Å. A small region of Hn, called the ‘belt’, wraps LC and prevents 
access to the catalytic site. At least two roles are proposed for the belt, one as a chaperone 
for the catalytic domain (Brünger et al., 2007) and the other as a regulatory element in 
membrane interaction (Galloux et al., 2008). 
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Figure 3.3. Crystal structure of LHn/A. (A) Ribbon diagram representation of LHn/A 
structure. LC in cyan; Hn in blue; “belt” in pink. Zinc ion shown as orange spheres. (B) 
Superposition of LHn/A on BoNT/A (grey) (PDB code 3BTA). (C) Electron density 
showing the engineered peptide break between LC and Hn. 2|Fo|-|Fc| map contoured at 1. 
All the residues are shown in grey and ball-and-stick model. Disulphide link between LC 
and Hn is shown and sulphur atoms are coloured yellow. 
 
Domain components of engineered LHn/A 
Requirement of optimal length for a functional LHn/A is critical in LHn/A 
engineering. Deletion analysis carried out by Kurazono et al. (1992), showed that removal of 
10 amino acids from the amino terminal and 57 amino acids from the carboxy terminal of 
LC abolished the toxicity even in the presence of Hn. Hence, a full length catalytic domain 
is a requisite. A construct up to Ser 877 was selected to be an optimal length for Hn domain 
ending at the linker between Hn and Hc. 
 
 The light chain (LC) 
The light chains from all serotypes exhibit high degree of structural similarity. The 
catalytic zinc site is conserved in all serotypes and zinc is essential for LC’s enzymatic 
activity. In the engineered LHn/A molecule, the zinc ion is tetrahedrally coordinated to His 
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223, His 227, Glu 262 and a water molecule involving Glu 224, as observed in LC structures 
of BoNT/A (Figure 3.4).  
 
 
Figure 3.4. Zinc coordination in LHn/A. Ribbon diagram representation of LC/D (cyan). 
Zinc ion is shown as an orange sphere, water molecule in dark blue. Residues involved in 
the zinc coordination are shown in stick and ball representation. 2|Fo|-|Fc| map contoured at 
1

The translocation domain (Hn) 
 
The non-toxic Hn domain is required after endocytosis of the toxin for translocation of 
LC within the cytosol (Koriazova and Montal, 2003) where it is released and cleaves its 
substrate, thereby blocking neurotransmitter release. Hn domain’s accessible surface area is 
6038 Å
2
 compared to its total area of 19992 Å
2
 excluding the belt. The absence of the 
binding domain did not cause any major conformational change in the translocation domain. 
Hn normally interacts with Hc through eight potential hydrogen bonds and some 160 van der 
Waals’ contacts (calculated using holotoxin structure, PDB code 3BTA) around the 650 loop 
and residues Pro 801, Lys 805, Glu 808 and Ser 845. Superposition with the holotoxin 
model shows a change in the position of loop 642–650 and in particular with Tyr 648 which 
would form a hydrogen bond with Hc at His 886. Hn stability could be explained by strong 
inter-helical interactions not influenced by the new solvent accessibility. 
 
3.1.3.1. Endopeptidase activity 
SDS-PAGE of the protein sample was carried out at various temperatures to assess its 
stability during storage and under crystallisation conditions. Analysis by densitometry 
revealed that LHn/A was more than 95% pure after the final purification step (Figure 3.5A). 
Reduced conditions put in evidence some residual non-activated (single chain) peptide at 
100 kDa, representing less than 4% of the sample. LHn/A’s stability is also not affected by 
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high concentration of ammonium sulphate (1.5 M) from the crystallisation condition. There 
was approximately 10% degradation observed after 36 days of incubation at 25 °C.  
 
 
Figure 3.5. Stability and activity of LHn/A. (A) SDS-PAGE analysis of LHn/A stability. 
Lanes 1, 3 and 5, oxidised samples; 2, 4 and 6, reduced samples. Lanes 1, 2 on day d1; 3, 4 
on day d36 in buffer A; 5, 6 on day d36 in crystallisation buffer. (B) SDS-PAGE analysis of 
SNAP-25 cleavage assay by LHn/A. GFP-SNAP-25 is 51 kDa. LC cleaves GFP-SNAP-25 
in two peptides of 28 (*) and 23 (**) kDa, respectively. Lanes 1, 5, 8, LHn/A (100 g/ml); 
2, 6, 9, LHn/A (20 g/ml); 3, 7, 10, LHn/A (4.0 g/ml). Lanes 4, 11, negative control. BSA 
visible at 70 kDa in all lanes. On lanes 1, 5, 8 the two bands below the non-cleaved substrate 
correspond to reduced LHn/A domains.  
 
The catalytic property of LHn/A was confirmed by the SNAP-25 cleavage assay. 
(Figure 3.5B). A SNAP-25-GFP substrate was engineered to monitor LHn/A proteolytic 
action resulting in two peptides of approximately 28 and 23 kDa respectively. The results 
were in correlation with the stability study since less than a 10% loss of activity was 
noticeable after 36 days of storage under crystallisation conditions at 25˚C. LHn/A tested at 
0.1 mg/ml showed complete substrate cleavage and uncleaved substrate was only just 
detected by densitometry with LHn/A at 0.02 mg/ml. Overall, LHn/A presented strong 
stability and kept its catalytic activity over a period of 36 days in the crystallisation storage 
conditions. This corresponds to the length required for crystal formation, implying that the 
structure described here correspond to a functional toxin with its native property. 
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The data presented here have led to the solution of the first crystal structure for an 
LHn fragment of botulinum neurotoxin and does not show any noticeable structural 
difference between the parent neurotoxin and the recombinant fragment lacking the Hc 
domain. LHn/A was shown to be catalytically active, and a recent study demonstrated its 
ability to translocate the active protease within the cytosol of target cells (Fischer et al., 
2008b). LHn/A thus represents a fully functional BoNT fragment. With a growing interest in 
the use of the LHn fragment for therapeutic and vaccine purposes (Acharya and Chaddock, 
2011), the structure presented here will facilitate the development of optimised proteins that 
will have greater applicability. LHn/A’s structural integrity is unlikely to alter the property 
of any fusion proteins and provides additional degree of freedom for the design of future 
novel ligands. 
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3.2. Structure and activity of LHn/B 
3.2.1. Introduction 
BoNT/B is synthesised as a single polypeptide cleaved by clostridial or host proteases 
to its active form. The C-terminal heavy chain composes the binding (Hc/B) and 
translocation (Hn/B) domains of 50 kDa each, and is linked by a single disulphide bridge to 
the catalytic light chain (LC/B), a zinc endopeptidase. The crystal structure of BoNT/B was 
reported in 2001 (Swaminathan and Eswaramoorthy, 2000) and confirmed the individual 
fold of each domain, as well as their three-dimensional linear arrangement.  
BoNT/B binds specifically to the nerve terminals by a dual interaction with a protein 
receptor, synaptotagmin, and a ganglioside (GT1b) (Baldwin and Barbieri, 2007). The 
complex is endocytosed into a vesicle where the acidic environment provokes 
conformational changes and mediates translocation of LC/B into the cytosol (Montal, 2010). 
The protease domain is then free to cleave the vesicle-associated membrane protein (VAMP, 
also known as synaptobrevin and cellubrevin.), one of the SNARE proteins. Impairing the 
function of the SNARE complex causes inhibition of neurotransmission and hence paralysis. 
BoNT/B substrate recognition relies on an extended set of exosites located 
downstream and upstream of the scissile bond. A number of mutation and kinetic studies 
with VAMP-2 identified some of the regions important for proteolysis by VAMP-specific 
Clostridial toxins (Chen et al., 2008; Sikorra et al., 2008). This suggests a common mode of 
an extended substrate binding, each presenting with a different set of enzyme-substrate 
interactions. 
The LHn fragment of BoNT/A was shown to conserve the proteolytic activity of its 
parent neurotoxin and was active on cells when added at high concentration (Chaddock et 
al., 2002; Fischer et al., 2008b). LHn are therefore attractive candidates as scaffolds for the 
design of novel biological therapeutics (Chaddock and Marks, 2006; Foster, 2009). BoNT/A 
and /B are the only serotypes currently approved for pharmaceutical applications. 
Characterisation of the LHn/B fragment is therefore necessary if it is to be used in novel 
therapeutic molecules. 
The crystal structure of the LHn fragment from serotype B botulinum neurotoxin 
described here was determined at 2.8 Å. It demonstrated the stability of the translocation 
domain in association with the catalytic light chain. The metalloprotease activity of the 
parent toxin was conserved and presented differences in VAMP substrates specificity. If 
applied at suitably high concentrations, this active protease could be translocated inside 
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neuronal cells despite the lack of a specific binding domain. It confirmed the relevance of 
LHn/B as a functional molecule and highlights the use of LHn as a tool for deciphering the 
mechanism of botulinum neurotoxin’s action. 
 
3.2.2. Materials and methods 
LHn/B cloning, expression and purification  
The synthetic gene encoding 880 amino acids of LHn/B was cloned into modified 
pET vector (Novagen, UK) with a C-terminal 6 x His-tag and transformed into E. coli BL21 
expression cells. The LHn/B gene was engineered to encode for Factor Xa cleavage site 
(IEGR) between the LC and Hn domain between positions 449-452. The clone was provided 
by Syntaxin Ltd. Expression cultures of LHn/B were grown in 1L terrific broth at 200 rpm, 
37°C until OD600 read 0.5-0.6. Then cultures were incubated at 16°C and induced with IPTG 
(1mM). Cells were harvested after 18 h, and stored at -80°C until further use.  
Cells were resuspended in 50 mM HEPES, pH 7.2, 0.2 M NaCl (buffer A) and lysed 
at 20,000 psi with a homogeniser (Constant Systems Ltd). Lysate was centrifuged for 45 
minutes at 18,000 g. Soluble fraction was loaded onto a Ni
2+
-charged chelating sepharose 
column (GE Healthcare). LHn/B eluted at 100 mM imidazole (dissolved in buffer A) and 
dialysed overnight at 4°C against buffer A. Activation of purified LHn/B is achieved by 
Factor Xa (New England BioLabs) treatment. The cleaved fusion protein was supplemented 
with ammonium sulphate to 1 M and loaded onto a Toyopearl Phenyl-650M column, 
equilibrated with 50 mM HEPES, pH 7.2, 1.0 M ammonium sulphate. LHn/B eluted at 0.7 
M ammonium sulphate (in buffer) and dialysed overnight against buffer A at 4°C. A SDS-
PAGE summary of LHn/B purification is presented in figure 3.6A. The sample was finally 
concentrated using Vivaspin 50000 MWCO concentrator (Millipore) to 9 mg/ml and stored 
at -20°C. All concentrations were determined by A280 measurement. 
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Figure 3.6. Purification and crystallisation of LHn/B. (A) SDS-PAGE summary of 
LHn/B purification. Lane 1, cell lysate supernatant; 2, pooled eluate from first purification 
step; 3, 4, Factor Xa-activated sample in oxidised (O) and reduced (R) conditions 
(respectively); 5, 6, Eluate from final purification step (O and R). (B) Crystals of LHn/B 
after optimisation in 15% PEG3350, 0.1 M BIS-TRIS-propane pH 6.5, 0.2 M sodium 
sulphate. (C) X-ray diffraction image collected at DLS, IO3 where LHn/B crystals diffracted 
at 2.8 Å. (D) LHn/B crystal mounted for data collection. 
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Crystallisation and structure determination 
Several crystallisation conditions were identified using PACT premier (Molecular 
Dimensions). The conditions which were repeatable by hanging-drop with 3 l drops (1.5 l 
protein and 1.5 l mother liquor) against a reservoir (500 μl) at 16°C were used in several 
round of optimisation. Crystals could be readily grown in 15% PEG3350, 0.1 M BIS-TRIS-
propane pH 6.5, 0.2 M sodium sulphate. Crystals had a tendency to grow as stacks of blade-
shaped forms. Macro-seeding was performed to obtain single crystals of suitable size and 
quality (Figure 3.6). 
X-ray diffraction data were collected at the Diamond Light Source, UK, beamline 
IO3. A complete dataset to 2.8 Å was collected from a single crystal at 100K (25% glycerol 
as cryoprotectant) using a Quantum-4 CCD detector (ADSC Systems, CA) (Figure 3.6). The 
data were processed and scaled in orthorhombic space group P21212 using MOSFLM and 
SCALA (CCP4, 1994; Leslie, 2006) (Table 3.2). Initial phases were obtained by molecular 
replacement using Phaser (McCoy et al., 2007) with the coordinates of a model based on the 
LHn fragment of the BoNT/B structure (PDB code 1EPW, Swaminathan and 
Eswaramoorthy, 2000). Crystallographic refinement was carried out using REFMAC5 
(version 5.5; Vagin et al., 2004). Manual adjustments and model fitting were done using 
Coot (version 0.6.1) (Emsley and Cowtan, 2004). Water molecules were added at positions 
where Fo–Fc electron density peaks exceeded 3σ and potential H-bonds could be made. The 
structure was validated using MolProbity (Davis et al., 2007). Structure figures were drawn 
with PyMOL (DeLano Scientific LLC). 
The atomic coordinates and structure factors (codes 2XHL and r2XHLsf, Masuyer et 
al., 2011) have been deposited in the Protein Data Bank, Research Collaboratory for 
Structural Bioinformatics, Rutgers University, New Brunswick, NJ (http://www.rcsb.org/). 
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Table 3.2. Data collection and refinement statistics of LHn/B 
 
A. Data collection statistics 
Space group P21212 
Number of molecules/asymmetric unit 1 
Cell dimensions a = 66.9, b =113.5, c =149.1Å ; = 90°
Resolution range (Å) 50-2.8 
Rsym
1 (%) 12.1 (51.4) 
I/I (outer shell) 10.3 (3.5) 
Completeness (outer shell) % 99.8 (100.0) 
Total no. of reflections  165,586 
Unique no. of reflections 28,644 
Redundancy 5.8 (5.8) 
Wilson B-factor (Å2) 57.6 
B. Refinement statistics  
Resolution range (Å) 50-2.8 
Rcryst
2 (%) 24.0 
Rfree
3 (%) 28.2 
Number of non-H atoms  
Protein 6,828 
Ligand  1 zinc ion 
Water 31 
Average temperature factor (Å2) 
Protein atoms- LC/B = 32.6, Hn/ B = 40.8  
(water molecules = 22.1) 
RMSD in bond lengths (Å) 0.006 
RMSD in bond angles (°) 0.86 
1Rsym = Σh Σi |I(h) – Ii(h)| / Σh ΣiIi(h), where Ii(h) and I(h) are the i
th and the mean 
measurements of the intensity of reflection h, respectively.  
2Rcryst = Σh |Fo| – |Fc| / ΣhFo, where Fo and Fc are the observed and calculated structure factor 
amplitudes of reflection h, respectively. 
3Rfree is equal to Rcryst for a randomly selected 5.0% subset of reflections not used in the 
refinement. 
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Enzymatic assay  
LHn/B and BoNT/B (Metabiologics, US) were diluted to 0.1 g/ml in buffer 
containing 50 mM HEPES pH 7.2, 20 M ZnCl2, 1 g/l BSA, 10 mM DTT, and incubated 
at 37°C for 30 minutes. Recombinant VAMP-1 (2-96), -2 (1-94) and -3 (2-77) substrates 
were expressed with a C-terminal GFP tag and purified. VAMP-GFP substrates were serial 
diluted and incubated with the test enzyme at 37°C for 1 hour. Reactions were stopped by 
adding 2x reducing sample buffer (Invitrogen). Samples were then loaded on to a 4-12 % 
BIS-TRIS gel (Invitrogen) along with BSA standards and visualised by staining with Simply 
Blue Safestain (Invitrogen). Assay results were quantified by densitometry (Syngene 
Bioimaging). 
Embryonic spinal cord neuron (eSCN) assay  
Spinal cords dissected from 14–15 day old foetal Sprague Dawley rats were cultured 
for 21 days using a modification of previously described method (Chaddock et al., 2002) 
and provided for the assay. eSCN were treated with serial dilutions of LHn/B and BoNT/B, 
and incubated at 37 °C with 10% CO2 for 24 hours. Cells were lysed by removing all media 
and adding sample buffer (25% NuPAGE buffer, 10 mM DTT). After 20 minutes, samples 
were transferred into microcentrifuge tubes and heated at 95°C for 5 minutes. All samples 
were run on 12 % BIS-TRIS gels (Invitrogen) and proteins were transferred onto 
nitrocellulose membranes (Invitrogen) using standard protocols. VAMP cleavage was 
monitored by measuring the disappearance of the specific VAMP immunoreactive bands 
compared to an internal control protein (GAPDH). Specific binding of VAMP-1, -2 and -3 
primary antibodies (Abcam #ab3346, #ab3347 and #ab43080) was visualised using 
peroxidase-conjugated secondary antibodies and an enhanced chemiluminescent (ECL) 
detection system (Thermo Scientific), analysis was performed by densitometry (Syngene 
Bioimaging). 
 
3.2.3. Results and discussion 
3.2.3.1. Structure 
The crystal structure of LHn/B has been determined at 2.8 Å resolution. The structure 
was refined to a final Rfree = 28.2%, and Rcryst = 24.1% (Table 3.2, Figure.3.7), with 97.8% of 
amino acids in the Ramachandran plot favoured region. 
The structure presents the two domains interacting tightly in a di-chain complex. The 
successful activation of LHn/B by Factor Xa at the engineered site was confirmed by SDS–
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PAGE analysis (Figure 3.6A) and the crystal structure, which shows a clear evidence of the 
cleavage by a break in electron density between LC and Hn (Figure 3.7C). This region is 
likely to be particularly important for BoNT activity and Hn-mediated delivery of LC in the 
cytosol. The resulting LC C-terminus and the disulphide bridge (A Cys 437– B Cys 461) 
between LC and Hn are stabilised through an anti-parallel -sheet arrangement.  
 
Figure 3.7. Crystal structure of LHn/B. (A) Ribbon diagram representation of LHn/B 
structure, Hn in blue, LC in cyan. Zinc ion is shown as orange spheres. (B) Superposition of 
LHn/B with BoNT/B (in grey, PDB 1EPW, Swaminathan and Eswaramoorthy, 2000). 
Overall root mean square deviation was calculated with Swiss PDB viewer and was 0.95 Å 
for 837 C-atoms. (C) LC-Hn interaction at the disulphide bridge (sulphur atoms in yellow) 
– Factor Xa cleavage site for activation. 2|Fo|-|Fc| map contoured at 1 (D) LHn/B 
molecule rotated 90° to highlight the C-terminal accessible solvent surface. Electrostatic 
potential calculated using APBS in PyMOL (Negative potential in red, Positive in blue). 
 
The overall structure of LHn/B (Figure 3.7) resembles BoNT/B without the binding 
domain, and superposition of LHn/B with its parent toxin gives an overall root mean square 
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deviation of 0.95 Å for 837 C-atoms (Figure 3.7B). The absence of the 50 kDa binding 
domain in LHn/B did not result in any major conformational change compared with the 
structure of full length BoNT/B. 
LC is a zinc protease with the catalytic ion coordinated by the conserved tetrahedral 
arrangement of His 229, His 233, Glu 267 and a water molecule bonded to Glu 230. While 
LC primary sequence is fairly conserved among BoNTs (Lacy and Stevens, 1999), its 
activity is regulated by a complex substrate binding mechanism relying on dispersed 
exosites, away from the catalytic site. In the structure of the LC/A-SNAP-25 complex, these 
sites consisted of dispersed flexible loop regions (Breidenbach and Brünger, 2004). The 
unstructured regions seen in LHn/B follow the same arrangements as seen in the full length 
toxin (Figure 3.7). Residues 208-218, downstream of the active site, could not be modelled 
due to the lack of electron density. This may be the result of the loop's flexibility, even 
though the holotoxin structure shows it to be stabilised by interactions with helices 17 and 
19 of Hn (Swaminathan and Eswaramoorthy, 2000). 
Two long anti-parallel helices structure the Hn domain. The newly accessible 
solvent area left open by the lack of binding domain represents 1880 Å
2
 and shows weak 
electrostatic potential (Figure 3.7D). The interface between Hn and Hc of the holotoxin is 
based on 12 potential hydrogen bonds and some weaker van der Waals’ contacts between 
loop 916-920 of Hc and helix 20 of Hn, as well as between the short linker helix of Hc 
subdomains and loop 610-615 (Hn) (Swaminathan and Eswaramoorthy, 2000). The loop 
between residues 626-630 and the last 10 C-terminal residues (including the poly-His tag) of 
LHn/B could not be modelled due to lack of electron density. Strong inter-helical 
interactions allow Hn to keep its long helical conformation as illustrated by the perfect 
superposition of LHn/B with BoNT/B (Figure 3.7B). The belt of Hn surrounding LC appears 
to be important for aspects of BoNT activity. The LHn/B structure demonstrates that the 
stability of this fold is based on strong interactions with LC and is similar to that seen in the 
holotoxin structure. 
The crystallographic studies of LHn, serotypes A and B, highlight the exceptional 
structural stability of these fragments when compared to their parent holotoxins. LHn/A has 
been shown to conserve not only the structure, but also the catalytic property of BoNT/A, as 
well as a potential for intracellular activity (Chaddock et al., 2002; Fischer et al., 2008b; 
Masuyer et al., 2009). Analysing the functionality of these fragments can therefore help 
understand the relationship between BoNT domains. 
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3.2.3.2. Endopeptidase activity 
Proteolytic activity of LHn/B 
The ability of LHn/B to retain its proteolytic activity was tested by looking at the 
cleavage of VAMP-1, -2 and -3. The three substrates were recombinantly produced as GFP-
tagged constructs and were successfully hydrolysed by LHn/B (Figure 3.8A). The cleavage 
site was checked for each substrate by N-terminal sequencing (Alta Bioscience, UK) and 
confirmed to be at the expected position, corresponding to the site of BoNT/B action (Figure 
3.8A).  
 
 
Figure 3.8. VAMP cleavage assay. (A) Enzymatic cleavage of VAMPs by LHn/B. Results 
were obtained by densitometry analysis and plotted. Non-linear fit was done with GraFit 
following Michaelis-Menten equation. Results for VAMP-1: Km= 12±3, Vmax= 157±12; 
VAMP-2: Km= 6.0±4.3, Vmax= 150±27; VAMP-3: Km= 3.2 ±1.4, Vmax= 27.9±3.5 (Km in 
M, Vmax in pmol/hour/g enzyme). (B) CLUSTALW alignment (EBI) of human VAMP-
1,-2 and -3. Regions important for VAMP-2 cleavage by BoNTs are coloured in grey (Chen 
et al., 2008; Sikorra et al., 2008), numbers correspond to VAMP-2 residues. The C-terminal 
transmembrane domain is indicated. 
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A quantitative analysis of VAMP cleavage was performed by testing a range of 
different substrate concentrations at a fixed concentration of LHn/B (0.01 g/ml). The 
plotted results were fitted according to a Michaelis-Menten equation. Substrate cleavage 
showed a higher maximal velocity (Vmax) for VAMP-1 and -2, (157±12 and 150±27 
pmol/hour/g enzyme respectively) than it did for VAMP-3 (27.9±3.5 pmol/hour/g 
enzyme). Similar results were obtained with the BoNT/B control (unpublished results). A 
precise calculation of Km is difficult due to the nature of the assay, making the visualisation 
of low product levels hard to quantify. However determinations of Km only varied between 
3.2 and 12 M. It is likely that these apparent differences are within the errors of the 
estimations. Extensive work on the requirements for VAMP cleavage by Clostridial toxins 
have demonstrated that residues 60-87 of VAMP-2 were sufficient for efficient cleavage by 
BoNT, with residues within close distance of the scissile bond influencing the catalytic rate 
of reaction whereas several exosites on both sides of the bond were involved in binding 
(Chen et al., 2008). The primary sequences of the three VAMP tested (Figure 3.8B) show 
that the scissile bond area is generally very conserved, apart for a minor difference at 
position P2 in VAMP-1 (VAMP-1/S – VAMP-2-3/T). This high degree of sequence 
conservation may explain the low variation in Km observed between the three substrates. 
The sequence alignment presents only one noticeable difference between VAMP-1 and -2 
compared to VAMP-3 that lies near to the previously identified BoNT binding regions 
(VAMP-1-2/ Ala 39, 37 respectively compared to VAMP-3/ Asn 20). Further work is 
necessary to determine if this change accounts for the Vmax difference observed for these 
substrates. Another obvious difference in VAMP-3 compared to VAMP-1 and -2 is the N-
terminal region which is considerably shorter and lacking the proline-rich region seen in 
VAMP-1 and -2. However, LC/B was proved to efficiently cleave a construct from VAMP-2 
lacking residues 1-59 (Chen et al., 2008). The C-terminal transmembrane regions of the 
VAMP proteins were not included in these recombinant substrates. These regions were 
replaced by a GFP-tag and are unlikely to affect substrate binding. 
Activity of LHn/B on embryonic spinal cord neurons  
Studies with BoNT/A have shown that Hn is necessary for the transport of LC into 
cells (Koriazova and Montal, 2003). LHn/B is similarly composed of the catalytic light chain 
with its translocating partner domain. The function of Hn in absence of the BoNT binding 
domain was investigated on embryonic spinal cord neurons (eSCN) and compared to the 
holotoxin's effect. VAMP cleavage was monitored by Western blotting eSCN lysates after 
incubation with each protein. The blots were quantified by densitometry and the proportion 
of uncleaved VAMP remaining after treatment was plotted (Figure 3.9).  
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The response followed dose-dependent sigmoidal curves for BoNT/B on VAMP-1 
and -2, with sub-picomolar EC50. High concentrations of LHn/B also showed a sigmoidal 
dose-dependent response with EC50 of 15 and 170 nM on VAMP-2 and -1, respectively. 
This suggests that the binding domain of BoNT/B confers the toxin with more than 10
5
-fold 
better efficiency in reaching its intracellular substrate. This is analogous to the phenomenon 
seen with BoNT/A and LHn/A where a 10
5
 fold difference in concentration was observed on 
the inhibition of neurosecretion in similar cells (Chaddock et al., 2002). It is expected that 
intracellular VAMP cleavage observed here would also result in a similar inhibition of 
neurotransmission, thus representing a reliable model to assay VAMP-specific BoNTs. 
 
Figure 3.9. Spinal cord neuron assay. (A) Western blot analysis of VAMP-2 from cell 
lysates after treatment with decreasing concentrations of LHn/B and BoNT/B. (B) Analysis 
of intracellular cleavage of VAMP-1 (circles and squares) and -2 (triangles and diamonds) 
after treatment with LHn/B and BoNT/B respectively. Results were obtained by 
densitometry analysis and plotted. Non-linear fit was done with GraFit. 
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The mechanism of entry of LHn/B into eSCN is unknown but is likely to rely on a 
non-specific process. Fisher et al. (2008) reported LHn/A’s ability to translocate LC over a 
wide pH range compared to the native toxin, therefore increasing the likelihood of 
translocation. On the other hand, the possibility of a low affinity receptor for LHn/B in this 
cell type should not be excluded. The effect observed here is enhanced by the high LHn/B 
concentration and the sensitivity of the system used for testing. However, further 
experimental evidence is required to fully understand the mechanism of internalisation by 
the LHn molecule. 
BoNT/B and LHn/B both showed higher apparent efficiency in cleaving VAMP-2 
compared to VAMP-1 in eSCN (Figure 3.9). The significance of this observation is not fully 
understood. Differences in the immunoreactivity, abundance and sub-cellular localisation of 
these two SNAREs may play roles in accounting for this observation. VAMP-2 is known to 
be the most abundant protein in synaptic vesicles (Takamori et al., 2006). One possibility is 
that VAMP-2 might compete with VAMP-1 for binding to the LC. VAMP-3 was also 
monitored in treated eSCN lysates and did not show any evidence for VAMP-3 cleavage 
(results not shown). The role of VAMP-3 (also called cellubrevin) has been previously 
investigated in non-neuronal cells using Clostridial tetanus toxin (McMahon et al., 1996). It 
highlighted its importance in the recycling of the plasma membrane, early endosome 
pathways, epithelial cell migration and adhesion (Proux-Gillardeaux et al., 2005). Despite 
VAMP-3 homology with VAMP-1 and -2 (Figure 3.8B), there is no strong evidence for a 
direct role of VAMP-3 in neurosecretion. The lower specificity of LHn/B for this substrate 
demonstrated in the cell-free assay, along with the lack of intracellular proteolysis in eSCN, 
suggests that the toxin may have evolved to specifically target SNAREs directly mediating 
neurotransmission. 
 
In the present study, the LHn/B fragment consisting of the catalytic and translocation 
domains of BoNT/B, is shown to retain its native structure after deletion of the Hc domain. 
The functionality of the fragment was also demonstrated in vitro with its ability to cleave 
several VAMP substrates. Similar to wild type BoNT/B, LHn/B showed higher specificity 
for VAMP-1, and -2 compared to VAMP-3. Furthermore, LHn/B retained an ability to 
cleave intracellular VAMP in spinal cord neurons, indicating an intrinsic capacity of Hn to 
transport its catalytic partner within the cytosol. A detailed understanding of the processes 
involved in internalisation and translocation into the cytoplasm is not yet available and 
requires further analysis, which may in turn give some indication on the translocation 
mechanism in the corresponding holotoxins. 
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LHn/B does not have the BoNT cell binding domain. The extent to which it can 
interact with and become internalised by other cell types represents an area for further study. 
This may reveal LHn/B as a useful pharmacological tool in the study of VAMP-mediated 
secretion events. 
LHn fragments studied so far constitute stable soluble proteins that conserve the 
functionality of their parent holotoxin but lack the neuron specific targeting conferred by the 
binding domains of full-length BoNT. These fragments provide additional tools for 
understanding the structure-function relationship of BoNT domains in the intoxication 
process, and offer a new strategy for therapeutic and vaccine development (Chaddock and 
Acharya, 2011). Determining the structure of other LHn serotypes will help refine our 
knowledge and explain the variations in activities seen between the botulinum neurotoxin 
serotypes. 
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3.3. Structure of LHn/D 
3.3.1. Introduction 
Of the seven types of botulism, A, B, E and F are known to cause the disease in 
human while C and D have only been observed in animal cases. More particularly, D has 
been responsible for several recent outbreaks of botulism in cattle (Steinman et al., 2007). 
This has raised some interest in this serotype and its precise mechanism of action. 
No cases of type D human botulism have ever been recorded. Coffield et al. (1997) 
investigated the impact of serotype D on human tissues and demonstrated its inability to 
block neuromuscular transmission when tested at level 10 times higher than that of serotype 
A. This result implies that BoNT/D lacks a specific receptor to target human neurons. 
BoNT/D however acts similarly to the other botulinum neurotoxins by targeting one of the 
intracellular SNARE proteins. Synaptobrevin (or VAMP) was identified as BoNT/D specific 
substrate (Schiavo et al, 1993). It is cleaved at a unique position, the Lys-59- Leu-60 peptide 
bond.  
Efforts to understand the mechanisms of BoNT/D have led to the determination of the 
crystal structures corresponding to the binding (Hc) and (LC) catalytic domains. 
Interestingly, several recent studies have focused on the Hc structure to explain the unusual 
entry of BoNT/D into neurons. As a summary, Hc/D was shown to lack a ganglioside 
binding motif common to other BoNT serotypes (H…SXWY) despite the domain 
conserving its typical -trefoil structure (Karalewitz et al., 2010). While one of the crystal 
structures highlighted the presence of two carbohydrate binding pockets (Strotmeier et al., 
2010) that could be involved in neuron recognition, a more recent structure along with 
binding and immunofluorescent assays seemed to favour a ganglioside-mediated entry 
(Kroken et al., 2011). Key residues unique to BoNT/D form a hydrophobic loop 
corresponding to the ganglioside binding region and are responsible for this serotype 
selectivity towards particular animal species.  
The high resolution crystal structure of LC/D (Arndt et al., 2006) showed features 
similar to the other BoNTs’ LC and gave some clues regarding its mode of substrate 
binding. LC/D is a zinc metalloprotease that possess the classical zinc binding motif 
(HEXXH) at the active site. It is of a mixed composition with nine -helices and twelve -
strands. The main differences with other LC are in the loop regions which share the lower 
sequence identity, and are likely to be involved in substrate binding (Breidenbach and 
Brünger, 2004). Indeed, the long substrate requirement for all LC is a feature shared by 
LC/D since the minimum substrate length corresponds to segment Thr27-Gln 76 of VAMP2 
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(Yamasaki et al., 1994). This was highlighted by modelling of the LC/D-VAMP2 interaction 
based on the LC/A-SNAP25 complex (Arndt et al., 2006), which showed a putative 
interface largely based on LC/D hydrophobic surface potential. 
Despite its lack of human toxicity, BoNT/D has been proposed as an alternative to 
other serotypes for engineering proteins able to transport active enzymes within neuronal 
cells. Bade et al. (2004) described the building of full length recombinant BoNT/D 
associated with various reporter enzymes. Intracellular function of BoNT/D was conserved 
and added activity observed when associated with an amino-terminal LC/A domain. 
Intracellular localisation was also confirmed by fluorescence microscopy with a GFP-tag 
construct, as well as with the successful transport of a luciferase-BoNT/D molecule. Overall 
it was observed that successful transportation of an enzymatic cargo depended not only on 
the size of the attached protein, but also on its structural ability to form unfolded 
intermediates. 
BoNT/A and /B are currently the only serotypes approved for medical uses. With the 
emergence of immuno-reactivity among patients, other serotypes could provide a useful 
alternative (Turton et al., 2002). BoNT/D efficiency at targeting intracellular VAMP 
(Schiavo et al, 1993) makes it an interesting candidate for protein engineering. Especially, 
the successful retargeting of BoNT activity for therapeutic purposes, by association of the 
LHn fragment with various ligand (Foster et al., 2009), highlights the relevance of using 
serotype D. In this context, BoNT/D inability to bind human neurons would not be an issue 
as Hc would be replaced by a specific targeting polypeptide. 
Structural and biochemical characterisation of the LHn fragments from serotypes A 
(Section 3.1; Masuyer et al., 2009) and B (Section 3.2; Masuyer et al., 2011) have 
demonstrated their stability and functionality, representing an important step forward for the 
design of novel molecules based on these frameworks. In order to assess its applicability for 
further pharmaceutical development, LHn/D was cloned, expressed and purified. 
Crystallisation trials were set up and yielded protein crystals that diffracted to 2.2 Å. Careful 
processing of the data showed that only the LC domain was present in the crystals. The 
structure of LC/D was therefore refined and compared to the published structure (PDB 
2FPQ, Arndt et al., 2006). An alternative LHn/D construct was also crystallised and showed 
a similar truncated LC/D. However, several noticeable differences were observed between 
these structures and are discussed below. 
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3.3.2. Materials and methods 
LHn/D cloning, expression and purification  
The synthetic gene encoding 872 amino acids of LHn/D was cloned into modified 
pET vector (Novagen, UK) with a C-terminal 6 x His-tag and transformed into E. coli BL21 
expression cells. The LHn/D gene was engineered to encode for an enterokinase cleavage 
site (DDDDK) between the LC and Hn domain between positions 448-452. The clone was 
provided by Syntaxin Ltd. Expression cultures of LHn/D were grown in 1L terrific broth at 
200 rpm, 37°C until OD600 reads 0.5-0.6. Then cultures were incubated at 16°C and induced 
with IPTG (1mM). Cells were harvested after 18 h, and stored at -80°C until further use.  
Cells were resuspended in 50 mM HEPES, pH 7.2, 0.2 M NaCl (buffer A) and lysed 
at 20,000 psi with a homogeniser (Constant Systems Ltd). Lysate was centrifuged for 45 
minutes at 18,000 g. Soluble fraction was loaded onto a Ni
2+
-charged chelating sepharose 
column (GE Healthcare). LHn/D eluted at 100 mM imidazole (dissolved in buffer A) and 
dialysed overnight at 4°C against buffer A. Activation of purified LHn/D is achieved by 
enterokinase (New England BioLabs) treatment. The cleaved fusion protein was 
supplemented with ammonium sulphate to 1 M and loaded onto a Toyopearl Phenyl-650M 
column, equilibrated with 50 mM HEPES, pH 7.2, 1.0 M ammonium sulphate. LHn/D 
eluted at 0.4 M ammonium sulphate (in buffer) and was dialysed overnight against buffer A 
at 4°C. The sample was finally concentrated using Vivaspin 50000 MWCO concentrator 
(Millipore) to 5.2 mg/ml and stored at -20°C. All concentrations were determined by A280 
measurement. A SDS-PAGE summary of the purification is shown in figure 3.10A. 
A non-activated, single-chain, form of LHn/D was also purified (scLHn/D). Briefly, 
initial preparation was identical to its activated counterpart and then followed by a two-step 
purification process. After a first affinity chromatography (His Trap HP, GE Healthcare), the 
fractions of scLHn/D were pooled and supplemented with ammonium sulphate to 1 M for 
loading onto a Phenyl-650M column (Toyopearl). The sample was dialysed and 
concentrated to 5.2 mg/ml (storage at -20°C). SDS-PAGE of the purified material is shown 
in figure 3.10B. 
A protein based on LHn/D with a Factor Xa activation site (LHn/D/Xa) was provided 
by Syntaxin Ltd for crystallographic analysis. SDS-PAGE of the purified material is shown 
in figure 3.10C, mass spectrometry confirmed the construct was of the expected size (results 
not shown). 
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Figure 3.10. SDS-PAGE analysis of LHn/D, scLHn/D, and LHn/D/Xa purifications. (A) 
Summary of LHn/D purification. Lane 1, cell lysate supernatant; 2, 3, enterokinase-activated 
eluate from first purification step in oxidised (O) and reduced (R) conditions (respectively); 
4, 5, eluate from final purification step (O and R). (B) Summary of scLHn/D purification. 
Lane 1, cell lysate supernatant; 2, eluate from first purification step; 3, eluate from final 
purification step. (C) Lanes 1, 2, purified LHn/D/Xa sample provided (O and R). 
 
Characterisation of LHn/D by Western-blot. 
Final sample of purified LHn/D was run on a SDS-PAGE gel and blotted on a PVDF 
membrane (Millipore). Primary detection was performed using anti-LC/D and anti-Hn/D 
antibodies raised in rabbit (obtained from Eurogentec), a Tetra-His (QIAGEN) antibody was 
used for the C-terminal tag detection. For secondary recognition, horseradish peroxidase-
conjugated anti-rabbit and anti-mouse antibodies (respectively) were applied (Sigma). 
Enhanced chemiluminescent (ECL) substrate reagent (Thermo Scientific) was utilised for 
detection. 
Crystallisation  
Different conditions gave crystallisation hits for LHn/D, all in the shape of thin 
needle-like crystals. A single condition was successfully repeated by hanging-drop with 
manual trials: 24% PEG1500, 20% glycerol (with 3 l drops - 2 l protein and 1 l mother 
liquor - against a reservoir 500 μl). After several rounds of optimisation and seeding, single 
larger needles were grown in 10% PEG1500, 20% glycerol and x-ray diffraction data could 
be collected (Figure 3.11).  
Crystals for scLHn/D were also obtained. Crystals grew in stack of thin rod-shape 
forms in 0.1 M BIS-TRIS-propane pH 6.5, 0.3 M potassium thiocyanate, 18% PEG3350. 
However, scLHn/D crystals failed to diffract to better than 6 Å. 
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A single LHn/D/Xa (long needle-shape) was obtained in 0.05 M sodium citrate, 20% 
PEG3350 in a single drop from primary sitting-drop crystallisation screens, observed after a 
one-year incubation period.  
 
Figure 3.11 Crystals and x-ray diffraction of LHn/D. (A) Diffraction image collected at 
DLS IO3 where LHn/D crystals diffracted at 2.2 Å. (B) Crystals of LHn/D after optimisation 
in 10% PEG1500, 20% glycerol. 
 
Data collection and structure determination 
X-ray diffraction data for LHn/D were collected at the Diamond Light Source, UK, 
beamline IO3. A complete dataset to 2.2 Å was collected from a single crystal at 100K (no 
cryoprotectant added) using a Quantum-4 CCD detector (ADSC Systems, CA). The data 
were processed and scaled in hexagonal space group P65 using MOSFLM and SCALA 
(CCP4, 1994; Leslie, 2006) (Table 3.3). 
Initial phases were obtained by molecular replacement (MR) using PHASER (McCoy 
et al., 2007). MR trials were first tested with the coordinates of LHn/A and B (PDB code 
2W2D, 2XHL respectively, Masuyer et al., 2009, 2011) but failed to give a solution. Then 
search parameters were set for a single LC domain (PDB code 2FPQ, Arndt et al., 2006). A 
convincing solution was found (Z score = 34.0) although it represented residues 1-400. Hn 
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searches with this LC solution were unfruitful. The final structure was solved after searching 
for two LC molecules per asymmetric units (Z score = 71.6).  
Crystallographic refinement was carried out using REFMAC5 (version 5.5) (Vagin et 
al., 2004). Manual adjustments and model fitting was done using Coot (version 0.6.1) 
(Emsley and Cowtan, 2004). Water molecules were added at positions where Fo–Fc electron 
density peaks exceeded 3σ and potential H-bonds could be made. The structure was 
validated using MolProbity (Davis et al., 2007). Structure figures were drawn with PyMOL 
(DeLano Scientific LLC). 
X-ray diffraction data for LHn/D/Xa were collected at the Diamond Light Source, 
UK, beamline I24 (microfocus beamline). A complete dataset to 3.2 Å was collected from a 
single crystal at 100K (after transferring the crystal to 25% PEG3350) using a PILATUS-6M 
(Dectris) detector. The data were processed and scaled in hexagonal space group P65 using 
MOSFLM and SCALA (CCP4, 1994; Leslie, 2006). The unit cell parameters (Table 3.4) 
being similar to the ones from the LHn/D diffraction, 2 LC molecules were used in the 
search parameters with Phaser (McCoy et al., 2007). This led to a straightforward solution 
that was set through refinement with REFMAC5 (version 5.5; Vagin et al., 2004) and 
confirmed that again, only LC was present in the crystal. 
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Table 3.3. LHn/D X-ray data collection and LC/D refinement statistics 
 
A. Data collection statistics 
Space group P65 
Number of molecules/asymmetric unit 2 
Cell dimensions 
a =99.2, b =99.2, c =223.9 Å; 
=90,=120° 
Resolution range (Å) 50-2.2 
Rsym
1 (%) 9.2 (63.7) 
I/I (outer shell) 9.9 (2.1) 
Completeness (outer shell) % 89.7 (86.3) 
Total no. of reflections  229,707 
Unique no. of reflections 32,013 
Redundancy 4.1 (4.0) 
Wilson B-factor (Å2) 33.2 
B. Refinement statistics  
Resolution range (Å) 50-2.2 
Rcryst
2 (%) 22.8 
Rfree
3 (%) 25.5 
Number of non-H atoms  
Protein 6,266 
Metal  2 Zinc atoms 
Water molecules 233 
Average temperature factor (Å2) 24.5 
RMSD in bond lengths (Å) 0.006 
RMSD in bond angles (°) 0.83 
1Rsym = Σh Σi |I(h) – Ii(h)| / Σh ΣiIi(h), where Ii(h) and I(h) are the i
th and the mean 
measurements of the intensity of reflection h, respectively. 
2Rcryst = Σh |Fo| – |Fc| / ΣhFo, where Fo and Fc are the observed and calculated structure factor 
amplitudes of reflection h, respectively. 
3Rfree is equal to Rcryst for a randomly selected 5.0% subset of reflections not used in the 
refinement. 
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Table 3.4. LHn/D/Xa X-ray data collection and LC/D refinement statistics 
 
A. Data collection statistics 
Space group P65 
Number of molecules/asymmetric unit 2 
Cell dimensions 
a =100.4, b =100.4, c =224.0 Å;  
=90, =120° 
Resolution range (Å) 69-3.2 
Rsym
1 (%) 13.9 (29.1) 
I/I (outer shell) 10.3 (5.5) 
Completeness (outer shell) % 93.3 (94.0) 
Total no. of reflections  89,970 
Unique no. of reflections 19,625 
Redundancy 4.6 (4.5) 
Wilson B-factor (Å2) 32.6 
B. Refinement statistics  
Resolution range (Å) 50-3.2 
Rcryst
2 (%) 21.9 
Rfree
3 (%) 24.9 
1Rsym = Σh Σi |I(h) – Ii(h)| / Σh ΣiIi(h), where Ii(h) and I(h) are the i
th and the mean 
measurements of the intensity of reflection h, respectively. 
2Rcryst = Σh |Fo| – |Fc| / ΣhFo, where Fo and Fc are the observed and calculated structure factor 
amplitudes of reflection h, respectively. 
3Rfree is equal to Rcryst for a randomly selected 5.0% subset of reflections not used in the 
refinement. 
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3.3.3. Results and discussion 
Structure of LC/D 
The crystal structure obtained from the crystallisation trials with LHn/D actually 
corresponds to a truncated version of LC/D, residues 1-400 (LC/D). LC/D crystallised as a 
dimer in space group P65 with two molecules per asymmetric unit and the structure was 
solved at 2.2 Å resolution. The structure was refined to a final Rfree = 25.5%, and Rcryst = 
22.8% (Table 3.3, Figure 3.12), with 99.7% of amino acids in the Ramachandran plot 
allowed region.  
 
Figure 3.12. Crystal structure of LC/D. (A) Ribbon diagram representation of LC/D 
structure, LC in cyan (molecule A and B in light and dark cyan respectively). Zinc ion is 
shown as orange spheres. N- and C-termini are marked (N and *, respectively). (B) Dimeric 
interface between the two LC molecules. Residues involved in the interaction are shown in 
stick and ball representation (light and dark blue for molecules A and B respectively), 
potential hydrogen bonds are linked by black dashes. 
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The structure presents two LCs interacting in a crystallographic dimer through 11 
potential hydrogen bonds and 17 van der Waals interactions, corresponding to an interface 
area of 892 Å
2
 (Figure 3.12B). The two LCs are nearly identical and superpose with a rmsd 
of 0.2 Å (over 383 C). No electron density was observed for residues 174-175, and 254-261 
of chains A and B. Regions 64-67 and 206-208 could not be modelled in chain B only. LC/D 
is a metalloprotease and the zinc atom could be seen in both molecules, with a classic 
tetrahedral coordination by His 229, His 233, Glu 269 and a water-mediated Glu 230 (Figure 
3.13).  
 
 
Figure 3.13. Zinc coordination in LC/D. Cartoon diagram representation of LC/D (cyan). 
Zinc ion is shown as an orange sphere, water molecule in dark blue. Residues involved in 
the zinc coordination are shown in stick and ball representation. 2|Fo|-|Fc| map contoured at 
1 
Overall, the LC/D structure solved here confirms the LC fold common to all BoNT, 
and is identical to the already published LC/D structure (PDB 2FPQ, Arndt et al., 2006) with 
an rmsd of 0.6 Å (over 391 C-atoms). However, comparison of the two structures (Figure 
3.14) highlighted some interesting differences. PDB 2FPQ was solved to 1.6 Å and 
corresponds to residues 1-424, thus with 24 additional C-terminal amino acids. 
Superposition of 2FPQ with our structure indicates that this C-terminal region would clash 
with the crystallographic dimer interaction, therefore the truncated LC molecule favoured 
the new crystal form.  
In 2FPQ, residues 166-170 appear in two possible conformations, one is a random coil 
close to the zinc atom (Figure. 3.14B) and in the second case this region makes up for the 
short -strand (8) of the active site. This latter conformation corresponds to what is 
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observed in our LC/D, confirming its more likely prominence and physiological relevance as 
it is also observed in the other LC structures (Arndt et al., 2006). This may indicate a degree 
of flexibility of this segment in vicinity of the active site, to provide space for substrate 
binding in the catalytic pocket. 
The LC/D structure presented here offers additional information regarding loop 206-
214 which was not visible in 2FPQ. The interactions of residues 208-216 (chain A) with the 
second LC/D of the crystallographic dimer (chain B) stabilises this loop into a random coil 
otherwise in a solvent accessible surface (such as in chain B). The full extent of the binding 
interaction between LC/D and its VAMP substrate is not known although it is likely to 
involve several exosites. It is therefore possible that several of the unstructured loops present 
around the catalytic pocket may be implicated, in particular loops 175, 210, and 250 (Figure 
3.14). Furthermore, loop 145 linking the and 6 strands shows a slight shift compared to 
2FPQ, this may be explained by the crystallographic packing.  
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Figure 3.14. Comparison of LC/D structures. (A) Superposition of LC/D structures, LC/D 
in cyan, PDB 2FPQ in purple, with their C-termini marked by * and ** respectively. Zinc 
ion is shown as orange spheres. (B) Alternative conformation of residues 166-170 in 2FPQ. 
Catalytic site shown in stick and ball representation. 
 
Truncation of LHn/D – possible explanation 
The crystal structure described here exposed an unexpected result in only showing the 
LC domain. The nucleotide sequence of the clone from which LHn/D was expressed had 
been checked. Analysis of cell expression indicated an overexpressed protein at the expected 
size of approximately 100 kDa (Figure 3.10). Purification of this protein was carried out. 
Specifically, a nickel-affinity column was used, and thus successfully utilised the poly-
histidine tag on the C-terminal end of the translocation domain. Activation of LHn/D into a 
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di-chain molecule was achieved using the engineered enterokinase cleavage site. A faint 
band corresponding to inactivated material is still visible at 100 kDa in reducing conditions 
but the activation yield was considered acceptable to complete the purification by 
hydrophobic interaction. The final concentrated material was over 90% pure (Figure 3.15). 
Integrity of the final sample was examined by Western blotting with domain specific 
antibodies. The blots confirmed the presence of both LC and Hn domains in reducing and 
oxidising conditions. The poly-His detection also demonstrated the presence of the full-
length Hn chain.  
 
Figure 3.15. Western blot analysis of LHn/D. Purified LHn/D sample in reduced and 
oxidised conditions (lanes 1 and 2 respectively) in (A) SDS-PAGE; (B) anti-LC/D Western 
blot (W.B); (C) anti-Hn/D W.B; (D) anti-His W.B. 
The solved LC/D structure leaves little ambiguity regarding the composition of the 
crystal from the LHn/D trials. Despite the starting sample containing an intact LHn/D, only a 
truncated LC was observed. At first it was hypothesised that truncation could result from 
unspecific cleavage by enterokinase which is used in the activation step of LHn/D. However 
from the SDS PAGE and Western blot analysis performed (Figure 3.15), there is no clear 
indication of the presence of truncated material, which would correspond to a protein of 45.8 
kDa. Also, analysis of the primary sequence did not indicate any potential cleavage site for 
enterokinase. To investigate this possibility further, a single-chain, non-activated, scLHn/D 
was purified (Figure 3.10) and crystallisation trials were performed. However, this construct 
failed to crystallise in the same condition as LC/D. Crystals were nonetheless obtained in a 
different set of conditions but did not diffract to better than 6 Å at the Diamond Light Source 
(UK). Additionally, a protein based on the LHn/D backbone but activated by an alternative 
exoprotease (Factor Xa) was provided (LHn/D/Xa). A single crystal was obtained from new 
conditions and data collected to 3.2 Å. Analysis of the resulting x-ray diffraction data 
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showed it corresponds to the same crystal form as LC/D with nearly identical cell 
parameters (Table 3.4). This structure did not provide any additional information than the 
one described previously. However, it did present a truncated LC molecule with the electron 
density ending at residue 400. 
In view of the structures solved from the various LHn/D constructs, it seems unlikely 
that the truncation observed in LC/D was due to the activation treatment by exoproteases. 
Despite not noticing any cleavage product in the stored LHn/D sample, the possibility of a 
proteolytic degradation during the crystallisation incubation period could not be ruled out. 
LHn/D is indeed a metallo-protease with high specificity for synaptobrevin (Schiavo et al., 
2000). Evidence of BoNT autoproteolysis has been described for several serotypes 
(DasGupta et al., 2005) and provided a basis for the identification of potential cleavage sites.  
Substrate recognition by BoNTs involves an essential nine-residue long motif 
common to all SNARE proteins (Rossetto et al., 1994). DasGupta et al. (2005) identified 
and characterised analogous SNARE motifs within BoNTs. The motifs discovered correlated 
with experimental results of autoproteolysis that were available for serotypes A, B and E. 
From these observations, DasGupta et al. (2005) predicted several such binding sites in other 
clostridial neurotoxins. These motifs were located in regions of the toxins that adopted a -
helical structure, were surface exposed and contained negatively charged residues. One of 
the predicted segments in LC/D was at position 387-395 (Figure 3.16). Noticeably, 
experimental observations (for types A, B and E) indicated that autoproteolytic cleavage 
occurred two to four amino acids away from the putative recognition site. This might 
therefore provide a possible explanation for the truncation observed at position 400 in the 
crystal structure.  
 
Figure 3.16. SNARE motif in LC/D. Sequence alignment of LC/D with VAMP-2. 
DasGupta et al., (2005) identified the putative SNARE motif “LDDNYTIR” in LC/D with 
“Y” the only disagreement for substrate recognition. 
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Other possible explanations for the observed truncation such as chemical proteolysis 
and dehydrogenase-like activity (DasGupta et al., 2005) may be discarded by considering 
the conditions under which LC/D crystallised here. 
Further characterisation of the crystallised molecule may be necessary to fully 
understand the cause of the truncation. Unfortunately crystallisation was not readily 
reproducible from a different purification batch of LHn/D. N-terminal sequencing or mass 
spectrometry would provide useful information on the precise cleavage site. Even though the 
electron density map was not present beyond residue 400 in the two structures presented 
here, an unobservable segment beyond this point, in the solvent accessible area, may not be 
excluded. 
Towards the crystallisation of LHn/D 
Determination of the LHn/D crystal structure may rely on preventing potential 
autoproteolysis. This may be achieved using several different methods. Firstly, 
crystallisation in the presence of a metal-chelating agent (like for example EDTA) could be 
tested. The zinc atom, although essential for enzymatic activity, is not involved in any 
structural role. Removal of the catalytic centre may thus lead to the structure of the 
apoprotein. Secondly, a more complex approach would be to mutate key residues involved in 
the coordination of the metal ion, so as to hinder the enzymatic activity of LC/D. Such 
method was successfully used to determine the structure of LC/A in complex with its 
substrate (Breidenbach and Brünger, 2004). Finally, mutations in the putative SNARE motif 
recognition site described above may offer an opportunity to crystallise a catalytically active 
form of LHn/D. However this latter option might disrupt the enzyme’s tertiary structure 
since it would involve a change of the local -helical conformation.  
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3.4. Small-angle x-ray scattering (SAXS) analysis of LHn fragments 
3.4.1. Introduction 
The crystal structures of BoNTs have highlighted a stable fold of their components, 
with each domain retaining its typical fold (Swaminathan, 2011). However there is little 
information available regarding the structure of these molecules in a more biologically 
relevant environment, i.e. in solution. Small angle x-ray scattering (SAXS) offers an 
alternative approach to study the molecular structure of proteins. Although it provides 
limited information on the size and shape of proteins, it may prove useful, in combination 
with other methods, to study inter- and intra-molecular interactions. 
One of the key elements for BoNT toxicity is the toxin’s ability to transport its 
catalytic domain (LC) into the cytosol of cholinergic motor neurons. This step is mediated 
by the translocation domain (Hn) and importantly is dependent upon the pH gradient 
between the endosome (pH 5.0) and the cytosol (pH 7.0) (Fischer et al., 2008b). There is 
therefore an essential pH-dependent structural transformation occurring at this stage of the 
intoxication process. Koriazova and Montal (2003) demonstrated that LC/A undergoes a 
complete secondary structure unfolding at pH 5.0, which allows for its passage through the 
putative narrow pore formed by Hn. However, analysis by circular dichroism spectroscopy 
(Li and Singh, 2000) showed low pH (4.7) had little consequences on LC/A secondary 
structure. More recently, another CD spectroscopy study concluded that the endosomal pH 
induced the transformation of LC/A into a molten globule state (Cai et al., 2006). This 
would result in a protein with similar secondary structure characteristics to its native 
counterpart, but with a different tertiary fold. Additionally, the crystal structures of BoNT/B, 
solved in different pH buffer conditions (pH 4.0 to 7.0) did not show any significant 
alterations (Eswaramoorthy et al., 2004). 
Small angle x-ray scattering is a pertinent technique to study the domain interactions 
within BoNT and identify potential structural differences between serotypes. Furthermore, 
the LHn fragment, which holds the functional domains responsible for the toxin’s 
intracellular activity, is a particularly interesting molecule to study to check the possible pH-
dependent mechanisms. Here, the details of the first solution scattering experiments carried 
on BoNT and an investigation into the effect of pH on the tertiary structure are described. 
Although data collection was not optimal, this study produced useful information on the 
structure of LHn/A, /B and /D in solution, including low resolution ab initio models. No 
structural modifications were observed under endosomal pH conditions. 
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3.4.2. Materials and methods 
Sample preparation 
Protein samples corresponding to LHn/A, LHn/B, LHn/D and scLHn/D were prepared 
for SAXS analysis. All samples were purified as described previously, and produced protein 
crystals. Monodispersity was checked by dynamic light scattering (Malvern Instruments). 
The four proteins were stored at -20°C in 0.05 M HEPES 7.2, 0.2 M sodium chloride. 
Buffer exchange was performed by dilutions in the appropriate buffers followed by a 
concentrating stage using Vivaspin 50000 MWCO concentrator (Millipore). Three different 
pH were tested corresponding to 0.05 M HEPES pH 7.0, 0.1 M TRIS acetate pH 5.0, and 0.1 
M TRIS acetate pH 4.0 respectively. The proteins were kept at 5.0 mg/ml and stored at 4°C 
until day of testing. On the day of the experiment, samples were diluted in the appropriate 
buffer to give three final concentrations at 5, 2.5 and 1 mg/ml. These dilutions were checked 
by absorbance measurement at 280 nm using a NanoDrop ND-1000 (Thermo Scientific), 
and concentration discrepancies were corrected for data analysis.  
Data collection and analysis 
Solution scattering data for the four LHn molecules were collected at DESY, 
Germany, EMBL Hamburg, beamline X33 (BioSAXS). For each sample, a buffer 
measurement was performed before and after the sample at room temperature, using a 
PILATUS-1M (Dectris) detector. SAXS measurements were performed for each sample at 
three concentrations. Calibration was carried out with BSA at 5mg/ml in 0.05 M HEPES pH 
7.5 as a molecular weight standard. The data were processed and averaged with PRIMUS 
(Konarev et al., 2003) followed by particle distance distribution function P(r) analysis using 
GNOM (Svergun, 1992). Data considered of good quality were further treated by using the 
on-line server for DAMMIF (Franke and Svergun, 2009) to produce twenty ab initio models 
that were averaged with DAMAVER (Volkov and Svergun, 2003). Successful models were 
compared to known crystal structures of LHn by manual docking (PyMOL, DeLano 
Scientific LLC). 
3.4.3. Results and discussion 
The first experiments analysing the structure of LHn fragments in solution by SAXS 
resulted in the production of several models. A few of the conditions tested did not yield 
reliable data. This was the case for most of the proteins tested at pH 4.0 that showed a high 
amount of aggregation during manipulation. All the molecules prepared have a theoretical pI 
of approximately 5.1, and thus did not survive under such acidic conditions. Furthermore, a 
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key element for SAXS experimentation is to have a background buffer control that matches 
exactly with the solution the sample is in. The method for sample preparation described 
above was not optimal and thus led to a difficult interpretation for some of the data collected 
(Table 3.5). 
 
Table 3.5. Summary of SAXS data collected at DESY (X33). 
 
pH 4.0 pH 5.0 pH 7.0 
LHn/A model (ag1.) model buf. mis.2 
LHn/B ag. model model (buf. mis.)  
LHn/D ag. model model (buf. mis.) 
scLHn/D ag. model model (buf. mis.) 
1 aggregation; 2 buffer mismatch. 
 
Despite the data quality not being optimal, the overall features of LHn in solution 
could be observed. The experiment was aimed at studying differences in solution scattering 
between the serotypes and the potential effect of acidic pH on LHn. An example of data 
collected for LHn/A at pH 5.0 is shown in figure 3.17. While the estimations for the 
maximum dimension Dmax, and the radius of gyration Rg should be treated carefully, it is 
interesting to notice their consistency for all of the proteins tested (Table 3.6). Comparison 
of the data indicated a good correlation between the four LHn molecules analysed. Ab initio 
models produced were consistent with these data and showed a common shape and size of 
the samples (Figure 3.18).  
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Table 3.6. Small angle x-ray scattering data statistics for LHn samples at pH 5.0. 
 P(r) function
1
 Structural modelling
2
 
 
Dmax (Å) Rg (Å) Discrepancy (
2
) NSD 
LHn/A 116±5 34.6±1.0 0.96 0.90 
LHn/B 118±6 34.2±0.1 1.20 0.81 
LHn/D 120±1 34.6±0.7 0.97 0.70 
scLHn/D 114±1 34.0±0.6 1.10 0.84 
1 
The distance distribution function (P(r)) function from GNOM was used to calculate the 
maximum dimension (Dmax) and the radius of gyration (Rg).  
2
The discrepancy (2) between experimental and ab initio data was calculated by the 
program DAMMIF, DAMAVER was used to average 20 models and gave the above value 
for normalised spatial discrepancy (NSD). 
 
 
Figure 3.17. SAXS analysis of LHn/A at pH 4.0. (A) Scattering curve of LHn/A. (I is a 
relative unit, s is expressed in nm
-1
) (B) The radius of gyration (Rg) was calculated using the 
Guinier approximation (Guinier, 1939) and was found to be 35.0 Å. (C) The interatomic 
distance function (P(r)) gave a maximum dimension Dmax of approximately 110 Å (x axis, r 
in nm). These values were calculated in GNOM (Svergun, 1992). 
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Rigid body modelling with the coordinates from the crystal structures of LHn/A and 
/B was attempted. However analysis with CRYSOL (Svergun et al., 1995) and trials with 
SASREF (Petoukhov and Svergun, 2005) did not produce realistic results. Manual docking 
allowed the drawing of a relatively convincing comparison between the ab initio bead 
models and the crystal structures (Figure 3.18). The rotational averaging of the molecules in 
solution limits the interpretation of the models. However, the distinctive shape of the two 
domains forming the LHn molecule can be clearly noticed. Indeed the atypical -helices of 
Hn give the models an extended form over 110 Å long whereas LC’s structure accounts for 
the globular central shape. 
 
 
Figure 3.18. Ab initio solution scattering models of LHn/A, /B and /D at pH 5.0. (A) and 
(B) Left, SAXS model of LHn generated by DAMMIF (Franke and Svergun, 2009) and 
averaged in DAMAVER (Volkov and Svergun, 2003). Right, crystal structure of LHn/A 
(red) and /B (blue). (C) SAXS model of LHn/D (left) and scLHn/D (right). 
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Overall, the LHn molecules tested seem to conserve their overall structural features in 
solution. The change of pH did not appear to have any dramatic influence on the molecules. 
Although the resolution of the data may not allow to visualise small structural details, the 
information collected for LHn/A and /B showed that the fragments kept their structural 
integrity from neutral to acidic pH. This may be expected as these fragments have low 
theoretical pI, just below the endosomal pH (5.0-6.0) where BoNTs are active.  
The first structural information obtained from LHn/D (in both forms, i.e. single chain 
and activated) seemed to indicate a conserved LHn fold. The scattering curves superposed 
well with LHn/A and /B, and the similarity is illustrated by comparable ab initio bead 
models (Figure 3.18C). Additional processing of the data by collaborators at EMBL 
Hamburg indicated a significant difference with the data collected for LHn/D at pH 7.0, 
compared to all the other curves. Further experiments would be necessary to characterise 
this variation. In particular, refinement of the experimental conditions and a narrower pH 
range may help determine any modifications in the LHn structures. 
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3.5. Discussion 
Structure of LHn 
Botulinum neurotoxins are complex molecules that present a deadly machinery able to 
specifically inhibit synaptic transmission of cholinergic motor neurons. Each of the toxin’s 
domains is essential for optimal potency and understanding their mechanism will allow to 
better harness this activity towards novel applications. Fragments of the toxin (LHn) 
comprising the catalytic and translocation domains of BoNT have been described as 
potential functional molecules from which could be designed a range of novel biological 
products aiming at targeted cell secretion inhibition (Foster and Chaddock, 2010). 
The production of recombinant engineered LHn fragments was achieved following the 
method described by Chaddock et al. (2002). As a first step towards the production of 
biological molecules, it is important to obtain reliable and consistent yields of active 
material. Engineering of the LHn fragment for optimal expression in Escherichia coli was 
achieved for several serotypes. Importantly it allowed the insertion of exoprotease 
recognition (i.e. cleavage) sites in order to mimic the post-translational “activation” of 
BoNT into active di-chain toxins. Additionally, the molecules could be designed to include 
for peptidic tags (poly-histidine) which are utilised in classical affinity chromatography 
techniques and thus facilitate the purification process. The aim of our study was to conduct 
biochemical and structural characterisation of several LHn constructs and hence required 
large quantities of highly pure material. Optimisation of the purification process by affinity 
and hydrophobic chromatography led to the production of LHn/A, /B and /D to standards 
required for protein crystallography. 
Determination of the crystal structures of LHn from serotypes A and B demonstrated 
the stability of this BoNT fragment. In both cases, the structures were similar to their 
corresponding parent neurotoxin lacking the binding domain (Hc). The catalytic domain 
(LC), a zinc metalloprotease with a globular structure composed of a mixture of -helices 
and -sheets, was particularly conserved with only minor differences observed in flexible 
loop regions. These loops are located in solvent accessible surfaces of LC, a number of 
which have been linked to substrate binding (Breidenbach and Brünger, 2004). In all the 
structures solved, the zinc ion was present and tetrahedrally coordinated by the HEXXH 
motif. LHn/A and /B were submitted to Factor Xa treatment for activation into a di-chain 
form. As a result, LC is linked to Hn by a single disulphide bridge that was clearly visible. 
Furthermore, the corresponding cleavage sites were confirmed by the lack of electron 
density at the expected sites. 
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The relationship between the two domains forming LHn is essential for BoNT’s 
activity and relies on a complex interaction, illustrated by the atypical “belt” region. This 
segment of Hn surrounds LC and by doing so prevents access to the catalytic site (Brünger 
et al., 2007) and potentially promotes membrane insertion (Galloux et al., 2008) in BoNT/A. 
Similar roles in other serotypes have not been demonstrated yet. Although the belt region 
partially occludes the active site in BoNT/B (LHn/B) and /E, the catalytic zinc is more 
accessible compared to BoNT A. Elucidation of the structures from other serotypes may 
help understand the function of this segment and why it represents the region with highest 
sequence variation (Lacy and Stevens, 1999).  
The translocation domain is constituted of long -helices believed to be responsible 
for pore-formation and allowing transport of LC within the cytosol (Fischer et al., 2008b). 
Surprisingly, the structures of Hn in LHn (/A and /B) are identical to the ones observed in 
the full length holotoxins. Removal of the BoNT binding domain left Hn mostly unperturbed 
despite presenting a new and consequent solvent accessible surface. Only small unstructured 
loop regions connecting these helices, and normally in direct contact with Hc, showed some 
changes and were not visible in the crystal structures. Strong inter-helical bonds hold this 
unusual fold together and make LHn an ideal framework on which to build novel molecules. 
The LHn C-termini would likely accommodate polypeptide partners without damaging the 
fragment’s structure. 
Trials with LHn/D led to the crystallisation of a truncated form with only the light 
chain. Crystallisation parameters were different from the previously published LC/D 
structure (Arndt et al., 2006) and noticeable differences were observed. The overall globular 
LC fold was conserved but details in several flexible loop regions that may be involved in 
substrate binding were noticed. Biochemical characterisation of several LHn/D constructs 
confirmed that full-length LHn/D was purified and represented the main component in all 
the samples. Truncation of LC/D is unlikely to be caused by unspecific cleavage from the 
exoprotease used for activation. Instead it is believed that crystallisation conditions, for 
example the high protein concentration and prolonged incubation period, would have 
favoured autoproteolysis. Such autoproteolysis phenomenon has been observed in several 
BoNT serotypes (DasGupta et al., 2005). A SNARE-like motif was identified in the primary 
sequence of LC/D and could provide additional explanation for cleavage of the molecule. 
This occurrence may be prevented by crystallisation trials in the presence of a chelating 
agent or by key mutations, thus enabling the presence of the full length LHn/D in the crystal, 
although this needs to be tested with further experiments. 
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The first observations based on small angle x-ray scattering experiments on BoNT 
molecules demonstrated the significance of the LHn crystallographic structures in a more 
biologically relevant environment. The data collected for LHn/A, /B and /D allowed for the 
determination of low resolution models. While direct rigid body modelling could not be 
performed, a convincing shape could still be obtained for each molecule. As observed in the 
LHn crystal structures, the SAXS models produced a consistent size and shape, in a neutral 
to acidic pH range. The individual LHn domains could be placed in the SAXS model 
without any ambiguity. More particularly, the longer axis fitted conclusively with Hn, and 
the length of the translocation domain’s helices corresponded to the experimental dimension 
measured by Guinier approximation (approximately 100-115 Å). The central globular shape 
matched with the LC fold seen in crystal structures. These structural features were also 
observed with LHn/D. For the first time, experimental evidence offered a glimpse of the 
structure of the Hn/D domain and indicated a conserved long -helical arrangement. The 
translocation domain, excluding the belt region, shows high sequence conservation. 
Organisation of the conserved residues across Hn was predicted to maintain the inter-helical 
interactions holding the domain together (Lacy and Stevens, 1999). In addition, the SAXS 
data confirmed the presence of the full length LHn/D in the sample that generated crystals of 
a truncated LC molecule. 
Activity of LHn 
The botulinum neurotoxins cause inhibition of neurotransmission in cholinergic motor 
neurons by cleaving one of the SNARE proteins. In order to utilise the LHn molecules as a 
biologically active material, they need to retain this critical catalytic property. Chaddock et 
al. (2002) demonstrated LHn/A had a similar enzymatic activity to BoNT/A. In vitro assays 
performed on a recombinant SNAP25-GFP substrate over time confirmed that the 
crystallised molecule was also catalytically active, and stable in solution for up to 36 days. 
Substrate cleavage assays were performed with LHn/B and BoNT/B using recombinant 
GFP-tagged VAMP-1, -2 and -3. LHn/B was able to cleave all of the three substrates tested 
although some differences in maximal velocity (Vmax) were noticed. Similarly to the full 
length toxin, LHn/B presented a better affinity for VAMP-1 and -2 over -3. Minor 
differences in the primary structures of these homologous substrates may explain this result 
and provide further information on the BoNT/B-VAMP interaction (Chen et al., 2008).  
Toxicity of the botulinum neurotoxins rely on these molecules reaching their 
intracellular SNARE substrates. BoNT associates with the vesicular membrane via its 
receptor binding domain and endocytosis. Once inside the vesicle, a conformational change 
is believed to allow membrane pore-formation by Hn and transport of LC within the cytosol. 
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Despite lacking the receptor binding domain, LHn/A was shown to cleave intracellular 
(embryonic spinal cord neurons) SNAP25 and prevent neurotransmission (Chaddock et al. 
2002). The study described here demonstrated LHn/B was able to cleave intracellular 
VAMP-1 and -2. The mechanism for LHn entry into neuronal cells is unknown but likely 
depends on Hn’s inherent pore-forming capabilities. Using single channel current 
measurements, Fischer et al. (2008) proved that LHn/A was sufficient to transport LC into 
the cytosol of target cells through channel formation. Interactions between LHn and the 
neuronal cells are likely to be unspecific considering the conditions of the in vitro assays 
described above, i.e. high cell density and LHn concentration, and it should be highlighted 
that LHn’s activity is greatly reduced (by a factor over 100,000) compared to BoNT. 
Nevertheless LHn appears as a fully functional molecule capable of LC translocation into 
neuronal cells where it can cleave cytosolic SNARE proteins. Further study would be 
necessary to determine whether LHn can act on other non-neuronal cell types and thus 
determine its utility as a pharmacological tool for the study of cellular SNARE-mediated 
processes. 
 
Conclusion 
LHn consists of the catalytic (LC) and translocation (Hn) domains of the botulinum 
neurotoxin but is devoid of the receptor binding domain. Crystallographic studies of 
serotypes A and B have established that the fragment is a structurally stable scaffold, with 
Hn constituted of long -helices and LC, a zinc protease presenting a globular fold. 
Preliminary experimental evidence suggests that this global structure is also conserved in a 
solution environment and extend to serotype D.  
LHn’s function was also verified in vitro by biochemical characterisation of 
recombinant SNARE substrate cleavage. Additionally, LHn maintains an ability to cleave 
intracellular SNARE proteins in neuronal cells, thereby showing its innate ability to 
transport the catalytic light chain within the cytosol of target cells.  
The recombinant LHn fragments described are soluble proteins with attenuated 
toxicity but retaining the capabilities of the botulinum neurotoxins. These fragments are 
proving to be significant tools to study the mechanisms responsible for BoNT potent toxicity 
(Fischer et al., 2008b). Finally they represent a fantastic framework on which to build novel 
engineered molecules with added therapeutic applications (Chaddock and Acharya, 2011). 
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Chapter 4. Engineering self-activating Clostridium botulinum 
neurotoxin fragments using SNARE-peptides 
4.1. Introduction 
BoNTs have been a point of focus for protein engineering since it was demonstrated 
that its functionality as secretion inhibitor could be extended to non-neuronal targets by 
engineering a new cell targeting domain onto the LHn fragment of BoNT. The proof-of-
concept was first provided with the use of lectin and growth factor conjugates (Chaddock et 
al., 2000a, 2004; Duggan et al., 2002). Subsequently, novel recombinant BoNT derivatives 
consisting of the catalytic LC and the Hn translocation domain, together forming the LHn 
fragment (Figure 4.1), coupled with retargeting polypeptides have been developed as a novel 
biologics platform - Targeted Secretion Inhibitors (TSI). 
An essential step in the production of fully active BoNT is the post-translational 
cleavage from a single chain polypeptide into its di-chain activated form (Wey et al., 2006). 
Treatment of BoNT with a non-specific protease such as trypsin can result in undesirable 
digestion and a mixture of heterogeneous proteins (Shone et al., 1985). Recombinant 
derivatives of BoNT can be engineered to incorporate specific recognition sites for 
exoproteases such as Factor Xa or enterokinase (Sutton et al., 2005). This process allows for 
a more controlled approach of activation. This is however a delicate and limiting process in 
terms of protein production.  
Thus the use of the BoNT LC proteolytic activity towards SNARE peptides was 
investigated as a tool for engineering both self-activating and LC-activating molecules. This 
resulted in several novel derivatives in which an optimum SNARE protein region was 
inserted in the LHn/A backbone. More precisely, a SNAP25 peptide was introduced between 
the carboxyl terminal cysteine of LC/A and the amino terminal cysteine of Hn/A. This 
substitution of the native activation site created a backbone with domains denoted LC/A-
SNAP25-Hn/A. LC/A-SNAP25-Hn/A is a novel, engineered backbone susceptible to 
activation by ‘self-cleavage’ with LC.  
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Figure 4.1. Representation of LHn/A domain structure and constructs engineered with 
SNARE. (A) Crystal structure of LHn/A based on PDB code 2W2D (Masuyer et al., 2009). 
The LC/A domain is shown in cyan, Hn/A domain in grey, Hn/A belt region in magenta and 
the disulphide bridge in gold. (B). Domain structure of LHn/A: LC/A (cyan), Hn/A (grey), 
His tag (HT, light blue), SNAP25 (red), SNAP23 (pink) and VAMP2 (orange). LC/B 
activating protease is shown in blue and disulphide bonds are represented (S-S). 
 
To investigate the broad applicability of this concept to other LHn serotypes and 
beyond self-cleavage, a VAMP2 substrate peptide was substituted in place of SNAP25 to 
create LC/A-VAMP2-Hn/A. VAMP2 is not cleaved by LC/A but is a substrate for LC/B. A 
backbone in which LC/A is coupled to Hn/A with a VAMP2 peptide therefore remains as a 
single-chain until it is activated by LC/B, which behaves as the exogenous activating 
protease.  
This study demonstrated that extended SNARE peptides corresponding to the 
carboxyl coiled coil region of SNAP25 and VAMP2 can be inserted between the LC/A and 
Hn/A of LHn/A and are effective substrates for activation of the LHn backbone. LC/A-
SNAP25-Hn/A acted as a self-processing enzyme that retained the ability to assemble into a 
functional protein with translocation and proteolytic properties. LC/A-VAMP2-Hn/A could 
be activated by LC/B, under controlled conditions, to maintain the integrity of the molecule. 
This novel engineering strategy has potential for alternative manufacturing approaches for 
TSI proteins and for understanding their enzymatic properties. 
The crystal structures for BoNT/A (Lacy et al., 1998), -B (Swaminathan and 
Eswaramoorthy, 2000) and -E (Kumaran et al., 2009) and more recently that of LHn/A and 
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LHn/B (Masuyer et al., 2009, 2011) have been determined. In all the structures available, the 
botulinum neurotoxin domains conserve their singular fold (Swaminathan, 2011). In 
particular, LHn (A and B) retain the structural stability of the LC-Hn interactions seen in the 
holotoxin despite lacking the Hc binding domain. This highlighted the relevance of LHn as 
useful and safe models for functional and structural studies of the botulinum neurotoxins. 
Molecular structures of the synaptosome-associated proteins (SNAP) have been 
reported as either functional heteromeric SNARE complexes (Sutton et al., 1998, Fiebig et 
al., 1999), self-assembling homotetrameric molecules (Freedman et al., 2003), or in complex 
with LC/A (Breidenbach and Brünger, 2004). While the crystal structures demonstrated the 
SNARE proteins tendency to form a helix bundle mediated by the coiled-coil SNAP 
domains, they are expected to be mainly unstructured in solution (Margittai et al., 2001). 
This is in accordance with the low activity of BoNT/A on the structurally stable SNARE 
complex compared to free SNAP25. The flexibility of SNAP25 is a requirement for 
substrate cleavage by LC/A (Breidenbach and Brünger, 2004). 
The crystal structures of two engineered derivatives of the LHn backbones from 
serotype A were solved to 2.7-3.0 Å and are described in this study. They correspond to 
constructs used as single chain controls in the self-cleaving LC-SNARE-Hn molecules study 
namely LC/A-SNAP23-Hn/A and LC/A(0)-SNAP25-Hn/A. SNAP23 is a non-cleavable 
SNAP25 homologue. LC/A(0) was mutated at key residues to impair LC/A proteolytic 
activity. Although the engineered fragment could not be modelled due to disorder, the 
structures demonstrate the remarkable stability of the LHn fold despite the addition of 
significant peptide segments at the LC-Hn interface. This strengthens the relevance of LHn 
as safe and useful molecules for the study of botulinum neurotoxin engineering. 
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4.2. Materials and methods 
Plasmid construction, Protein Expression, Purification and Detection 
Synthetic DNA, codon optimised for E. coli expression, encoding human SNAP25 
(145-206), human SNAP23 (151-211) and human VAMP2 (24-94) was obtained from 
Entelechon GmbH. SNARE encoding DNA was cloned into pET26b expression vector 
(Novagen) in which the pelB signal leader is removed. These plasmids contained open 
reading frames (ORF) for LHn/A encoding 842 amino acids, or for LC/A encoding 430 
amino acid and LC/B encoding 437 amino acids. In frame fusion was achieved by use of 
unique restriction sites introduced into the DNA encoding the C terminus of the LC, N 
terminus of Hn and the SNARE peptide linker. LC/A(0)-SNAP25-Hn/A contained mutations 
in the active site at positions E224Q and H227Y as well as GS linkers flanking the SNAP25 
fragment. Poly-GS linkers correspond to GGGGS repeats. The clones were provided by 
Syntaxin Ltd (Stancombe et al., 2011). 
Plasmids encoding open reading frames were expressed in E. coli (BL21 (DE3), 
Novagen) and purified as previously described (Masuyer et al., 2009). Briefly, expression 
cultures were grown to mid log growth phase in enriched terrific broth, the temperature 
reduced from 37°C to 16°C and protein expression induced with 1 mM IPTG. Cells were 
harvested after 18h, and stored at -80°C until further use.  
Homogenised cell lysate, clarified by centrifugation, was loaded onto a Ni
2+
-charged 
chelating sepharose column (GE Healthcare). Proteins eluting at either 100 or 200 mM 
imidazole in 50 mM HEPES (pH 7.2), 0.2 M NaCl buffer were dialysed overnight at 4°C 
against the same buffer to remove salt. Protein sample volume was reduced using Vivaspin 
50000 MWCO concentrators (Millipore) and stored at -20°C. Protein concentration was 
determined by A280 measurement using a NanoDrop 2000 instrument (Thermo Scientific). 
Rabbit polyclonal antibodies specific to LC or Hn, obtained from Eurogentec, were 
evaluated by cross reaction with a panel of recombinant A, C, D and F serotype LHn 
proteins and the E. coli lysate used for their expression. Antisera raised against either LC/A 
protein or Hn/A peptide (CQLSKYVDNQRLLSTL), displayed high specificity to antigen 
and low reactivity to other serotypes and to E. coli proteins. 
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Table 4.1. Summary of domain structure and function in SNARE-LHN constructs.  
Construct Serotype Domain linker 
Activation 
status 
Molecule 
function 
LHn/A A Ek
1
 Activated Non-SNARE LHn 
scLHn/A A Ek
1
 Non-activated Non-SNARE LHn 
LC/A-SNAP25-Hn/A A 
Human SNAP25 
(145-206)
 2
 
Activated Self-activating 
LC/A(0)-SNAP25-Hn/A A 
Human SNAP25 
(145-206)
 2
 
Non-activated 
Endopeptidase 
inactive control 
LC/A-SNAP23-Hn/A A 
Human SNAP23 
(151-211)
 2
 
Non-activated 
Non-substrate 
homologue 
LC/A-VAMP2-Hn/A A 
Human VAMP2 
(24-94)
 2
 
Activated Activated by LC/B 
LC/A-VAMP2 A 
Human VAMP2 
(24-94)
 2
 
n/a 
Non-translocating 
control 
LC/B-SNAP25 B 
Human SNAP25 
(145-206)
 2
 
n/a Activation protease 
1
 Engineered enterokinase site for activation.  
2
 Numbers correspond to region of SNARE used as a linker. 
 
Recombinant SNAP25 cleavage 
The catalytic activity of the endopeptidase component of engineered LHn backbones 
was assessed using a recombinant SNAP25 assay. Cleavage of recombinant SNAP25 (2-
206) substrate with a carboxyl-terminal GFP was assayed in triplicate in three experiments 
for each molecule (Masuyer et al., 2009). Briefly, test enzymes were diluted to 1.0 mg/ml in 
buffer containing 50 mM HEPES pH 7.2, 20 M ZnCl2, 1 mg/ml BSA, 10 mM DTT, and 
pre-incubated at 37°C for 30 minutes. SNAP25-GFP was diluted to 8 M and incubated 
with the diluted test enzyme in the range from 1 mg/ml to 10 ng/ml at 37°C for 1 hour. In the 
case of the competition experiment, the procedure included pre-incubation of the test 
enzyme with 30 M LC/B-SNAP25 at 37°C for 30 minutes, before addition of substrate. 
SNAP25 cleavage was measured by comparison of cleaved product to un-cleaved substrate 
and percentage cleavage calculated by densitometry of coomassie stained SDS PAGE using 
GeneSys software (SynGene Bioimaging). Data was normalised to account for signal 
intensity from molecular weight differences between cleaved and un-cleaved substrate. 
Calculations and curve fitting were done with Prism5 (GraphPad Software). 
In vitro spinal cord neuron SNAP25 cleavage 
The functionality of engineered LHn backbones was also assessed in embryonic spinal 
cord neurons (eSCNs). eSCNs prepared from embryos of 14–15 day old foetal Sprague 
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Dawley rats were cultured for 21 days as described previously (Duggan et al., 2002). 
Briefly, cell preparations were treated in triplicate with serial dilutions (range 3 M to 3 nM) 
of LHn/A and LC/A (Syntaxin Ltd) proteins and incubated at 37°C with 10% CO2 for 24h. 
Cells were lysed by removing media and adding 25% NuPAGE buffer in 10 mM DTT. 
Samples were heated at 95°C for 5 minutes and resolved by SDS-PAGE on 12% BIS-TRIS 
NuPAGE gels (Invitrogen) before transfer to nitrocellulose membrane (Millipore). SNAP25 
cleavage was measured by comparison of cleaved product to un-cleaved substrate and 
percentage cleavage calculated by densitometry of enhanced chemiluminescent (ECL) signal 
from specifically immunoreactive primary anti-SNAP25 antibody (Sigma catalog. No. 
S9684). Each assay was performed three times. Data were normalised to account for signal 
intensity from molecular weight differences between cleaved and un-cleaved substrate. 
Calculations and curve fitting were done with Prism5 (GraphPad Software). 
Crystallisation of LC/A-SNAP23-Hn/A and LC/A(0)-SNAP25-Hn/A 
Further purification was necessary for crystallisation trials performed on two of the 
constructs previously prepared. Briefly, LC/A-SNAP23-Hn/A was further purified by 
hydrophobic interaction chromatography (Phenyl Sepharose HP, GE Healthcare). LC/A(0)-
SNAP25-Hn/A was lastly purified by gel filtration (Superdex 75, GE Healthcare). Final 
samples were concentrated to 6.1 mg/ml and 5.1 mg/ml respectively. 
Initial crystallisation condition for LC/A-SNAP23-Hn/A was identified using the 
Stura Footprint Screen + MacroSol (Molecular Dimensions) corresponding to 0.1 M 
imidazole malate pH 7.0, 15% PEG4000. Optimisation was carried out by the hanging-drop 
vapour diffusion method at 16°C, with 3 l drops (2 l protein and 1 l mother liquor 
against a 500 μl reservoir). LC/A-SNAP23-Hn/A crystals were grown in 2-3 months in 0.1 
M imidazole malate pH 6.0, 15% PEG3350. X-ray diffraction data to 2.95 Å from a single 
crystal cryo-protected with 25% PEG3350 were collected at the Diamond Light Source, UK, 
beamline IO3. Data were processed and scaled in monoclinic space group P21 using 
MOSFLM and SCALA (Leslie, 2006; CCP4, 1994) (Table 4.3). Initial phases were obtained 
by molecular replacement using Phaser (McCoy et al., 2007) with the coordinates of LHn/A 
(PDB 2W2D, Masuyer et al., 2009).  
Initial crystallisation condition for LC/A(0)-SNAP25-Hn/A was identified using 
Heavy + Light Twin Pack (Molecular Dimensions) corresponding to 0.1 M TRIS pH 8.5, 
21% PEG4000. Optimisation was performed by the hanging-drop vapour diffusion method 
(2 l protein and 1 l mother liquor against a 500 μl reservoir) at 16°C. LC/A(0)-SNAP25-
Hn/A crystals were grown in 2-3 months in 0.1 M TRIS pH 7.5, 15% PEG3350, 0.2 M 
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lithium sulphate. X-ray diffraction data to 2.7 Å from a single crystal cryo-protected with 2 
M lithium sulphate were collected at the Diamond Light Source, UK, beamline IO2. Data 
were processed and scaled in orthorhombic space group P212121 using MOSFLM and 
SCALA (Leslie, 2006; CCP4, 1994; Table 4.3). Initial phases were obtained by molecular 
replacement using Phaser (McCoy et al., 2007) with the coordinates of LHn/A. 
The atomic coordinates and the structure factors have been deposited with the RCSB 
Protein Data Bank under accession codes 3ZUS, 3ZUR for LC/A-SNAP23-HA, LC/A(0)-
SNAP25-HA respectively. 
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Figure 4.2. Crystals of LC/A-SNAP23-Hn/A and LC/A(0)-SNAP25-Hn/A. (A) X-ray 
diffraction of LC/A-SNAP23-Hn/A crystal at IO3 (Diamond Light Source, UK). (B) LC/A-
SNAP23-Hn/A crystal mounted for data collection (red square is 100x100 m). (C) X-ray 
diffraction of LC/A(0)-SNAP25-Hn/A crystal at IO2 (Diamond Light Source, UK). (D) 
LC/A(0)-SNAP25-Hn/A crystal mounted for data collection (red square is 100x100 m).  
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4.3. Results 
4.3.1. Production of engineered LHn-SNARE molecules 
Use of SNARE peptide sequences as activation linkers for LHn backbones 
Multiple species alignments of sequences for R-SNARE and Q-SNARE proteins 
compiled in FunShift (Abhiman and Sonnhammer, 2005) were used to identify the extent of 
homology within the soluble carboxyl region for each subfamily (Stancombe et al., 2011). 
The cleavage kinetics of different length SNARE peptides as substrates for LC was also 
considered (Chen and Barbieri, 2006; Shone et al., 1993). The minimum SNARE segment 
selected was based on retaining full cleavage properties of the SNARE peptide relative to 
the full length protein and included at least one, nine residue recognition SNARE motif, 
proximal to the cleavage site (Washbourne et al., 1997). 62 amino acid SNAP25 (145-206), 
61 amino acid SNAP23 (151-211) and 67 amino acid VAMP2 (28-94) peptides were 
synthesised based on these criteria. Figure 4.1 and Table 4.1 illustrate the domain structure 
of the LHn/A backbones used in this study. 
Purification of self-cleaving LHn backbones  
Lysate from LC/A-SNAP25-Hn/A E. coli expression media showed prominent over-
expressed proteins that migrated at approximately 50 and 56 kDa when analysed by reducing 
SDS PAGE. These are the expected sizes of Hn/A and LC/A-SNAP25 protein domains 
respectively. Western blot analysis using anti-LC/A and anti-His antibodies confirmed these 
molecules were cleavage products derived from the 106 kDa LC/A-SNAP25-Hn/A protein 
(with a C-terminal His-tag) (Figure 4.3.H). It can therefore be deduced that LC/A-SNAP25-
Hn/A had been cleaved within the host cell or during cell lysis. 
Purification of intact LC/A-SNAP25-Hn/A by affinity chromatography using Hn/A’s 
His tag was demonstrated by Western blot with the detection of a protein that migrated at 
106 kDa and cross reacted with anti-LC/A, anti-Hn/A and anti-His antibodies (Figure 4.3.C). 
Reduction of LC/A-SNAP25-Hn/A by the addition of 10 mM DTT fully dissociated the LHn 
backbone, indicating that all single-chain polypeptide had been cleaved. This also indicated 
that the assembled LHn backbone was covalently associated by disulphide bonding (Figure 
4.3.C). Western blotting confirmed the presence of 56 kDa LC/A-SNAP25 and 50 kDa 
Hn/A monomers. 
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Figure 4.3. SDS PAGE and western blot of purified LHn/A proteins and host cell 
lysate. SDS PAGE and western blot of purified LHn/A proteins (A-G) and host cell lysate 
(H). Comparison of oxidised and reduced purified proteins (left and right lanes respectively, 
A-G) and lysate (oxidised only, H) by coomassie staining (PAGE), anti-LC/A (LC/A), anti-
Hn/A (Hn/A) and anti-His (HIS) antibodies. 
 
LHn backbone dissociation is dependent upon LC endopeptidase 
The assembled LC/A-SNAP25-Hn/A backbone was reduced and analysed by N-
terminal sequencing. The reduced proteins were found to correspond to LC/A and SNAP25. 
Cleavage had occurred between amino acids Q197 and R198 in the SNAP25 peptide; 
precisely the expected proteolytic site for BoNT/A endopeptidase. Non-specific cleavage 
products were not detected.  
To control for non LC/A mediated cleavage of the SNAP25 peptide, enzymatically 
inactive LC/A(0)-SNAP25-Hn/A and non-substrate SNAP23, LC/A-SNAP23-HN/A, LHn 
backbones were created. The LC of LC/A(0)-SNAP25-HN/A contained mutations in the 
active site at positions E224Q (Kukreja et al., 2007) and H227Y (Duggan et al., 2002). 
LC/A-SNAP23-Hn/A contained the non-neuronal homolog of human SNAP25, SNAP23, 
which is not a substrate for LC/A. LC/A(0)-SNAP25-Hn/A and LC/A-SNAP23-Hn/A 
(Figures 4.3.D and E respectively) did not display the same pattern of dissociation when 
reduced to that of either LC/A-SNAP25-Hn/A or LC/B treated LC/A-VAMP2-Hn/A 
(Figures 4.3.C and 4.3.F respectively). Lack of specific dissociation of LC/A(0)-SNAP25-
Hn/A and LC/A-SNAP23-Hn/A was linked to a reduced level of in vitro SNAP25 cleavage 
and was indicative of a non-activated state (Figure 4.4). 
In order to investigate the function of LC as an exogenous activating protease, 
serotype A LHn backbone was constructed with a non-substrate SNARE linker. LC/A-
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VAMP2-Hn/A remained as a single-chain polypeptide when expressed and purified. This 
was to be expected as VAMP2 is the substrate for LC/B and SNAP25 is substrate for LC/A. 
This also confirmed the specificity of LC and SNARE pairing required to achieve activation.  
A methodology was developed to capture intact, serotype homogenous di-chain 
molecules. Exogenous LC protease activation was achieved by immobilisation of oxidised, 
single-chain, LC/A-VAMP2-Hn/A on an affinity matrix followed by a washing step with 
LC/B-SNAP25. This treatment was sufficient to completely cleave the VAMP2 linker in the 
target LC/A-VAMP2-Hn/A protein. LC/B protease was not retained on the affinity column, 
thus allowing for the recovery of homogenous, di-chain LC/A-VAMP2-Hn/A (Figure 4.3.F). 
 
4.3.2. Activity of engineered LHn-SNARE molecules 
LHn backbones cleave recombinant SNAP25  
The enzymatic activities of LHn backbone proteins were measured in cell free 
cleavage assays. Characterisation of the molecules was assessed by cleavage of a 
recombinant SNAP25-GFP substrate. The assay was performed under reducing conditions to 
allow release of LC from Hn in activated proteins.  
LHn backbones clustered into two groups based on the level of substrate cleavage 
activity detected. The more active group consisted of activated LHn/A and LC/A-VAMP2-
Hn/A as well as LC/A-VAMP2. A less active group was represented by scLHn/A, self-
activated LC/A-SNAP25-Hn/A and non-activated LC/A-SNAP23-Hn/A. The effectiveness 
of each LHn backbone was established by plotting concentration against percentage 
cleavage (Figure 4.4) and calculating half maximal effective concentrations (EC50) for 
cleaved SNAP25-GFP (Table 4.2). Compared to activated LHn/A (0.01 M), observed 
reductions in enzymatic activity were 60 fold for self-activated LC/A-SNAP25-Hn/A (0.46 
M), 30-fold for non-activated LC/A-SNAP23-Hn/A (0.2 M), and 70 fold for scLHn/A 
(0.51 M). Enzymatically inactive LC/A(0)-SNAP25-Hn/A was greater than 1000-fold 
reduced in proteolytic activity in comparison to activated LHn/A. 
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Figure 4.4. In vitro SNAP25-GFP assay. Comparison of SNARE-LHn molecules in a 
recombinant SNAP25-GFP cleavage assay. Reduced purified protein was assayed for 
activated LHn/A (closed circle/dashed line), scLHn/A (closed square/dotted line), self-
activated LC/A-SNAP25-Hn/A (closed triangle/dashed line), non-activated LC/A(0)-
SNAP25-Hn/A (open circle/dashed line), activated LC/A-VAMP2-Hn/A (closed 
diamond/dotted line), LC/A-VAMP2 (open diamond/solid line) and non-activated LC/A-
SNAP23-Hn/A (open square/dashed line). 
 
The lower activity of self-activated LC/A-SNAP25-Hn/A compared to other forms of 
activated LHn/A was further investigated. Possible competition between the SNAP25 linker 
and the SNAP25-GFP assay substrate for LC was considered. Comparison of activated 
LHn/A and self-activated LC/A-SNAP25-Hn/A activity in the presence and absence of a 
SNAP25 competitor (LC/B-SNAP25) is shown in figure 4.5. SNAP25 spiked LHn/A (0.15 
M) and LC/A-SNAP25-Hn/A (33 M) showed a 5 and 9 fold increase in EC50 
concentration respectively, compared to un-spiked LHn/A (0.01 M) and LC/A-SNAP25-
Hn/A (0.46 M) (Table 4.2). Performing the substrate cleavage assay with increasing dose 
of LC/B-SNAP25 resulted in a dose-dependent loss of potency (data not shown). This 
indicated that SNAP25 peptide present within LC/A-SNAP25-Hn/A is likely to be 
competing with SNAP25-GFP assay substrate for enzyme catalysis. This might also explain 
the reduced activity of self-activated LC/A-SNAP25-Hn/A in this assay. 
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Figure 4.5. In vitro SNAP25-GFP competition assay. Comparison of LHn/A and self-
activated LC/A-SNAP25-Hn/A in presence and absence of LC/B-SNAP25. Reduced 
purified protein was assayed for LHn/A only (closed circle/solid line), LHn/A with LC/B-
SNAP25 (open circle/dashed line), LC/A-SNAP25-Hn/A only (closed triangle/solid line) 
and LC/A-SNAP25-Hn/A with LC/B-SNAP25 (open triangle/dashed line). 
 
Table 4.2. Half maximal effective concentration (EC50) values (M) for in vitro 
SNAP25 cleavage. 
Construct 
SNAP25-GFP 
assay
1
 
SNAP25-GFP 
competition assay
1
 
eSCN SNAP25 
assay
1
 
LHn/A 0.01 0.01 0.6 
LHn/A + LC/B-SNAP25 - 0.15 - 
scLHn/A 0.51 - 9.6 
LC/A-SNAP25-Hn/A 0.46 0.46 0.5 
LC/A-SNAP25-Hn/A  
+ LC/B-SNAP25 
- 33 - 
LC/A(0)-SNAP25-Hn/A >10 - 0 
LC/A-SNAP23-Hn/A 0.20 - ND
2
 
LC/A-VAMP2-Hn/A 0.01 - ND
2
 
LC/A-VAMP2 0.01 - ND
2
 
LC/A - - 54.4 
1 
Values are the average of three experiments performed in triplicate. Data calculated using 
Prism5 (GraphPad).  
2 
ND, not determined.  
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LHn backbones cleave eSCN SNAP25 
The divergence in enzyme activity between the methods used to activate LHn 
backbones observed in the cell free assay was not reproduced in eSCN cells. Cleavage of 
intracellular SNAP25 by LHn backbones was independent of the protease used for 
activation. Half-maximal effective concentrations (EC50) for eSCN SNAP25 cleavage by 
each molecule are shown in table 4.2. Self-activated LC/A-SNAP25-Hn/A (0.5 M) cleaved 
SNAP25 in eSCN cells at a rate equivalent to activated LHn/A (0.6 M) (Figure 4.6). 
SNAP25 cleavage activity for single-chain, scLHn/A (9.6 M) was 16 fold reduced 
compared to activated LHn/A. SNAP25 cleavage activity for LC/A (translocation negative 
control) (54 M), was 90-fold reduced compared to activated LHn/A. Enzymatic inactive 
LC/A(0)-SNAP25-Hn/A had no detectable SNAP25 cleavage activity. 
 
Figure 4.6. In vitro eSCN SNAP25 cleavage assay. Comparison of SNARE-LHn 
molecules in a cell based assay. Activated LHn/A (closed circle/solid line), scLHn/A (closed 
square/dashed line), self-activated LC/A-SNAP25-Hn/A (closed triangle/dotted line), non-
activated LC/A(0)-SNAP25-HN/A (open circle) and LC/A (closed circle/dotted line). 
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4.3.3. Crystal structures of engineered LHn-SNARE molecules 
Structures of LC/A-SNAP23-Hn/A and LC/A(0)-SNAP25-Hn/A 
The crystal structure of LC/A-SNAP23-Hn/A was determined at 2.95Å resolution 
(Figure 4.7.A). A straightforward molecular replacement solution was found with Phaser 
(McCoy et al., 2007) using LHn/A as a search model, with 4 molecules per asymmetric unit. 
While the whole LHn/A backbone could be fitted, no electron density was visible for 
SNAP23 at the LC-Hn interface, corresponding to a 63 residue long peptide due to disorder 
(Figure 4.8.A). The structure was refined to a final Rfree = 29.3%, and Rcryst = 25.0% (Table 
4.3), with 96.2% of amino acids in the Ramachandran plot favoured region, and 71 water 
molecules in the asymmetric unit. 
LC/A(0)-SNAP25-Hn/A crystal structure was solved at 2.7Å resolution (Figure 
4.7.B). Again, LHn/A was used as a search model in Phaser (McCoy et al., 2007) and led to 
a molecular replacement solution, with 2 molecules per asymmetric unit. However, a 98-
residues long region corresponding to the engineered SNAP25 peptide flanked by GS linkers 
between LC and Hn, could not be located due to disorder (Figure 4.8.B). The structure was 
refined to a final Rfree = 26.6%, and Rcryst = 21.5% (Table 4.3), with 94.8% of amino acids in 
the Ramachandran plot favoured region. Solvent molecules (154 water molecules) and 5 
sulphate ions were included in the model. 
 
Figure 4.7. Crystal structures of LC/A-SNAP23-Hn/A and LC/A(0)-SNAP25-Hn/A. (A) 
Structure of LC/A-SNAP23-Hn/A, LC/A (light blue), Hn/A (dark blue), Zinc ion (orange 
sphere), disulphide bridge (gold sticks). (B) Structure of LC/A(0)-SNAP25-Hn/A, LC/A 
(light cyan), Hn/A (dark cyan), disulphide bridge (gold sticks).  
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Table 4.3. Data collection and refinement statistics of LC/A-SNAP23-Hn/A and 
LC/A(0)-SNAP25-Hn/A. 
A. Data Collection Statistics LC/A-SNAP23-Hn/A LC/A(0)-SNAP25-Hn/A 
Space Group P21 P212121 
Cell 
a =89.2, b=205.0, c=130.9 Å; 
= 90°, ° 
a =79.0, b=157.5, c=209.4 Å; 
= 90° 
Resolution range (Å) 50-2.95 30-2.7 
Rsym
1
 (%) 13.0 (55.0) 10.0 (49.6) 
I/I (outer shell) 10.4 (3.0) 14.5 (2.9) 
Completeness % 99.6 (99.2) 96.6 (79.7) 
Redundancy 5.3 (5.1) 7.3 (4.7) 
B. Refinement Statistics   
Resolution range (Å) 130-2.95 126-2.7 
No. of reflections 515,451 508,979 
Unique no. of reflections 97,807 69,459 
Rcryst
2
 (%) 25.0 21.5 
Rfree
3
 (%) 29.3 26.6 
Number of non-H atoms   
Protein 27,586 13,649 
Ligand 4 Zinc atoms 5 Sulphate ions 
Solvent 71 149 
Average temperature factor 
(Å
2
) 
54.5 
41.0 
RMSD for bond lengths (Å) 0.006 0.008 
RMSD for bond angles (°) 0.821 1.094 
1
 Rsym = Σh Σi |I(h) – Ii(h)| / Σh ΣiI(h), where Ii(h) and I(h) are the ith and the mean 
measurements of the intensity of reflection h, respectively 
2
 Rcryst = Σh |Fo – Fc| / ΣhFo, where Fo and Fc are the observed and calculated structure factor 
amplitudes of reflection h, respectively. 
3
 Rfree is equal to Rcryst for a randomly selected 5.0 % reflections not used in the refinement. 
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Figure 4.8. Missing segment at the LC-Hn interface in LC/A-SNAP23-Hn/A and 
LC/A(0)-SNAP25-Hn/A. (A) Structure of LC/A-SNAP23-Hn/A (blue), LC-Hn interface 
highlighting the disulphide bridge and missing electron density above the LHn backbone. 
Fo-Fc map at 1. (B) Structure of LC/A(0)-SNAP25-Hn/A (cyan), LC-Hn interface 
highlighting the disulphide bridge and missing electron density above the LHn backbone. 
Fo-Fc map at 1. Stick and ball representation with Oxygen atoms in red, Nitrogen in blue, 
Sulphur in yellow. 
 
Comparison with LHn/A structure 
The structures present the two domains of LHn interacting strongly. Despite inclusion 
of the SNARE peptides between the LC and Hn domains, each retains the fold seen in the 
structures of the full length toxin and LHn/A (Figure 4.9), including the “belt” region of Hn 
surrounding LC (Leu 500 – Leu 595, and Leu 534 – Leu 627, respectively for LC/A-
SNAP23-Hn/A and LA(0)-SNAP25-HA) which is stabilised by a single disulphide bridge. 
This is highlighted by root mean square deviations with LHn/A of 0.8 and 0.7 Å respectively 
(over 847 C-atoms). In contrast to the structure obtained for LHn/A, the SNAP-engineered 
constructs are single chain molecules. Analysis by SDS-PAGE (Figure 4.2.D and E) 
confirmed the two molecules are not subject to self-proteolysis since SNAP23 is not a 
natural substrate for BoNT/A, and the SNAP25 construct proteolytic activity is prevented by 
a double mutation at the active site.  
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Figure 4.9. Crystal structures of LHn/A backbones. Ribbon representations of LHn/A 
(pink, PDB 2W2D, Masuyer et al., 2009), LC/A-SNAP23-Hn/A (blue) and LC/A(0)-
SNAP25-Hn/A (cyan) Asterisk marks location of the LC-Hn bridge. 
 
In native BoNT/A, the zinc ion is tetrahedrally coordinated by His 223, His 227, Glu 
262 and water-bounded Glu 224 (Figure 4.10.A, Table 4.4). This was observed in the LC/A-
SNAP23-Hn/A structure. The mutations engineered into LC/A(0)-SNAP25-Hn/A, although 
different from the previously reported inactive LC/A mutant structure (Glu224Gln and 
Tyr366Phe, Breidenbach and Brünger, 2004), prevent binding of the catalytic zinc ion 
necessary for proteolytic activity. More particularly the hydroxyl group of Tyr 227 of 
LC/A(0) is in the position held by the zinc atom and is stabilised by a hydrogen bond with 
His 223. Interestingly this causes the side chain of Glu 262 to change orientation and form 
hydrogen bonds with residues Glu 257 and Ser 259. Mutation at position 224 from Glu to 
Gln prevents interaction of this amino acid with residues previously involved in the active 
site. Gln 224 is stabilised by direct interactions of its carboxyl group with Phe 163, and 2 
water molecules, one of which is mediating a potential link with Thr 220 (Figure 4.10.B, 
Table 4.4). 
117 
 
 
Figure 4.10. Structural consequences of mutations at LC/A catalytic site. Stereo figures 
of the crystal structures of (A) LHn/A (PDB code 2W2D, magenta), and (B) LC/A(0)-
SNAP25-Hn/A (cyan). Residues involved in catalytic site interactions are highlighted in 
stick and ball, along with water molecules (light blue spheres) and zinc ion (orange sphere). 
 
Table 4.4. Differences in catalytic sites interaction due to mutations in LC/A(0)-
SNAP25-Hn/A 
Potential bonds in LC/A (distance Å) Potential bonds in LC/A(0) (distance Å) 
His 223 NE2 Zinc 2.7 His 223 NE2 Y227 OH 3.0 
His 227 NE2 Zinc 2.3 Gln 224 OE1 Water 1 2.8 
Glu 224 OE2 Water 2.5 Gln 224 OE1 Water 2 3.1 
Water Zinc 2. Thr 220 CG2 Water 1 3.2 
Glu 262 OE1 Zinc 2.1 Glu 262 OE2 Ser 259 OG 3.0 
Glu 262 OE2 Tyr 366 OH 3.3 Glu 262 OE2 Ser 259 N 2.6 
   Glu 262 OE2 Glu 257 O 2.7 
   Glu 262 OE1 Tyr 366 OH 2.7 
 
Superposition of the three LHn/A backbones (Figure 4.9) indicated a slight shift at the 
extremities of the translocation domain long -helices. These areas of Hn seem to be located 
in solvent pockets and are not involved with symmetry related molecules (Figure 4.11). The 
most pronounced change is for LC/A-SNAP23-Hn/A which presents the lowest solvent 
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fraction. It is likely that some of these regions are involved in membrane insertion upon pH-
mediated changes. Recent evidence pointed to conformational changes of the 659-681 
region, while residues 826-835 were identified in membrane association experiments with 
LHn/A (Mushrush et al., 2011). The solvent accessible loop corresponding to residues 561-
564 is not visible in LC/A(0)-SNAP25-Hn/A. 
 
Figure 4.11. Crystal packing in LC/A-SNAP23-Hn/A and LC/A(0)-SNAP25-Hn/A 
structures. (A) Structure of LC/A-SNAP23-Hn/A (molecules of the crystallographic dimer 
in dark and light blue). (B) Structure of LC/A(0)-SNAP25-Hn/A (molecules of the 
crystallographic dimer in dark and light cyan). Symmetry-related molecules in grey. 
 
Common dimeric arrangement in the LHn/A backbone structures 
Despite the different crystallisation conditions and crystallographic unit cells (Table 
4.3), dimeric interactions of the crystallographic LHn/A backbones appeared similar in the 
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three LHn/A-backbone structures (Figure 4.12). In this packing, orientation of the short -
strands at the LC-Hn interface is in a solvent accessible pocket. This may explain why the 
SNAP peptides linking the two domains are not visible. SNAP have been shown to be of a 
flexible nature in solution (Margittai et al., 2001) and as a coiled-coil fold when in complex 
with its SNARE partners (Sutton et al., 1998). Localisation of this peptide in the two 
constructs studied along with the favoured LHn crystal packing prevented SNAP-SNAP 
interaction into a coiled-coil structure.  
 
Figure 4.12. Dimeric interaction in LC/A-SNAP23-Hn/A and LC/A(0)-SNAP25-Hn/A 
crystal structures. Superposition of dimers from LHn/A (PDB 2W2D, magenta), LC/A-
SNAP23-Hn/A (blue), and LC/A(0)-SNAP25-Hn/A (cyan) crystal structures. Molecules of 
the crystallographic dimer in dark and light colours. 
SNAP25 forms partial secondary structural arrangements when bound to LC/A 
(Breidenbach and Brünger, 2004) which explain the long substrate requirements for optimal 
activity. Brünger et al. (2007) demonstrated that the belt region of Hn and SNAP25 
superpose well. Competition between these two components for binding to LC might be 
expected. The structures presented here show that SNAP peptides do not disturb the strong 
domain interactions within LHn. LC/A-SNAP23-Hn/A and LC/A(0)-SNAP25-Hn/A are 
single chain proteins and crystallised in non-reducing conditions, thus favouring the stability 
of the two domains.  
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4.4. Discussion 
Engineering self-activating LHn backbones 
LHn backbones incorporating a SNARE linker were specifically cleaved by LC. 
Cleavage of the SNAP25 linker by LC/A accounted for the dissociation of reduced LC/A-
SNAP25-Hn/A. It is likely that structural constraints would prevent intra-molecular 
enzymatic cleavage of the SNAP25 linker, and that inter-molecular cleavage accounts for 
proteolysis. Support for inter-molecular cleavage was seen by the cross-activating properties 
of LC/A-VAMP2-HN/A and LC/B-SNAP25 proteins when incubated together.  
Engineering multi-domain proteins for optimal expression often involves empirical 
testing of polypeptide variants. It is well known that BoNT/A requires an extended substrate 
interaction for optimal cleavage kinetics (Breidenbach and Brünger, 2004; Chen et al., 
2007). SNARE inter-domain linkers that correspond to the complete coiled coil region 
underwent complete activation by self-cleavage or when treated with an exogenous LC 
protease. The SNAP25 and VAMP2 peptide linkers used in this study included the binding 
and recognition sites for all of the botulinum serotypes known. The minimum SNAP25 
peptide length effective for complete activation was not determined, but shorter SNAP25 
peptide linkers were tested that either failed to self-activate or to do so to completion (results 
not shown). This is in agreement with previous observations that shorter SNARE peptides 
are less effective substrates for LC (Chen and Barbieri 2006, Shone et al., 1993). 
Activated LHn are di-chain molecules that take the form of separate LC and Hn 
proteins paired by a di-sulphide bond. However, self-cleaving LHn backbones were seen to 
dissociate into LC and Hn domains during protein expression in E.coli. LC and Hn 
subsequently assembled spontaneously upon oxidisation during purification. Disulphide 
bond formation remained possible with the cysteines at the carboxyl end of LC/A and 
amino-terminal side of Hn/A. Nevertheless, as could be expected from uncontrolled 
association, both homomeric and heteromeric dimers were observed when reconstituted 
from LC and Hn monomers. Assembly of LC/A and HC/A to form functionally active, 
disulphide bonded BoNT/A has been reported previously (Zhou et al., 1995). In addition, a 
disulphide bonded carboxyl heavy chain (HC) dimer has also been observed during vaccine 
development for the recombinant HC binding domain of BoNT/A (Bouvier et al., 2003).  
Use of different expression cell lines which could enhance disulphide bond formation 
in the cytoplasm, may help maintain oxidised cysteines and retain an intact disulphide bond 
in self-activating LC/A-SNAP25-Hn/A. Alternatively, LC activation under oxidising 
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conditions, as performed with other exogenous proteases, preserved molecular integrity of 
the disulphide bond. 
To improve the recovery of intact LHn backbone, LC was employed as an exogenous 
protease for activation. Oxidised LC/A-VAMP2-Hn/A single-chain polypeptide was 
activated by LC/B, while immobilised in an affinity matrix. The use of immobilised 
proteases for post translational modification of target proteins is an established technique 
(Kubitzki et al., 2008). However, use of BoNT LC and SNARE sequences in such a role has 
not previously been reported. Rapid, on column activation of single-chain LC/A-VAMP2-
Hn/A polypeptide by LC/B was achieved. The high specificity of LC/B for VAMP2 means 
that use of large quantities of enzyme does not lead to secondary cleavage events within the 
LC/A-VAMP2-Hn/A target backbone. Use of the inherent endopeptidase property of LHn 
backbones for post translational intermolecular self-processing offers a distinct benefit to 
that of other commonly used proteases. The exquisite interaction between LC and SNARE 
proteins for optimal substrate binding and catalysis (Breidenbach and Brünger, 2004), 
reduces the probability of secondary cleavage events occurring using these enzymes. 
Differences in the relative potency of self-activated LC/A-SNAP25-Hn/A compared 
to activated LHn/A were observed. More particularly, LC/A-SNAP25-Hn/A presented a 
lower potency in cell free cleavage assays whereas it showed equivalent activity in spinal 
cord neurons (Figures 4.4 and 4.6). The control molecule, non-activated, scLHn/A, here and 
reported by Fischer et al, (2008) cleaved SNAP25 at a much reduced rate compared to 
activated LHn/A in both cell free and cellular assays. This suggests the difference in relative 
potency of self-activated LC/A-SNAP25-Hn/A to activated LHn/A between the two assays 
is a consequence of the molecule itself rather than assay conditions. The reason for reduced 
potency of LC/A-SNAP25-Hn/A in cell free assays is most likely caused by the SNAP25 
peptide that remains part of the LC/A and Hn/A after self-cleavage (LC/A-SNAP25[145-
197] and SNAP25[198-206]-Hn/A). Indeed the potency of LHn/A in cell free SNAP25 
cleavage assays can also be reduced by the addition of LC/B-SNAP25 as a source of 
SNAP25[145-197] (Figure 4.5). Further support for this hypothesis is that LC/A-VAMP2-
Hn/A (di-chain) did not exhibit reduced potency in the SNAP25-GFP assays. This is in 
agreement for an LHn backbone containing a SNARE peptide that is not susceptible to 
binding or cleavage by LC/A. 
There are several noticeable differences between the two functional assays performed 
in this study that may have an impact on the results described above. Firstly, the two assays 
measure the cleavage of different SNAP25 substrates. In the cell free assay, catalysis of an 
artificial SNAP25-GFP substrate was assessed, while in the eSCN assay endogenous 
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SNAP25 cleavage was measured. SNAP25 fusion to the 27 kDa GFP tag might cause 
alterations in substrate structure and its interaction with the enzyme. Lack of post 
translational modification of the recombinant substrate compared to native SNAP25 might 
also contribute to the differences observed between assays. Secondly, other proteins 
interacting with SNAP25, such as other SNARE proteins that are present in eSCNs but are 
not present in the cell free assays, may influence the activity of the LHn-SNARE 
derivatives. Thirdly, the mechanism by which the LHn backbone delivers LC inside 
neuronal cells is not known. Thus the interactions between LC and Hn may impact on the 
molecules activity depending on their redox state and the ability of the two domains to 
separate. A study by Gul et al. (2010) demonstrated the higher specific activity of LC/A 
moiety in comparison to LHn/A and BoNT/A. 
Crystal structures of LHn-SNARE derivatives 
The crystal structures of two constructs designed around the LHn/A scaffold and 
engineered to contain an extended SNARE peptide at the LC-Hn interface were determined. 
In order to maintain an intact protein assemblage, these constructs were engineered to 
prevent self-activation either by use of a non-cleavable substrate homologue (SNAP23) or 
an enzymatically inactive light chain mutant. They therefore offer interesting models to 
study the stability of engineered LHn derivatives. Despite not observing the entire 
molecules, the structure of the main framework could be solved. These demonstrated the 
stability of LHn/A, and also its flexibility in supporting additional engineered peptide 
segments.  
The light chain structure was unchanged. Mutations at key residues of the catalytic 
site had for consequences a movement of the residues normally responsible for the zinc 
coordination, explaining the loss of LC/A proteolytic activity in LC/A(0)-SNAP25-Hn/A. 
The long helices of Hn/A did not present any significant conformational change and are 
stabilised by strong inter-helical interactions, although a slight shift in the solvent accessible 
extremities was observed. Interestingly, there appear to be a strong dimeric interaction due 
to crystallographic packing between LHn/A molecules which is similar in all the LHn/A 
structures solved. This interaction has no biological implications but seemed to favour the 
crystallisation of LHn/A-based molecules. 
Engineered peptides at the LC-Hn interface were not visible. The localisation of such 
peptides in solvent pockets of the crystal, as well as the flexible structure of these peptides 
may explain this phenomenon. It would be interesting to design larger inserts with known 
secondary structures to study their impact on the LHn fold. 
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Conclusion 
This study demonstrated that it is feasible to engineer LHn backbones to incorporate 
highly specific protease recognition sites based on SNARE polypeptides. These engineered 
backbones were proven to be susceptible to both self-activation and activation by treatment 
with exogenous LC. Importantly they are functional molecules in vitro. LHn backbones 
incorporating SNARE peptides provide an opportunity to optimise their manufacture process 
by an alternative activation strategy to traditional methods. They were shown to retain the 
ability to translocate LC across the endosome membrane and deliver it into the cytosol to 
cleave endogenous SNARE proteins.  
LHn fragments are safe and reliable tools to study the mechanism of action of the 
botulinum neurotoxins (Fischer et al., 2008b; Mushrush et al., 2011). The crystal structures 
presented in this study show that LHn provides a fantastic framework for protein 
engineering where functional peptides can be added without disturbing the overall structure 
of these proteins. 
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Chapter 5. Purification and crystallisation of Clostridium botulinum 
neurotoxin derivatives 
5.1. Other LHn molecules 
5.1.1. Introduction 
The structures of the LHn fragment from botulinum neurotoxin serotypes A and B 
have been described and demonstrated the stability of these molecules. Furthermore, both 
serotypes showed that they are functional fragments, retaining the catalytic properties of 
BoNT as well as the ability to cleave intracellular SNARE proteins in neurons. Retargeted 
toxins with therapeutic potential based on the LHn backbones are therefore likely to 
maintain some of the biochemical properties of their parent neurotoxins, in terms of catalytic 
activity and translocation of the light chain within the target cells cytosol.  
Interestingly, each serotype presents variations in specificity and toxicity (Montal, 
2010). For example, BoNT/C was shown to be particularly cytotoxic compared to serotype 
A (Williamson and Neale, 1998). Additionally, serotype C is the only BoNT able to cleave 
two of the SNARE proteins, SNAP25 and syntaxin (Schiavo et al., 2000). On the other 
hand, BoNT/E was demonstrated to have a faster translocation rate and thus the ability to act 
more rapidly (Wang et al., 2008). 
The level of primary sequence homology between the seven serotypes (approximately 
35% identity, Lacy and Stevens, 1999) indicates that the structure for all serotypes is likely 
to be conserved. While this is true of the domain structures determined so far (Swaminathan, 
2011), the crystal structure of BoNT/E showed that the domains’ spatial organisation may 
differ (Kumaran et al., 2009).  
The LHn fragments, composed of the catalytic (LC) and translocation (Hn) domains, 
represent useful tools to study the domain interactions underlying the mechanism of BoNT 
toxicity. The production of recombinant LHn has been described previously for LHn/A, /B 
and /C (Sutton et al., 2005, Chapter 3). These engineered fragments were optimised for 
expression in E. coli. They include a specific exoprotease cleavage site between LC and Hn, 
to allow for activation into biologically active di-chain molecules. 
Harnessing the different LHn serotypes may provide further flexibility in the design of 
novel molecules derived from BoNTs. The variations seen between the serotypes offer a 
selection of biochemical properties that could prove useful for tailoring a therapeutic 
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molecule against a particular disease. The production and characterisation of the LHn 
molecules should therefore provide valuable information for protein engineering.  
In this study, the crystal structure of a molecule representing an LHn/B backbone was 
solved at 2.7 Å. This construct included peptide linker segments around the exoprotease 
activation site, with the aim of analysing the differences made to primary sequence changes 
in this essential region of the botulinum neurotoxins. Although the additional engineered 
fragment could not be modelled due to disorder, the structure confirmed the significant 
stability of the LHn fold. Furthermore, the production of recombinant LHn serotypes C and 
E was achieved. Both serotypes were successfully crystallised and preliminary x-ray 
diffraction data were obtained for LHn/C.  
 
5.1.2. Methods 
Protein expression and purification 
The synthetic gene encoding 863 amino acids of LHn/B was cloned into modified 
pET vector (Novagen, UK) with a C-terminal 6 x His-tag and transformed into E. coli BL21 
expression cells. The LHn/B gene was engineered to encode for a Factor Xa cleavage site 
(IEGR) flanked by three GGGGS repeats between the LC and Hn domains (LC/B Asp 439 – 
Hn/B Leu 477). The clone was provided by Syntaxin Ltd. Expression and purification of 
LC/B-GS-Hn/B was performed as described previously for LHn/B (Masuyer et al., 2011). 
Briefly, expression cultures were grown in terrific broth and induced with IPTG (1mM). 
After cell lysis, LHn/B in the soluble fraction was purified by affinity chromatography 
(HisTrap HP, GE Healthcare), activated by Factor Xa cleavage (New England BioLabs) and 
finally hydrophobic interaction chromatography (Phenyl Sepharose HP, GE Healthcare), 
prior to concentration to 6.5 mg/ml (Figure 5.1). All concentrations were determined by A280 
measurement. 
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Figure 5.1. SDS-PAGE analysis of LC/B-GS-Hn/B purification. Lane 1, cell lysate 
supernatant; 2, 3, eluate from first affinity purification step in oxidised (O) and reduced (R) 
conditions (respectively); 4, 5, sample activated by Factor Xa (O and R); 6, 7, eluate from 
hydrophobic interaction purification. 
 
The synthetic gene encoding 868 amino acids of LHn/C was cloned into a modified 
pET vector (Novagen, UK) with an N-terminal (cleavable) 6 x His-tag and transformed into 
E. coli BL21 expression cells. The LHn/C gene was engineered to encode for a Factor Xa 
cleavage site (IEGR) between the LC and Hn domains at position 440-445. The clone was 
provided by Syntaxin Ltd. Expression cultures and cell preparation of LHn/C were 
performed as per previously reported for other LHn (Chapter 3). Soluble fraction was loaded 
onto a Ni
2+
-charged chelating sepharose column (GE Healthcare). LHn/C eluted at 100 and 
250 mM imidazole (dissolved in buffer A) and was dialysed overnight at 4°C against buffer 
A. Activation of purified LHn/C was achieved by Factor Xa (New England BioLabs) 
treatment. The cleaved fusion protein sample was loaded onto a HisTrap column (GE 
Healthcare) and the flow-through collected to be dialysed against 50 mM HEPES, pH 7.2. 
This material was then applied to an anion exchange Q HiTrap FF column (GE Healthcare). 
LHn/C eluted at 200 mM NaCl. (in 50 mM HEPES, pH 7.2). The sample was finally 
concentrated using Vivaspin 50000 MWCO concentrator (Millipore) to 12.0 mg/ml (Figure 
5.2A). 
The synthetic gene encoding 859 amino acids of LHn/E was cloned into a modified 
pET vector (Novagen, UK) with a C-terminal 6 x His-tag and transformed into E. coli BL21 
expression cells. The clone was provided by Syntaxin Ltd. The LHn/E gene was engineered 
to encode for a Factor Xa cleavage site (IEGR) between LC and Hn at positions 414-419. 
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Expression cultures and cell preparation of LHn/E were carried out as described for other 
LHn (Chapter 3). Soluble LHn/E was purified by affinity chromatography (HisTrap HP, GE 
Healthcare), followed by hydrophobic interaction chromatography (Phenyl Sepharose FF, 
GE Healthcare). The final sample consists of a single chain LHn/E and was concentrated to 
5.3 mg/ml (Figure 5.2B). 
 
Figure 5.2. SDS-PAGE analysis of LHn/C and /E purifications. (A) Summary of LHn/C 
purification. Lane 1, cell lysate supernatant; 2, 3, eluate from first affinity purification step 
in oxidised (O) and reduced (R) conditions (respectively); 4, 5, sample activated by Factor 
Xa (O and R); 6, 7, eluate from second affinity purification (O and R); 8, 9, eluate from 
hydrophobic interaction purification (O and R). (B) Summary of LHn/E (single chain) 
purification. Lane 1, cell lysate supernatant; 2, eluate from first affinity purification step (O); 
3, 4, eluate from hydrophobic interaction purification (O and R). 
 
Crystallisation 
Initial crystallisation condition for LC/B-GS-Hn/B was identified using the JCSG-plus 
screen (Molecular Dimensions) corresponding to 0.1 M TRIS pH 8.5, 0.2 M magnesium 
chloride, 20% PEG8000. Optimised crystals were grown manually in 2-3 weeks by the 
hanging drop method (2 l protein and 1 l mother liquor against a 500 μl reservoir) at 16°C 
in 0.1 M TRIS acetate pH 8.5, 0.2 M magnesium chloride, 12% PEG6000. X-ray diffraction 
data were collected at the Diamond Light Source, UK, beamline IO3 (Figure 5.3). A 
complete dataset to 2.7 Å was obtained from a single crystal. The data were processed and 
scaled in orthorhombic space group P212121 using MOSFLM and SCALA (Leslie, 2006; 
CCP4, 1994; Table 5.1). Initial phases were obtained by molecular replacement using Phaser 
(McCoy et al., 2007) with the coordinates of LHn/B (PDB 2XHL, Masuyer et al., 2011). 
Crystallographic refinement was carried out using REFMAC5 (version 5.5) (Vagin et al., 
2004) and manual model fittings were done using Coot version (0.6.1) (Emsley and Cowtan, 
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2004). The structures were validated using MolProbity (Davis et al., 2007). Figures were 
drawn with PyMOL (DeLano Scientific LLC). 
The atomic coordinates and the structure factors have been deposited with the RCSB 
Protein Data Bank under accession code 3ZUQ. 
 
 
Figure 5.3. Crystal and x-ray diffraction of LC/B-GS-Hn/B. (A) Diffraction image 
collected at DLS IO3 where LC/B-GS-Hn/B crystals diffracted at 2.7 Å. (B) Crystals of 
LC/B-GS-Hn/B mounted for data collection, optimised crystal grew with 0.1 M TRIS 
acetate pH 8.5, 0.2 M magnesium chloride, 12% PEG6000. (Red square is 167x167 m). 
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Table 5.1. Data collection and refinement statistics for LC/B-GS-Hn/B 
A. Data Collection Statistics LC/B-GS-Hn/B 
Space Group P212121 
Molecules/asymmetric unit 1 
Cell a=89.4, b=103.8, c=115.0 Å; = 90° 
Resolution range (Å) 58-2.7 
Rsym
1
 (%) 13.4 (49.2) 
I/I (outer shell) 8.5 (3.3) 
Completeness % 93.3 (100.0) 
Redundancy 5.2 (5.4) 
B. Refinement Statistics  
Resolution range (Å) 77-2.2 
No. of reflections 146,733 
Unique no. of reflections 28,039 
Rcryst
2
 (%) 25.0 
Rfree
3
 (%) 28.2 
Number of non-H atoms  
Protein 6953 
Ligand 1 Zinc atom 
Solvent (water) 44 
Average temperature factor (Å
2
) 36.5 
RMSD for bond lengths (Å) 0.006 
RMSD for bond angles (°) 0.844 
1
 Rsym = Σh Σi |I(h) – Ii(h)| / Σh ΣiI(h), where Ii(h) and I(h) are the ith and the mean 
measurements of the intensity of reflection h, respectively 
2
 Rcryst = Σh |Fo – Fc| / ΣhFo, where Fo and Fc are the observed and calculated structure factor 
amplitudes of reflection h, respectively. 
3
 Rfree is equal to Rcryst for a randomly selected 5.0 % reflections not used in the refinement. 
 
For LHn/C, several crystallisation conditions were identified in the PACT premier 
and Heavy + Light Twin Pack screens (Molecular Dimensions). The conditions were 
repeated manually by the hanging-drop method and optimised. Crystals could be readily 
grown in a few days in 0.1 M HEPES pH 7.2, 1.5 M lithium sulphate. Crystals grew only as 
stacks of very thin needles. Streak and macro-seeding was performed to optimise the crystal 
size. Single needles were finally obtained but were too weak to allow for collection of a 
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complete dataset. Few low resolution (4.0 Å) images were taken at the Diamond Light 
Source, UK, beamline I24 (Figure 5.4). The images could not be indexed precisely due to 
the weak x-ray diffraction. The cell dimensions obtained using MOSFLM (CCP4, 1994; 
Leslie, 2006) were a= 139, b= 150, c= 239 Å; = 101°. 
 
Figure 5.4. Crystal and x-ray diffraction of LHn/C. (A) Optimisation of LHn/C 
crystallisation. Crystals grew in 0.1 M HEPES pH 7.2, 1.5 M lithium sulphate. From left to 
right respectively, thin needle stacks, single needles, and crystal of LHn/C mounted for data 
collection at DLS I24 (red square is 55x56 m). (B) Diffraction image collected at DLS I24 
where LHn/C crystals diffracted at >4.0 Å. Zoom around beam centre (blue circle). 
 
Concerning LHn/E, a few crystallisation conditions were identified in the primary 
screening. Some of the conditions could be repeated manually by the hanging-drop method, 
particularly with 3.0M sodium formate or 0.1 M TRIS pH 8.5, 0.2 M ammonium sulphate, 
15% PEG3350. Extremely thin single needles were visible, and crystallisation optimisation 
trials were set up. The crystals however disappeared after a few days and none were of good 
enough quality for x-ray diffraction. 
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5.1.3. Results and discussion 
Crystal structure of LC/B-GS-Hn/B 
The crystal structure of LC/B-GS-Hn/B has been determined at 2.7Å resolution. A 
straightforward molecular replacement solution was found with PHASER using LHn/B as a 
search model, with 1 molecule per asymmetric unit and 50.2% solvent content. The LHn/B 
backbone, composed of LC-Hn in its di-chain form linked by a disulphide bridge, was 
observable but no electron density could be seen for the GS linkers (GGGGS repeats), 
inserted on both side of the Factor Xa cleavage site between LC and Hn. This corresponds to 
32 missing residues (excluding the “IEGR” protease site). The structure was refined to a 
final Rfree = 28.1%, and Rcryst = 25.0% (Table 5.1, Figure 5.5), with 96.1% of amino acids in 
the Ramachandran plot allowed region and 44 water molecules per asymmetric unit. 
 
Figure 5.5. Crystal structure of LC/B-GS-Hn/B. (A) Representation of LHn/B domain 
structures. With LHn/B (orange, PDB 2XHL, Masuyer et al., 2011) and LC/B-GS-Hn/B 
(yellow), His tag (HT, light blue), disulphide bonds are represented (S-S). (B) Ribbon 
representation of the crystal structures of LC/B-GS-Hn/B (yellow) superposed with LHn/B 
(orange). Asterisk marks the LC-Hn interface where the disulphide bridge and GS linkers 
(not visible) are located.  
132 
 
Overall, LC/B-GS-Hn/B superposed well with the solved structures of LHn/B and 
BoNT/B (Figures 5.5 and 5.7A), with a root mean square deviation of 1.2Å over 839 C-
atoms with LHn/B. SDS-PAGE analysis of the purified LC/B-GS-Hn/B confirmed its Factor 
Xa activation into a di-chain molecule (Figure 5.1). Addition of GS-linker sequences 
between LC and Hn did not alter the structure of the protein nor the two domains interaction. 
Indeed, the Hn belt region surrounds LC at similar position to BoNT/B, and ends in a short 
-sheet arrangement that stabilises the disulphide bridge linking the two domains. Electron 
density is only visible around the residues delimited by the LHn/B backbone, with nothing 
visible between LC – Gly 440 and Hn – Leu 477 (Figure 5.6). GS linkers are flexible protein 
segments by nature, and in the context of the crystal packing are within a solvent accessible 
area, it is therefore not surprising to be missing this region of the structure.  
 
Figure 5.6. Missing segment at the LC-Hn interface in LC/B-GS-Hn/B. Structure of 
LC/B-GS-Hn/B (yellow), LC-Hn interface highlighting the disulphide bridge and missing 
electron density above the LHn backbone. Fo-Fc map at 1. 
 
Comparison of LC/B-GS-Hn/B with previous structures highlights several noticeable 
differences, particularly around three loop regions (Figure 5.7). (i) Firstly, the loop 
corresponding to residues 142-150 is protruding off the globular fold of LC and has a 
different orientation to that seen in the previous LC/B structures. The electron density in this 
area is weak, indicative of the loop’s movement. (ii) Secondly, residues 208-218 
downstream of the active site, which could not be modelled in the first LHn/B structure, 
present a different arrangement to that seen in BoNT/B where it was stabilised by 
interactions with helices 17 and 19 of Hn. In the LC/B-GS-Hn/B structure, it interacts 
mainly with 19 through different potential hydrogen bonds and van der Waals interactions. 
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The alternative orientation of this loop confirms its flexibility and may have some 
implications for substrate binding or access to the nearby catalytic site. (iii) Additionally, 
loop 625-631 of Hn could not be modelled due to the lack of electron density, similarly to 
LHn/B. This loop is stabilised by the binding domain in BoNT/B, which is missing in this 
structure. On another hand, the Hn domain showed little difference with what had been 
observed in previous structures with only a slight shift in its long helices extremities that are 
not involved in crystal packing interactions (Figure 5.7B). In a parallel with BoNT/A these 
regions might be involved in pH-dependent conformational changes and membrane insertion 
(Mushrush et al., 2011). 
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Figure 5.7. Structure of LC/B-GS-Hn/B, compared to BoNT/B, and crystal packing. 
(A) Cartoon representation of LC/B-GS-Hn/B (yellow), and BoNT/B (grey; PDB 1EPW, 
Swaminathan and Eswaramoorthy, 2000) superposed crystal structures. Loops with a 
different conformation are highlighted. (B) Lattice structure of LC/B-GS-Hn/B. Symmetry-
related molecules are shown in grey. 
 
Purification and crystallisation of LHn/C and /E 
Recombinant LHn/C was successfully purified from E. coli. A high expression yield 
was obtained and purification using metal chelate affinity chromatography was sufficient to 
obtain the purity required for crystallography (Figure 5.2A). A final anion exchange 
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purification step was performed but did not appear to eliminate some of the minor 
contaminants visible by SDS PAGE. Activation by Factor Xa treatment was highly effective 
with only a very faint band visible at approximately 100 kDa in the reduced sample 
corresponding to single-chain LHn/C. Noticeably, LHn/C was concentrated up to 12 mg/ml. 
Only a slight precipitate was observable at this concentration while other LHn (/A, /B, /D 
and/E) would typically not subsist at concentration higher than 5 mg/ml in similar buffer 
conditions. 
Crystallisation trials with LHn/C led to several hits. All were very thin needles as 
presented in figure 5.4A. It took several rounds of optimisation using streak seeding first 
with a lower LHn/C concentration and different levels of precipitants to obtain single 
crystals. All the crystals obtained were needle-like and the best ones only showed weak x-
ray diffraction on a microfocus beamline at the DLS synchrotron (Figure 5.4B). The couple 
of images obtained could not be indexed accurately, however the presumed cell dimensions 
(a= 139, b= 150, c= 239 Å) were consistent with crystals from other LHn molecules. 
Optimisation of these crystals is still on-going. 
The production of a recombinant LHn/E was achieved and is reported for the first 
time here. The expression level in E. coli was lower than for other proteins (Figure 5.2B) but 
yielded enough material for purification. A first affinity purification step using the poly-His 
tag combined with hydrophobic interaction chromatography produced a highly pure protein 
when analysed by SDS-PAGE. Despite having a Factor Xa cleavage site engineered between 
LC and Hn, the sample was not activated. Previous activation experiments had proven 
unsuccessful with Factor Xa displaying poor cleavage results, and trypsin yielding to non-
specific cleavage products (results not shown). While LHn/E in its single chain form might 
have reduced activity, it still represented an interesting molecule for crystallographic studies. 
Preliminary crystallisation conditions were determined and showed long and very thin single 
needles. The crystals however disappeared after a few days and were difficult to reproduce. 
Optimisation of these crystals is still on-going. 
Conclusion 
Production and crystallisation of recombinant LHn/B (LC/B-GS-Hn/B), /C and E/ 
were accomplished. Preliminary x-ray diffraction data were collected for LHn/C and further 
crystal optimisation will be necessary to obtain the protein structure. Additionally, the 
crystal structure of LC/B-GS-Hn/B was solved at 2.7 Å. While it confirmed the structural 
stability of the LHn conformation, the engineered peptides (GS) at the domain interface 
were not visible.  
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5.2. Recombinant ZZ-LHn derivatives 
5.2.1. Introduction 
Protein A is a polypeptide from Staphylococcus aureus known for its capacity to bind 
immunoglobulin G (IgG). Nilsson et al. (1987) described a synthetic IgG binding domain, Z, 
based on an optimised B domain of protein A. This molecule subsequently proved useful as 
a protein engineering tool by showing enhanced expression and solubility of proteins 
expressed with a ZZ-tag, as well as offering a capacity for protein purification by IgG 
affinity chromatography (Moks et al., 1987). The IgG-binding property of ZZ-fusion 
proteins may also be used for functional studies. Nizard et al. (2001) demonstrated the 
successful anchoring of a ZZ protein at the cell surface when attached to the diphtheria toxin 
transmembrane domain. 
 
Figure 5.8. Crystal structure of the B domain of protein A. Cartoon representation of the 
B domain structure of protein A (red, PDB 1BDD, Gouda et al., 1992). N and C termini are 
labelled. Z is homologous to B and is expected to retain the three helices bundle 
conformation. 
 
Each of the Z domains is about 7.5 kDa. The three-dimensional structure of the B 
domain of staphylococcal protein A (Gouda et al., 1992), on which Z is based, is a bundle of 
three short anti-parallel -helices (Figure 5.8). Association of a ZZ tag with the LHn 
fragment of the botulinum neurotoxin was achieved to assess its impact on protein 
expression and solubility. It may also confer to the fragment further functionality by binding 
the Fc domain of IgG. The recombinant proteins produced represented interesting molecules 
to study the structure and stability of LHn when associated with a large peptide. Constructs 
corresponding to ZZ-LHn serotypes A and D were purified and successfully crystallised. 
Purification, crystallisation and preliminary analysis are described here. 
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5.2.2. Methods 
Protein expression and purification 
The genes encoding LHn/A and LHn/D (Chapter 3) were cloned into modified pET 
vector (Novagen, UK) along with a synthetic gene corresponding to two Z domains (129 
amino acids) at the C-terminal of LHn and with N and C-terminal poly-His tags. The 
constructs were transformed into E. coli BL21 expression cells. The sequence was 
engineered to encode for an enterokinase cleavage site between LC and Hn. The clone was 
provided by Syntaxin Ltd. Expression was performed as described previously. Both 
constructs are approximately 115 kDa. ZZ-LHn/A in the soluble fraction was purified by 
affinity chromatography (HisTrap HP, GE Healthcare), activated by enterokinase cleavage 
(New England BioLabs) and a final chromatography step by HisTrap HP (GE Healthcare). 
Sample was concentrated to 11.3 mg/ml (Figure 5.9B).  
ZZ-LHn/D protein was provided by Syntaxin Ltd for crystallisation trials and had 
been purified following a similar method to ZZ-LHn/A. The sample was at a concentration 
of 7.3 mg/ml. 
Crystallisation 
For ZZ-LHn/A, one crystallisation condition was identified in the ProPlex screen 
(Molecular Dimensions). The condition could not be repeated manually but was obtained 
twice with the crystallisation robot (Art Robbins). The crystals took over 10 months to grow 
in 1.4 M sodium malonate pH 6.0. Crystals grew as small prisms. The crystal obtained the 
first time showed x-ray diffraction at low resolution (7.0 Å) on beamline IO3 (Figure 5.9D) 
and the second one diffracted to 4.5 Å on the I24 microfocus beamline at the Diamond Light 
Source, UK. Diffraction images could be indexed in orthorhombic space group I222 using 
MOSFLM and scaled with SCALA (CCP4, 1994; Leslie, 2006) with dimensions a= 220, b= 
245, c= 254 Å, = 90° (Table 5.2). 
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Figure 5.9. Purification and crystallisation of ZZ-LHn/A. (A) ZZ-LHn/A construct. 
LHn/A (green) Z domain (red), and poly-His tag (light blue). (B) Summary of ZZ-LHn/A 
purification. Lane 1, cell lysate supernatant; 2, 3, eluate from first affinity purification step 
in oxidised (O) and reduced (R) conditions (respectively); 4, 5, sample activated by 
enterokinase (O and R); 6, 7, eluate from second affinity purification (O and R). (C) Crystals 
of ZZ-LHn/A mounted for data collection, crystal grew in 1.4 M sodium malonate pH 6.0. 
(Red square is 167x167 m). (D) Diffraction image collected at DLS IO3 where ZZ-LHn/A 
crystals diffracted >7.0 Å. 
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In the case of ZZ-LHn/D, two crystallisation conditions were identified in the JCSG-
plus screen (Molecular Dimensions): 20% PEG3000, 0.1 M citrate pH 5.5; and 20% 
PEG6000, 0.1 M sodium citrate pH 5.0 (Figure 5.10A). Manual trials were set up and 
crystals were grown in citrate buffers (pH 5.0-6.0) with various PEGs (2000 to 6000). 
However, the best crystals were obtained with the solution identified in the screen and 
purchased from Molecular Dimensions (20% PEG6000, 0.1 M sodium citrate pH 5.0). 
Crystals were readily obtained in 2-3 days by the hanging drop method (2 l protein and 1 l 
mother liquor against a 500 μl reservoir at 16°C). The crystals grew in good sizes with an 
arrowhead shape (Figure 5.10A). Several crystals were tested and all showed limited x-ray 
diffraction. The best dataset obtained was at 5.0 Å, at the Diamond Light Source, UK, 
beamline I24 (Figure 5.10B). The crystal was quickly soaked in 25% PEG6000 for cryo-
protection. Images could be indexed in a primitive tetragonal space group (likely P41212) 
using MOSFLM and scaled with SCALA (CCP4, 1994; Leslie, 2006) with cell dimensions 
a= 108, b= 108, c= 478 Å, = 90°. With the large cell dimension, images were 
collected with a small oscillation range, however data were difficult to process and yielded 
an unsatisfactory R merge (> 0.18) due to weak diffraction (Table 5.2). 
 
Figure 5.10. Crystal and x-ray diffraction of ZZ-LHn/D. (A) Optimisation of ZZ-LHn/D 
crystallisation. From left to right respectively, small arrowhead crystals grew in 20% 
PEG3000, 0.1 M citrate pH 5.5, single crystal grew in 20% PEG6000, 0.1 M sodium citrate 
pH 5.0, and crystal of ZZ-LHn/D mounted for data collection at DLS I24 (red square is 
55x56 m). (B) Diffraction image collected at DLS I24 where ZZ-LHn/D crystals diffracted 
at >5.0 Å. Zoom around beam centre. 
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Table 5.2. ZZ-LHn X-ray data collection 
A. Data collection statistics ZZ-LHn/A ZZ-LHn/D 
Space group I222 P41212 
Molecules/asymmetric unit (6)2 (2)2 
Cell dimensions 
a=220, b=245, c=254 Å; 
=90° 
a=108, b=108, c=478 Å; 
=90° 
Resolution range (Å) 30-4.5 41-5.0 
Rsym
1 (%) 14 18 
I/I (outer shell) 10.4 (6.0) 6.6 (5.2) 
Completeness (outer shell) % 99.2 (99.9) 99.6 (99.9) 
Total no. of reflections  230,662 73,570 
Unique no. of reflections 41,036 14,145 
Redundancy 5.6 (5.7) 5.6 (5.8) 
1Rsym = Σh Σi |I(h) – Ii(h)| / Σh ΣiIi(h), where Ii(h) and I(h) are the i
th and the mean 
measurements of the intensity of reflection h, respectively. 
2
 most likely value based on Matthews coefficient. 
5.2.3. Results and discussion 
Purification and crystallisation of ZZ-LHn/A 
ZZ-LHn/A was successfully purified from E. coli. The ZZ tag had been demonstrated 
to enhance solubility and expression (Moks et al., 1987) and the yield seemed higher than 
for LHn/A. This allowed a straightforward purification process by Ni
2+
-chelate affinity 
chromatography, illustrated by SDS-PAGE analysis in figure 5.9B, leaving only a faint 
persistent protein band at approximately 65 kDa and low molecular weight residuals. 
Activation by enterokinase was not entirely complete as demonstrated by the faint band at 
approximately 115 kDa in reduced conditions. Overall, the sample was considered pure 
enough for crystallisation trials and could be concentrated up to 7.3 mg/ml without any 
stability issues. In comparison, LHn/A would not sustain concentration higher than 5 mg/ml 
(in similar buffer conditions). 
Crystals of ZZ-LHn/A were obtained twice in the same condition from preliminary 
crystallisation screening. These crystals could not be repeated and took more than 10 months 
to grow. One of the crystals diffracted to 4.5Å and a full dataset was collected on the 
microfocus beamline (I24) at DLS. Despite a relatively high R merging value (14%), the 
scaled statistics were acceptable and showing a high completeness (Table 5.2). Since the 
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crystal structure of all the elements composing ZZ-LHn/A are known and available, 
molecular replacement was used for phasing. Several trials were set up using Phaser 
(McCoy et al., 2007) and MolRep (Vagin and Isupov, 2001) with either ZZ domains and 
LHn/A, LHn/A on its own or LC/A as search models, however all attempts failed to deliver 
a solution. Further crystallisation trials are on-going in an effort to reproduce the crystals and 
optimise data collection at better resolution. 
Crystallisation of ZZ-LHn/D 
Purified ZZ-LHn/D protein was provided by Syntaxin Ltd for crystallisation trials. 
Crystallisation conditions were identified from the preliminary screens and could be readily 
reproduced (Figure 5.10A). Single crystals with sharp edges and good size were obtained. 
Crystals would typically diffract to over 6 Å. Optimisation of the cryo-protectant solution 
allowed for collection of a full dataset at 5.0 Å at the microfocus beamline (I24, DLS). 
Analysis of the data showed a primitive tetragonal space group with POINTLESS (CCP4, 
1994) indicating P41212 as the most likely option. The long cell dimension (c= 478 Å) with 
very close diffraction spots (Figure 5.10B) made the data difficult to process, particularly at 
higher resolution. This is illustrated by the high Rsymm (18%) observed. Data were 
nonetheless used for molecular replacement. No solution was found when searched for ZZ 
and LHn, LHn or LC/D. Optimisation of the crystallisation conditions was carried out, 
including experiments with commercially available additive screens (Hampton Research) 
using the Phoenix crystallisation robot (Art Robbins Instruments). None of the crystals 
produced diffracted to better than 5 Å resolution.  
Conclusion 
The two ZZ-LHn constructs were crystallised and x-ray diffraction data were 
collected at low resolution. No molecular replacement solution could be found and further 
crystallisation optimisation will be necessary to obtain higher resolution data. Furthermore, 
while the ZZ domain may confer the molecules better solubility, its position at the C-
terminal end of LHn, in an accessible surface area, may cause some instability in the 
crystals. Since the Z domain has the capacity to bind the Fc region of IgGs (Nilsson et al., 
1987), co-crystallisation in the presence of such fragment may help obtain crystals of a 
stable complex. 
  
142 
 
5.3. Recombinant VIP-LHn derivatives 
5.3.1. Introduction 
The potential of retargeting BoNT activity for therapeutic purposes was demonstrated 
by coupling the LHn fragment to Erythrina cristagalli lectin (Duggan et al., 2002), a ligand 
capable of specific binding on nociceptive afferent neurons. This novel molecule was proved 
to inhibit neurotransmission release in vitro and in vivo thereby offering possibilities for pain 
relief. Consequently, BoNT activity was demonstrated on neuronal cells different from its 
natural target. It is therefore of interest to consider other ligands with which to associate 
LHn, so as to target neuronal populations of therapeutic relevance. 
Vasoactive intestinal peptide (VIP) is a 28-residue neuropeptide which is part of the 
glucagon/secretin superfamily and acts through interactions with VPAC (1 and 2), class II G 
protein-coupled receptors (Laburthe et al., 2007). VIP is widely present in the central and 
peripheral nervous systems. It is involved in a diverse range of pathological processes 
related to development, growth, and the control of neuronal and endocrine cells. Its role has 
also been highlighted in major physiological mechanisms such as the immune response and 
digestive, respiratory, and cardiovascular systems (Dickson and Finlayson, 2009). Several 
studies have highlighted the therapeutic potential of VIP and VIP agonist, for example in the 
treatment of inflammatory diseases (Smalley et al., 2009). 
The solution structure of VIP was solved by nuclear magnetic resonance (NMR; Tan 
et al., 2006; Umetsu et al., 2011) and reported to form a long -helix and an unstructured N-
terminal region (Figure 5.11). VIP structural features are similar to that of other ligands from 
the same family (Laburthe et al., 2007) and modelling with the VPAC receptor was reported 
based on homologous interactions (Tan et al., 2006). It was predicted that VIP would bind to 
the N-terminal extracellular domain of VPAC. 
 
 
Figure 5.11. NMR structure of VIP. Cartoon representation of VIP (blue, PDB 2RRH, 
Umetsu et al., 2011). N and C termini are labelled.  
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A novel molecule with therapeutic potential, VIP-LHn/A, was cloned, expressed and 
purified for structural analysis by x-ray crystallography. Information on the structure would 
help understand the interface between ligand and LHn. Crystallisation and analysis of x-ray 
diffraction data are presented. Furthermore, the VPAC1 extracellular domain was produced 
with the aim of studying the fusion molecule interaction with its receptor. 
 
5.3.2. Methods 
Cloning, expression and purification of VIP-LHn/A 
Clones were provided by Syntaxin Ltd for LHn/A (Chapter 3) and VIP in modified 
pET vectors (Novagen, UK). Both genes had been obtained synthetically and were included 
in a cloning cassette. By digestion of the DNA vectors with appropriate restriction enzymes 
followed by ligation, the two genes were fused on a single vector so that VIP would be 
located at the C-terminal end of LHn/A in the same open reading frame. The construct also 
included a C-terminal poly-His tag and a Factor Xa cleavage site engineered between LC 
and Hn. The plasmid was transformed into E. coli BL21 expression cells. Expression was 
performed as described previously for LHn/A. The construct was approximately 100 kDa. 
Soluble VIP-LHn/A was purified by affinity chromatography (HisTrap HP, GE Healthcare), 
activated by Factor Xa cleavage (New England BioLabs) and a final hydrophobic interaction 
purification step (Phenyl-650M, Toyopearl). Sample was concentrated to 4.5 mg/ml. 
Crystallisation of VIP-LHn/A 
VIP-LHn/A crystallisation trials were set up manually by the hanging drop method 
with the conditions that had produced LHn/A crystals (i.e. 15% sucrose, 0.1 M TRIS Acetate 
pH 8.5, 1.5 M ammonium sulphate). Crystals grew in 3-4 days at 16°C with a similar 
morphology to the LHn/A ones (thin rod-shaped crystals; Figure 5.12B).  
X-ray diffraction data were collected from a single crystal at the Diamond Light 
Source, UK, beamline IO2 (Figure 5.12A). The crystal diffracted to 3.25 Å. Analysis of the 
diffraction images using MOSFLM (CCP4, 1994; Leslie, 2006) allowed indexing with a cell 
similar to LHn/A, in the orthorhombic space group P212121. The dimensions were a= 78.4, 
b= 156.1, c= 209.7 Å, = 90°. Processing of the data appeared difficult since two 
lattices may have been present in the crystal. Scaling was done with SCALA (CCP4, 1994) 
and the resulting statistics are presented in table 5.3.  
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Figure 5.12. Crystal and x-ray diffraction of VIP-LHn/A. (A) Diffraction image collected 
at DLS IO2 where VIP-LHn/A crystal diffracted at 3.25 Å. (B) VIP-LHn/A crystallisation. 
Thin rode-shaped crystals grew in 15% sucrose, 0.1 M TRIS Acetate pH 8.5, 1.5 M 
ammonium sulphate. 
 
Table 5.3. VIP-LHn/A x-ray data collection. 
A. Data collection statistics  
Space group P212121 
Molecules/asymmetric unit 2 
Cell dimensions a=78.4, b=156.1, c=209.7 Å; =90° 
Resolution range (Å) 80-3.25 
Rsym
1 (%) 16.8 
I/I (outer shell) 7.2 (2.1) 
Completeness (outer shell) % 92.6 (93.3) 
Total no. of reflections  111,165 
Unique no. of reflections 38,096 
Redundancy 2.9 (3.0) 
1Rsym = Σh Σi |I(h) – Ii(h)| / Σh ΣiIi(h), where Ii(h) and I(h) are the i
th and the mean 
measurements of the intensity of reflection h, respectively. 
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Western-blot analysis of VIP-LHn/A 
The purified VIP-LHn sample was run on SDS-PAGE and blotted on a PVDF 
membrane (Millipore). Primary detection was performed using an anti-VIP antibody 
targeting the C-terminal epitope (#Sc7841, Santa Cruz Biotechnology). Secondary 
recognition was performed with a horseradish peroxidase-conjugated anti-goat antibody 
(Sigma). Enhanced chemiluminescent (ECL) substrate reagent (Thermo Scientific) was used 
for revelation. 
Cloning, expression and purification of VIP receptor extracellular domain (VPAC1 ECD) 
Couvineau et al., (2008) achieved the production of recombinant VPAC1 ECD from 
an E. coli expression system and the resulting protein was able to bind VIP. A similar 
system was therefore used for the production of VPAC1 ECD suitable for crystallographic 
study. The sequence for residues 31-142 of VPAC1 (UniProt P32241) was back-translated 
and the corresponding gene optimised for E. coli codon usage (Entelechon tool). Restrictions 
sites were added to the 5’ (NdeI and EcoRI) and 3’ (HindIII) ends for sub-cloning. A C-
terminal poly-His tag was also included. The designed synthetic gene was purchased 
(GeneArt) and cloned into modified pMal (New England BioLabs) and pGEX vectors (GE 
LifeSciences). These vectors allowed for inclusion of cleavable (by Factor Xa) N-terminal 
MBP and GST tags respectively (Figure 5.13A). The constructs were transformed into E. 
coli Origami expression cells (Novagen). 
Expression was carried out as described previously and soluble VPAC1 ECD was 
observed with both constructs (results not shown). Cells were resuspended in 25 mM TRIS 
pH7.2, 200 mM NaCl (Buffer A). Purification was performed with the MBP-VPAC1 ECD 
protein and consisted firstly of an affinity chromatography step using an amylose resin (New 
England BioLabs). MBP-VPAC1 ECD was eluted with 10 mM maltose (in buffer A). The 
resulting sample was treated by Factor Xa for removal of the N-terminal MBP tag and 
dialysed against buffer A. This was followed by another amylose purification. The flow-
through was collected and loaded on a HisTrap HP column (GE Healthcare). VPAC1 ECD 
was eluted in 250 mM imidazole (in buffer A). SDS-PAGE analysis of the purification is 
presented in figure 5.13B.  
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Figure 5.13. SDS-PAGE analysis of VPAC1 ECD purification. (A) VPAC1 ECD 
construct. MBP-tag (dark blue), Factor Xa cleavage site (black), VPAC1 ECD (green) and 
poly-His tag (light blue). (B) Summary of VPAC1 ECD purification. Lane 1, cell lysate 
supernatant; 2, eluate from first amylose purification step; 3, sample treated by Factor Xa; 4, 
flow-through from second amylose purification; 5, eluate from second amylose purification; 
6, flow-through from HisTrap purification; 7, eluate from HisTrap purification. Asterisks 
mark unspecific cleavage products. 
 
5.3.3. Results and discussion 
Production and crystallisation of VIP-LHn/A 
Recombinant VIP-LHn/A was successfully cloned and expressed in E. coli. The 
purification was optimised from the LHn/A process (Chapter 3) and consisted of two 
chromatography steps using the engineered poly-His tag and the protein’s hydrophobic 
properties. VIP-LHn/A was completely activated by treatment with Factor Xa protease. This 
is illustrated by SDS-PAGE analysis of the purified di-chain sample presented in figure 
5.14B. Furthermore, integrity of the molecule was investigated by Western blot. Detection 
with a specific anti-VIP antibody highlighted the presence of the peptide at the C-terminal 
end of the protein where it is associated to the translocation domain (upper band at 
approximately 50 kDa in the reduced sample). Although the yield obtained was lesser than 
for previous LHn molecules, the level of purity achieved (>95%) was suitable for 
crystallisation. 
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Figure 5.14. SDS PAGE and western blot of purified VIP-LHn/A. (A) VIP-LHn/A 
construct. LHn/A (green) VIP (dark blue), and poly-His tag (light blue). (B) SDS PAGE and 
(C) Anti-VIP Western blot; Lanes 1 and 2, VIP-LHn/A in oxidised and reduced conditions 
respectively. 
 
The difference between LHn/A and VIP-LHn/A is the engineered VIP peptide 
corresponding to less than thirty residues. Since similar purification processes were used, it 
was not surprising to observe VIP-LHn/A crystals with the conditions identified for its LHn 
counterpart. Additionally, the crystals obtained had similar morphology to LHn/A as well as 
an identical crystallographic cell when tested at the synchrotron light source (Table 5.3). 
Processing of the 3.25 Å x-ray diffraction images was difficult and this is reflected by the 
high merging value (17%). A close inspection of the images (Figure 5.12) indicated the 
presence of two possible lattices in the crystal.  
The data were nevertheless used for molecular replacement using LHn/A as a search 
model. While a solution was found with two LHn/A molecules per asymmetric unit (as seen 
in LHn/A, Masuyer et al., 2009), initial refinement was not conclusive (R factor > 38%). 
This may be the result of the experimental at data low resolution. However, inspection of the 
unrefined model did not indicate any Fourier difference density at the C-terminal end of the 
translocation domain, and thus failed to show the VIP peptide. This part of the protein is 
solvent accessible, and the C-terminal region of the LHn/A structure was already observed 
to be missing (including 6 amino acids and the poly-His tag). VIP is expected to present with 
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an -helical structure. Surface exposure to the solvent and flexibility of the peptide might 
explain the disorder in this region of the structure. Optimisation of the crystallisation and 
data collection could improve interpretation of these results. An alternative method to 
determine the structure of the VIP fusion protein may rely in stabilising the C-terminal 
region. This may be achieved by co-crystallisation of VIP-LHn/A with a molecule binding 
specifically to the peptide.  
Production of VIP receptor extracellular domain (VPAC1 ECD) 
VIP interacts with VPAC (1 and 2) class II G protein-coupled receptors by binding to 
their N-terminal extracellular domain (Laburthe et al., 2007). A method for expression of 
recombinant VPAC1 extracellular domain in E. coli was reported (Couvineau et al., 2008). 
A similar system was used in this study in which VPAC1 ECD was associated with a 
cleavable N-terminal MBP tag. Such protein fusion partner was added to improve protein 
solubility. Indeed, VPAC1 ECD contains three disulphide bridges and is prone to 
precipitation. To further address this issue, the E. coli Origami cell line (Novagen) was 
chosen for expression. These cells were engineered to promote disulphide bond formation in 
the host cytoplasm and thus supporting correct protein folding.  
VPAC1 ECD was successfully cloned and expressed in soluble form. The expression 
yield was satisfactory and pure MBP-tagged material could be recovered by amylose affinity 
chromatography (Figure 5.13B). Removal of the MBP tag is however necessary as VIP is 
known to bind the N-terminal region of VPAC1 (Laburthe et al., 2007). The construct 
included a Factor Xa cleavage site between the tag and the protein of interest. Treatment 
with the protease was carried out and led to cleavage of the MBP tag. SDS-PAGE analysis 
of the treated sample showed that tag removal was not complete (MBP-VPAC1 ECD at 
approximately 56 kDa). Along with the expected cleavage products (MBP at 43 kDa, and 
VPAC1 ECD at 13 kDa), the sample presented two unidentified protein bands at 
approximately 50 and below 10 kDa. These were likely the results of unspecific proteolysis 
by Factor Xa. N-terminal sequencing (AltaBioscience) was performed on the lower band and 
the residues identified were part of the VPAC1 ECD sequence corresponding to a fragment 
of 49 amino acids at the VPAC1 ECD carboxyl end. No potential protease sites were 
identified when verifying the protein sequence. Furthermore, the final purification step by 
Ni
2+
-chelate affinity was efficient in removing most of the cleaved MBP but overall, intact 
and pure VPAC1 ECD could not be extracted. Further work is required to purify the VPAC1 
ectodomain which would include optimisation of the purification process and trials with 
alternative proteases for efficient tag removal. 
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Conclusion 
Cloning, purification and crystallisation of a novel VIP-LHn/A fusion protein were 
achieved. Crystallographic analysis did not allow the observation of the VIP fusion partner 
in the structure. The target receptor for this molecule, VPAC1 extracellular domain, was 
cloned and expressed in a soluble form. Further optimisation of the purification will be 
necessary to use it in crystallographic experiments.   
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5.4. Recombinant EGF-LHn derivatives 
5.4.1. Introduction 
Inhibition of neurotransmission by retargeting the botulinum neurotoxin has been 
established (Duggan et al., 2002). Exocytosis is a universal mechanism of secretion 
mediated by SNARE proteins in eukaryotic cells (Bonifacino and Glick, 2004). Thus there is 
a potential to retarget BoNT not only on neuronal cells but on all other cell types, where 
inhibition of secretory events could be therapeutically useful. This broader principle was 
demonstrated by Foster et al. (2006). In their study, a recombinant molecule consisting of 
LHn/C in combination with the epidermal growth factor (EGF) domain was shown to inhibit 
mucus secretion in a respiratory epithelial cell line. Such molecule could have applicability 
in the treatment of chronic respiratory pathologies such as asthma.  
The work by Foster et al. (2006) also represented the first report of a recombinant 
liganded-LHn molecule produced in E. coli. This molecule was engineered with a Factor Xa 
recognition site between LC and Hn for activation, and a cleavable C-terminal MBP 
(maltose binding protein) tag. Catalytic activity was demonstrated by cleavage of syntaxin 
which led to inhibition of mucin secretion in epithelial cells. 
Human epidermal growth factor (hEGF) is a polypeptide of 53 amino acids in length 
with three internal disulphide bridges. Its crystal structure in a dimeric state has been 
reported (Lu et al., 2001). The EGF structure is composed of two domains (Figure 5.15). 
The N-domain (residues 1–32) has an unstructured N-terminal segment and an antiparallel 
-sheet. The C-domain (residues 33–53) consists of a short antiparallel -sheet and a flexible 
C-terminal region.  
With knowledge of the functional potential of EGF-LHn molecules, several constructs 
corresponding to serotypes A, C and D were expressed and purified in order to study their 
molecular structures. Such structural information would help understand the stability of the 
EGF ligand in fusion with LHn, and the interaction between the two partners. The three 
proteins were used in crystallisation trials and preliminary crystallisation and x-ray 
diffraction results are presented below. 
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Figure 5.15. Crystal structure of human EGF. Cartoon representation of hEGF crystal 
structure, N-terminal domain (green), C-terminal domain (blue) (PDB 1JL9, Lu et al., 2001). 
N and C termini are labelled.  
 
5.4.2. Methods 
Protein expression and purification 
The genes encoding LHn/A, /C and /D (Chapters 3 and 5.1) were cloned into modified 
pET vector (Novagen, UK) along with a synthetic gene corresponding to EGF at the C-
terminal of LHn (71 residues). EGF-LHn/A and /C have a C-terminal 10 x His-tag, while /D 
has a N-terminal one. The constructs were transformed into E. coli BL21 expression cells. 
The sequences were engineered to encode for an enterokinase cleavage site between LC and 
Hn. The clones were provided by Syntaxin Ltd. Expression was performed as described 
previously. The three preparations were performed following a similar method. The 
purification process consisted of affinity chromatography using a Ni
2+
-charged chelating 
sepharose column (GE Healthcare), activation by enterokinase cleavage (New England 
BioLabs), second affinity chromatography (HisTrap HP, GE Healthcare) and then a 
hydrophobic interaction step (Phenyl Sepharose HP, GE Healthcare). Only EGF-LHn/A was 
further purified by size exclusion (Superdex 200, GE Healthcare). Samples were 
concentrated to 2.5 mg/ml (EGF-LHn/A), 2 mg/ml (EGF-LHn/C) and 2.9 mg/ml (EGF-
LHn/D). A summary of EGF-LHn/C purification by SDS-PAGE analysis is presented in 
figure 5.16. 
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Figure 5.16. SDS-PAGE analysis of EGF-LHn/C purification. Summary of EGF-LHn/C 
purification. Lane 1, cell lysate supernatant; 2, eluate from first affinity purification step; 3, 
4, sample activated by enterokinase (oxidised (O) and reduced (R) respectively); 5, 6, eluate 
from second affinity purification (O and R). 
 
Western-blot analysis 
The three purified EGF-LHn samples were run on SDS-PAGE and blotted on a PVDF 
membrane (Millipore). Primary detection was performed using an anti-EGF antibody 
(#Sc275, Santa Cruz Biotechnology), and a Tetra-His (QIAGEN) antibody was used for the 
tag detection. For secondary recognition, horseradish peroxidase-conjugated anti-rabbit and 
anti-mouse antibodies (respectively) were applied (Sigma). Enhanced chemiluminescent 
(ECL) substrate reagent (Thermo Scientific) was utilised for revelation. 
Crystallisation 
For EGF-LHn/A, automated crystallisation screens did not yield any hits. Manual 
crystallisation trials were set up in conditions that produced the LHn/A crystals (15% 
glycerol, 0.1 M TRIS pH 8.5, 1.5M ammonium sulphate), performing cross-streak seeding 
with LHn/A crystals. A few needle-like crystals were obtained after several weeks of 
incubation. The crystals were too small to be tested for diffraction. 
In the case of EGF-LHn/C, several conditions were identified in the PACT premier, 
Heavy + Light Twin Pack and JCSG-plus screens (Molecular Dimensions). Manual 
crystallisation trials were set up in order to optimise these conditions. Most of the crystals 
obtained were stack of thin needles. The best looking crystals from the first screenings (with 
15% glycerol, 0.1 M HEPES pH 7.5, 1.0 M lithium sulphate) were used for streak-seeding. 
Rod-shaped crystals were obtained manually in 1-2 weeks by the hanging drop method (2 l 
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protein and 1 l mother liquor against a 500 μl reservoir at 16°C; Figure 5.17B). Several 
crystals were tested in the x-ray beam and all showed diffraction. The best diffraction 
obtained was at 6.0 Å, at the Diamond Light Source, UK, beamline IO2. A couple of images 
were collected but could not be indexed precisely (Figure 5.17A). Using MOSFLM (CCP4, 
1994; Leslie, 2006) a possible cell with dimensions a= 125, b= 278, c= 300 Å in P1 space 
group was obtained. 
Concerning EGF- LHn/D, a single crystallisation condition was identified in the 
JCSG-plus screen (Molecular Dimensions) corresponding to 0.1 M CHES pH 9.5, 20% 
PEG8000. A single small and thin rod-shaped crystal was observed after several months of 
incubation. The condition could not be repeated despite setting up optimisation trials. The 
crystal was too small to be tested for diffraction and used for seeding in further 
crystallisation experiments. 
Cloning of EGF receptor extracellular domain (EGFR ECD) 
Kim et al. (2006) described the engineering, through directed evolution and yeast 
surface display, of the extracellular domain from the epidermal growth factor receptor 
(EGFR ECD) for optimal expression in Saccharomyces cerevisiae. The protein sequence 
(621 residues) made available was back-translated and the nucleotide sequence optimised for 
codon usage in yeast using the Entelechon server. The corresponding synthetic gene was 
purchased (GeneArt) which also included a C-terminal poly-His tag (x6) and the restriction 
sites (5’ EcoRI, and 3’NotI) require for cloning into a pPICZ vector (Invitrogen). Cloning 
into pPICZ was achieved and checked by sequencing. Transformation into Pichia pastoris 
expression cells is under investigation. 
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Figure 5.17. Crystal and x-ray diffraction of EGF-LHn/C. (A) Diffraction image 
collected at DLS IO2 where EGF-LHn/C crystals diffracted at >6.0 Å. (B) EGF-LHn/C 
crystallisation. Needles grew in 15% glycerol, 0.1 M HEPES pH 7.5, 1.0 M lithium sulphate. 
 
5.4.3. Results and discussion 
Purification of EGF-LHn 
EGF-LHn fusion proteins of serotypes A, C and D were purified using a different 
method to the one previously reported for EGF-LHn/C (Foster et al., 2006). Analysis by 
SDS-PAGE and Western blot (Figure 5.18) of the purified samples confirmed the presence 
of the EGF peptide. Furthermore, although activation was overall successful for the three 
proteins, the band at approximately 105 kDa in the reduced samples indicated a low level of 
single-chained material remained in EGF-LHn/A and /C. Other minor residual proteins were 
visible, with a persistent protein at 25 kDa in EGF-LHn/A and /C. The anti-EGF and anti-
His Western blots highlighted several bands in EGF-LHn/A and /C that may be the results of 
truncated material, however some of the detection may be due to unspecific cross-reaction 
with the primary antibodies used. EGF-LHn still represented the main component of the 
purified samples which were used for crystallisation trials. 
Crystallisation of EGF-LHn 
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Crystals were obtained for the three constructs prepared. EGF-LHn/A and /D only 
seldom crystallised in conditions that were not reproducible. Efforts were focused on EGF-
LHn/C for which several crystallisation conditions were observed and replicated, even with 
different purification batches. Noticeably, the crystal morphology was very similar to the 
one observed for LHn/C crystals, i.e. thin needle clusters (Figure 5.4). After optimisation 
and seeding, larger crystals were obtained (Figure 5.17B). These crystals were tested for x-
ray diffraction but they could not withstand the damage inflicted by x-ray radiation. Only a 
couple of images were obtained and spots were obtained only at low resolution (6 Å). The 
same crystallisation conditions also yielded thin plate-like crystals once, however these 
crystals also only showed weak diffraction to >8 Å. Further optimisation of the 
crystallisation is necessary to acquire data suitable for structure determination. 
 
 
Figure 5.18. SDS PAGE and western blot of purified EGF-LHn proteins. (A) EGF-LHn 
constructs. LHn/A (green), LHn/C (purple), LHn/D (blue), EGF (red), and poly-His tag 
(light blue). (B) SDS PAGE, (C) Anti-EGF and (D) Anti-His Western blot; Lanes 1 and 2, 
EGF-LHn/A; 3 and 4, EGF-LHn/C; 5 and 6, EGF-LHn/D, with each sample in oxidised and 
reduced conditions respectively.  
 
Towards the production of EGFR extracellular domain 
Epidermal growth factor (EGF) was shown to regulate cell proliferation and 
differentiation by binding to the EGF receptor extracellular domain (EGFR ECD; Carpenter 
and Cohen, 1979). An alternative way to approach the structure determination of the EGF-
liganded molecules would be to investigate their interaction with EGF receptor partner. 
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Crystallisation of EGF-LHn in complex with EGFR ECD may provide stability to the EGF 
domain (and hence crystals suitable for structural study), and also deliver valuable 
information regarding the retargeted toxin-receptor interaction. The structure of EGF in 
complex with the EGFR ECD has been reported by Ogiso et al. (2002). Details of the 
ligand-receptor interface and comparison with previously known structures may prove 
useful in optimising future EGF-LHn fusion molecules. With this knowledge in mind, 
production of EGFR ECD was considered. Based on the data available in literature, a yeast 
expression system was preferred (Kim et al., 2006) in order to allow for post-translational 
modification and extracellular secretion. Furthermore the yield of expression in P. pastoris 
should provide enough material for crystallisation studies. While the gene was successfully 
cloned into the appropriate vector, transformation and expression trials are under 
investigation. 
 
Conclusion 
Three recombinant EGF-LHn fusion proteins were successfully purified and 
crystallised. X-ray diffraction was shown for EGF-LHn/C. Further optimisation of the 
crystallisation would be necessary to lead to structure determination. Purification and co-
crystallisation with the protein’s receptor was investigated and EGFR ECD was cloned into 
a yeast vector for future recombinant expression in P. pastoris.  
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Chapter 6. General discussion 
 
The Clostridium botulinum neurotoxin is a fascinating protein with the potency to 
inhibit synaptic transmission of cholinergic motor neurons, making it both the most 
fearsome of poisons and yet also an attractive therapeutic molecule. Structural studies by x-
ray crystallography have been fundamental in understanding the toxin’s complex mechanism 
of action (Montal, 2010). Essentially, there is evidence for a modular structure of BoNT in 
which each domain is responsible for one of the key functions: cell binding, intracellular 
transport and proteolytic activity (Swaminathan, 2011). This unique modality, along with the 
universality of the SNARE-mediated secretion process, has led to the development of novel 
BoNT-derived molecules capable of inhibiting the secretion of a specific cell type (Foster, 
2009). The common features of these molecules consist of the catalytic (LC) and 
translocation domains (Hn) of BoNT, a fragment that was first isolated by trypsinisation of 
the holotoxins (Shone et al., 1985) and referred to as LHn. It was therefore essential to 
assess the structure and biological functions of LHn in order to provide the basis for future 
protein engineering.  
The production of the LHn fragments from five of the seven serotypes of BoNT has 
been achieved by recombinant expression in E. coli. This was carried out using an optimised 
protocol following the work by Chaddock et al. (2002). The constructs were efficiently 
purified with the help of affinity chromatography techniques following the insertion of 
peptide tags in the constructs. Furthermore, the design of the constructs included a specific 
exoprotease cleavage site between the two domains, allowing for an effective and controlled 
activation of the molecules in their di-chain form. High levels of purity were obtained and 
allowed for structural studies of these proteins by x-ray crystallography. Crystals were 
obtained for all the LHn fragments after extensive crystallisation experiments using 
automated and manual methods.  
The x-ray crystal structure of LHn/A at a resolution of 2.6 Å was first obtained. 
Interestingly it presented a conformation identical to its parent neurotoxin, with the 
exception of the deleted binding domain (Hc). The structural features common to other 
BoNT were observed with the globular fold of the catalytic light chain, including the 
tetrahedral coordination of the zinc ion, as well as the atypical coiled-coil fold formed by the 
long -helices of the translocation domain. Additionally the structure of LHn was 
particularly useful to study the interactions between LC and Hn and demonstrated the 
activation of LHn/A into a di-chain form and the capacity of the belt region to stabilise 
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around LC. The belt region is believed to play an essential role in the translocation 
mechanism but is not as yet fully understood, thus LHn may be a beneficial tool in 
investigating parts of the toxin’s intoxication processes. Secondly, the crystal structure of 
LHn/B was determined at 2.8 Å. Analysis of this structure led to similar observations to 
LHn/A in that it showed a stable molecule retaining the structural characteristics of BoNT/B 
lacking the Hc domain with minor differences observed in flexible loop regions. 
Furthermore, crystals were obtained for serotypes C, D and E although these studies did not 
lead to the determination of their structures. Interesting data were collected for LHn/D at 2.2 
Å but a thorough analysis showed only the truncated catalytic domain had crystallised and 
thus provided limited information since the structure of LC/D at high resolution (1.6 Å ) had 
been previously reported (Arndt et al., 2006). An alternative approach using small-angle x-
ray scattering showed that LHn/D is likely have a similar fold to the other LHn. Although 
further experiments are required to confirm this result, the solution structure of LHn (from 
serotypes A, B and D) correlated well with the crystal structures reported here. 
The botulinum neurotoxins cause inhibition of neurotransmission by cleaving one of 
the SNARE proteins. The biological activity of the LHn fragment could therefore be 
assessed by testing their proteolytic activity in vitro. When LHn/A was first characterised 
Chaddock et al. (2002) demonstrated it retained the catalytic properties of BoNT/A towards 
SNAP-25. Here, a study of the stability of LHn/A showed the molecule was active over 
several weeks and thus confirmed its catalytic property on a recombinant SNAP-25 
substrate. Additionally, the catalytic properties of LHn/B towards several VAMP substrates 
were determined following a similar assay. It demonstrated a preference of LHn/B for the 
neurotransmission-associated VAMP-1 and -2 over VAMP-3. However, the activity of the 
botulinum neurotoxins is dependent on their ability to reach their substrate intracellularly. 
Recent studies showed LHn/A is a sufficient molecule to allow pore formation and transport 
of LC inside the cells (Fischer et al., 2008), as well as inhibiting neurotransmission release 
in cultured cells, albeit at high concentrations (Chaddock et al., 2002). The results presented 
here showed LHn/B was able to cleave intracellular VAMP-1 and -2 in spinal cord neurons 
in a dose-dependent manner, although with less potency than the full length toxin. The 
process by which LHn gains entry into neuronal cells is unknown but certainly relies on the 
pore-forming capabilities of Hn and the high levels of proteins applied to the cells in this 
assay.  
Characterisation of the structure and activity of the LHn from serotypes A and B have 
demonstrated the stability and functionality of the BoNT fragment. It has validated the 
relevance of using LHn as a safe and reliable tool to study the mechanism of action of the 
botulinum neurotoxins (Fisher et al., 2008; Mushrush et al., 2011). On another hand, the low 
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toxicity of LHn and its lack of a specific cell binding feature make it an interesting tool to 
study SNARE-mediated cellular mechanisms. However further work is required to 
determine the effect of LHn alone on non-neuronal cells. Importantly, the LHn structure 
provides a stable framework for protein engineering and the development of novel 
pharmaceutical molecules.  
The production of LHn-derived molecules in their active di-chain form is particularly 
challenging although the use of specific exoprotease sites by recombinant techniques has 
been developed efficiently (Chaddock et al., 2002). In this study, an alternative approach 
was investigated and consisted in using the BoNT’s own proteolytic activity. Several 
constructs were produced in which a SNARE peptide region, substrate of BoNT, was 
inserted between the LC and Hn domains. These molecules were biochemically 
characterised by SDS-PAGE and Western blotting, and successfully demonstrated the 
production of integral di-chain LHn backbones and thus the principle of LHn activation by 
LC. The activity of these molecules was verified in vitro by substrate cleavage and spinal 
cord neuron assays. Although the LC/A-SNAP25-Hn/A construct was less efficient in the 
cell-free SNAP-25 cleavage assay, its activity in neurons was consistent with LHn/A on its 
own.  
The crystal structures of two molecules produced for the investigation of SNARE-
mediated activation, namely LC/A-SNAP23-HN/A and LC/A(0)-SNAP25-Hn/A, were 
determined to 3.0 and 2.7 Å respectively. These molecules proved useful in analysing the 
structure of LHn backbones fusioned to functional polypeptides. Interestingly, it 
demonstrated again the stability of the LHn fold, being stabilised by the strong interactions 
between LC and Hn. Unfortunately, the additional SNARE peptide located at the interface 
between the two domains could not be observed in these structures. This was likely due to 
the flexible nature of the SNARE proteins and their localisation in solvent accessible 
pockets. Importantly, they did not seem to interact with LHn, thus not interfering with its 
activity. 
One of the limitations of using x-ray protein crystallography was not being able to 
observe some flexible regions in the structures that were solved. This was highlighted by the 
SNARE-LHn structures and also in the case of LC/B-GS-Hn/B, an alternative LHn/B 
backbone with an extended peptide linker region between LC and Hn, in which the 32-long 
additional peptide was not observed, despite determination of the structure at 2.7Å. In these 
examples, the fusion peptide was inserted between LC and Hn and did not interrupt the 
overall structure.  
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Several other LHn-based molecules were produced for structural investigations. These 
consisted in ligand-LHn fusion proteins designed with the potential to inhibit secretion in 
specifically targeted cells, and included a variety of ligands, each partnered with various 
LHn serotypes. In all molecules, the peptidic ligand was located at the C-terminal end of 
LHn, thus replacing the cell binding domain of BoNT. The crystal structure of VIP-LHn/A 
was determined at 3.25 Å but did not provide any information on the ligand’s structure due 
to the low quality of the data. Furthermore, VIP is a short peptide (28 residues) expected to 
take a -helical fold, and thus may be too flexible to observe in the crystal structure. In all 
the structures of LHn determined in this study, the C-terminus of LHn was in a widely open 
solvent accessible area. Indeed the Hn domain’s long -helical conformation is left 
unchanged by the removal of its Hc domain in the full length toxin, and leaves an open 
surface that may thus accommodate new polypeptide without disturbing the main backbone. 
Determination of the crystal structures of other fusion proteins with different ligands should 
provide useful information as to how these ligands interact with LHn. The crystallisation 
conditions for several of these molecules were described in this study and should be the 
basis for further optimisation. The difficulties seen in obtaining crystals diffracting to high 
resolution might be due to the flexibility of these additional C-terminal ligands. An 
alternative approach to investigate their structure may include stabilising this region to 
support crystallisation. Early work on preparing receptor targets for two of the fusion 
molecules was described. This may help determining the crystal structures of BoNT-
derivatives, as well as providing valuable information on the ligand-receptor interactions.  
 
One of the future priorities should be to determine the crystal structure of the other 
LHn serotypes, and LHn/D in particular since its potential use in protein engineering to 
develop new therapeutics has already been reported (Bade et al., 2004). In this study, LHn/D 
was shown to be subject to auto-proteolytic activity under crystallisation conditions. Thus 
alternative approaches should be investigated, including crystallisation trials with metal 
chelating agents, or the production of a mutant inactive LHn/D construct. Additionally, 
further small-angle x-ray scattering experiments should provide useful structural information 
to model these molecules at low resolution and confirm or not the stability of the LHn fold 
across all the serotypes. 
Finally, one of the most challenging aspects of the work in this study has been the 
crystallisation of fusion molecules with therapeutic potentials. Although crystallisation 
conditions were identified, none of the data collected from x-ray diffraction facilitated 
structure determination. Further investigations should now focus on co-crystallisation of the 
161 
 
fusion proteins with their molecular receptors. This would involve production of the binding 
region of the receptors, which in the case of the VIP and EGF fusion molecules, corresponds 
to soluble extracellular domains. Determination of the crystal structure of such a complex 
would be a unique opportunity to study the interaction between the protein and the receptor, 
and thus giving the basis to optimise future therapeutic molecules, particularly in terms of 
affinity and specificity. 
 
The results presented in this study have demonstrated the stability and functionality of 
the LHn fragment from the botulinum neurotoxins. They have showed the multiple assets 
LHn can provide as a biological tool to safely investigate the mechanism of action of the 
most poisonous protein toxin, as well as the cellular secretion processes. Finally, this study 
has provided the structural basis for the design of future therapeutic molecules that harness 
the potency of the botulinum neurotoxin into powerful targeted secretion inhibitors. 
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